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Abstract 
Background  The role of Fas (CD95) and its ligand, Fas ligand (FasL/CD95L), is 
poorly understood in the intestine.  Whilst Fas is best studies in terms of its function 
in apoptosis, recent studies suggest that Fas ligation may mediate additional, non-
apoptotic functions such as inflammation.  Toll like Receptors (TLRs) play an 
important role in mediating inflammation and homeostasis in the intestine.  Recent 
studies have shown that a level of crosstalk exists between the Fas and TLR 
signalling pathways but this has not yet been investigated in the intestine.  Aim  The 
aim of this study was to evaluate potential cross-talk between TLRs and Fas/FasL 
system in intestinal cancer cells.  Results  Treatment with TLR4 and TLR5 ligands, 
but not ligands for TLR2 and TLR9 increased the expression of Fas and FasL in 
intestinal cancer cells in vitro.  Consistent with this, expression of Fas and FasL was 
reduced in the distal colon tissue from germ-free (GF), TLR4 and TLR5 knock-out 
(KO) mice but was unchanged in TLR2KO tissue, suggesting that intestinal cancer 
cells display a degree of specificity in their ability to upregulate Fas and FasL 
expression in response to TLR ligation.  Expression of both Fas and FasL was 
significantly reduced in TRIF KO tissue, indicating that signalling via TRIF by 
TLR4 and TLR5 agonists may be responsible for the induction of Fas and FasL 
expression in intestinal cancer cells.  In addition, modulating Fas signalling using 
agonistic anti-Fas augmented TLR4 and TLR5-mediated tumour necrosis factor 
alpha (TNFα) and interleukin 8 (IL)-8 production by intestinal cancer cells, 
suggesting crosstalk occurs between these receptors in these cells.  Furthermore, 
suppression of Fas in intestinal cancer cells reduced the ability of the intestinal 
pathogens, Salmonella typhimurium and Listeria monocytogenes to induce the 
expression of IL-8, suggesting that Fas signalling may play a role in intestinal host 
defence against pathogens.  Inflammation is known to be important in colon 
tumourigenesis and Fas signalling on intestinal cancer cells has been shown to result 
in the production of inflammatory mediators.   Fas-mediated signalling may 
therefore play a role in colon cancer development. Suppression of tumour-derived 
Fas by 85% led to a reduction in the tumour volume and changes in tumour 
infiltrating macrophages and neutrophils.  TLR4 signalling has been shown to play a 
role in colon cancer via the recruitment and activation of alternatively activated 
ix 
 
immune cells.  Given the crosstalk seen between Fas and TLR4 signalling in 
intestinal cancer cells in vitro, suppressing Fas signalling may enhance the efficacy 
of TLR4 antagonism in vivo.   TLR4 antagonism resulted in smaller tumours with 
fewer infiltrating neutrophils.  Whilst Fas downregulation did not significantly 
augment the ability of TLR4 antagonism to reduce the final tumour volume, Fas 
suppression may augment the anti-tumour effects of TLR4 antagonism as neutrophil 
infiltration was further reduced upon combinatorial treatment.  Conclusion  
Together, this study demonstrates evidence of a new role for Fas in the intestinal 
immune response and that manipulating Fas signalling has potential anti-tumour 
benefit. 
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Success is failure turned inside out--  
The silver tint of the clouds of doubt,  
And you never can tell how close you are,  
It may be near when it seems so far,  
So stick to the fight when you're hardest hit--  
It's when things seem worst that you must not quit. 
- Author unknown – 
  
xi 
 
Acknowledgements 
First and foremost, I am forever indebted to the teachings and guidance from my 
supervisors, Dr Aileen Houston and Dr Elizabeth Brint.  I thank both of them 
sincerely for the many hours (and sleepless nights!) they have given me in the quest 
to earn my doctoral degree. 
My motivation and indeed ability to undertake this body of work was defrayed, in 
part, by the members of the Departments of Medicine and Pathology, many of whom 
I am delighted to consider as true friends.  Helen, this work has been made possible 
by your unwavering cheerful attitude and hard work and I am very grateful for all 
your help over the past 4 years. Caitríona, you are my partner in crime!  I’m not 
sure quite how, but we did it!!  The last four years have been at times, difficult and 
exhausting, but we have made it to the finish line at last.  Charlotte, your unfaltering 
dedication and motivation has inspired me in many ways and I sincerely thank you 
for making the in vivo work bearable, dare I say it, even enjoyable at times!!  We 
have shared delirious laughs, nonsense (and sensible!) conversations and all round 
great times – I really hope there will be more to come.  Ciara, what can I say.  You 
are a true friend.  We’ll need to agree to disagree on some topics (say no more!) but 
your incredible warmth and genuine personality has honestly made life in the 
Clinical Sciences Building so very enjoyable.  I hope that our friendship will 
continue to blossom over the years.  John, I’m still not 100% sure what you mean 
half the time, but, regardless, we love you all the same!  Thank you for your endless 
wit, sarcasm and ability to chat about most anything.  Kevin, well WHERE will I go 
for my daily Vitamin D updates now??  And who will I turn to for advice on all 
things Google??  Together with Brendan, the helpful (and, at times, not so helpful!) 
conversations have made me smile over these 4 years.  It remains to be seen whether 
a marathon can be done in less than four and half hours, but sure we’ll give it a go 
this year! 
I would also like to thank all other members of the Departments of Medicine and 
Pathology, (Amruta, your exceptional cooking abilities have not gone unnoticed!) 
It’s been a joy to know each and every one of you and, don’t you worry, I’ll be back 
(if only for Bernie’s pavlova and Liam’s chilli chocolate brownies!).  
xii 
 
The support and encouragement from my dearest friends has been invaluable in 
getting here and I would like to thank Karen, Rachel and Thérèse for their ability to 
help me to let my hair down when I needed it the most. 
Last, but by no means least, I’d like to thank my devoted boyfriend Paul, who has 
counselled me through the lows and shared the incredible highs throughout this 
journey.  I love you and couldn’t have done it without you by my side, each and 
every step of the way.  You are the chocolate at the end of my Cornetto! 
I wish to dedicate this thesis to my parents, dearest Dada and Mama, my inspiration 
in all my endeavours.  You’ve ignited a passion for knowledge in me that I hope will 
never be extinguished and your support and love has made me into the person I am 
today.  I hope I make you proud. 
  
xiii 
 
Abbreviations 
AOM  azoxymethane 
ALPS Autoimmune lymphoproliferative syndrome 
APC antigen presenting cells 
ARG 1 arginase 1 
β-actin beta-actin 
BBB blood brain barrier 
BSA bovine serum albumin 
BMT bone marrow therapy 
CAC colitis associated cancer 
CCL C-C chemokine ligand 
CCR C-C chemokine receptor 
CD Crohn’s disease 
cDNA complementary DNA 
c-FLIP cellular FLICE-like inhibitory protein 
CLR C-type lectin receptor 
CNS central nervous system 
COX cyclooxygenase 
CRC colorectal cancer 
CTL cytotoxic T lymphocytes 
CXCL C-X-C chemokine ligand 
CXCR C-X-C chemokine receptor 
DAMP danger associated molecular pattern 
DAPI 4',6-diamidino-2-phenylindole 
DC dendritic cells 
DISC death inducing signalling complex 
DSS dextran sodium sulphate 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
EPEC enteropathogenic Escherichia coli 
ERK extracellular signal-regulated kinases 
FADD fas associated death domain 
FCS foetal calf serum 
xiv 
 
GF germ free 
GVHD graft versus host disease 
H&E hematoxylin and eosin 
HRP horseradish peroxidase 
HSP heat shock protein 
IAP inhibitor of apoptosis 
IBD inflammatory bowel disease 
IEC intestinal epithelial cell 
IFN interferon 
IL interleukin 
iNOS inducible nitric oxide synthase 
IP immunoprecipitation 
i.p Intraperitoneal 
IRAKm interleukin-1 receptor-associated kinase monocytes/macrophages 
IRF interferon regulatory factor 
JNK c-Jun N-terminal kinases 
KO knockout 
LBP LPS binding protein 
LPS Lipopolysaccharide 
mAB monoclonal antibody 
MAP mitogen activated protein 
M-CSF monocyte macrophage colony stimulating factor 
MCP-1 Monocyte chemoattractant protein-1 
MDSC myeloid derived suppressor cells 
MIP3α macrophage inflammatory protein-3 alpha 
MMP matrix metalloprotease 
mRNA messenger RNA 
MyD88 myeloid differentiation primary response gene 
NF-κB nuclear factor kappa b 
NGS normal goat serum 
NK natural killer 
NLR nucleotide binding oligomerisation domain receptor 
ODN oligodeoxynucleotide 
PAMP pathogen associated molecular pattern 
xv 
 
PBS phosphate buffered saline 
PGN peptidoglycan 
PMA phorbol 12-myristate 13-acetate 
PMN polymorphonuclear leukocytes 
PPAR-γ peroxisome proliferator-activated receptor gamma 
PRR pathogen recognition receptor 
RA rheumatoid arthritis 
RHIM rip homotypic interaction motif 
RIPA radio-immunoprecipitation assay 
RLR RIG-I-like receptor 
RNA Ribonucleic acid 
ROS reactive oxygen species 
RT room temperature 
RT enzyme reverse transcriptase 
s.c. subcutaneous 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
SEM standard error of the mean 
shRNA short hairpin RNA 
SIGIRR Single Ig IL-1-related receptor  
SLE systemic lupus erthymatosis 
T3SS type III secretion system 
TAM Tumour associated macrophage 
TAN tumour associated neutrophil 
TBS Tris Buffered Saline 
Th T helper 
TIR Toll/interleukin-1 (IL-1) receptor domain 
TIRRAP TIR-domain containing adapter protein 
TLR toll-like receptor 
TNF-α tumour necrosis factor alpha 
TOLLIP toll interacting protein 
TRAIL TNF-related apoptosis-inducing ligand 
Tregs T regulatory cells 
TRIF TIR-domain-containing adapter-inducing interferon-β 
UC ulcerative colitis 
xvi 
 
WT wild type 
qRT-PCR quantitative real time polymerase chain reaction 
 
  
1 
 
1.  General introduction 
1.1 The colon 
The colon is a muscular tube that connects the small intestine to the rectum and its 
primary function is to absorb water, vitamins and minerals from food matter.  The 
colonic mucosa, composed of a single layer of columnar epithelial cells, separates 
the luminal contents from the underlying vascular mucosal tissue. The mucosa is 
invaginated to provide increased surface area for transport and microvilli on the 
surface of the epithelial layer serve to further increase surface area.  The mucosa also 
contains several specialised cells, such as the goblet, Paneth and entero endocrine 
(EC) cells, which secrete mucus, antibacterial molecules and peptide hormones, 
respectively [1, 2].  The layer of loose connective tissue beneath the mucosa is 
known as the lamina propria and is home to cells of the innate and the adaptive 
immune system such as macrophages, dendritic cells as well as B and T 
lymphocytes. The lamina propria is attached to the muscularis mucosa which is an 
innervated thin layer of outer longitudinal and inner circular smooth muscles that 
lends structural support to the intestine.  
The intestinal lumen, in turn, is colonised by approximately 10
14
 resident commensal 
microbes which enable fermentation of otherwise non-digestible dietary 
polysaccharides thus providing nutrients and energy [3].  These bacteria also 
synthesize essential metabolites for the host such as vitamin K, as well as regulating 
important physiological functions of the host, such as those related to energy 
expenditure, satiety and glucose homeostasis [4-6].
 
 Furthermore, the presence of 
large healthy populations of commensal bacteria prevents the emergence and 
proliferation of potentially harmful invading pathogens by outcompeting them for 
space and nutrients.  Studies using germ-free (GF) mice have shown that the gut 
microbiota also plays an important role in the development of the gastrointestinal 
immune system [7]. GF mice have decreased antibody-producing lymphocytes as 
well as defects in the differentiation of T cell subsets and in the development of 
isolated lymphoid follicles, all of which culminates in a delayed immune response 
following antigenic challenge, relative to conventional animals [6-8].  
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1.1.1 Inflammation in the colon 
 
The gut epithelium provides a structural barrier to both commensals and pathogenic 
bacteria and secretes a protective coat of mucus that contains antimicrobial peptides, 
including defensins and leukocyte protease inhibitors [9] that restrict microbial 
translocation.  When this barrier is breached through injury or infection, or when 
microorganisms undergo epithelial cell transcytosis or translocation via M cells or 
dendritic cells (DCs), an array of subepithelial innate defence cells, especially 
resident mucosal macrophages, are poised for response. Located strategically in the 
subepithelial lamina propria, gut macrophages rapidly produce inflammatory 
mediators such as transforming growth factor-β (TGF-β), interleukin (IL)-8 and 
tumour necrosis factor alpha (TNFα) to recruit monocytes and other leukocyte 
populations to help contain the infection. This exerts a domino effect leading to 
sequential release of lipid mediators, cytokines, and chemokines that drive 
recruitment and activation of additional inflammatory cells.  Microbes and/or their 
products are transported by dendritic cells via the lymphatics to draining lymph 
nodes where they induce an adaptive immune response.  Under normal 
circumstances, the pathogen is successfully eliminated and inflammation is resolved.  
Failure to regulate and therefore resolve the normally protective cell-mediated 
immune response in the intestinal and/or colonic mucosa results in the sustained 
activation of the mucosal immune system and inflammation.   
 
1.1.2 Chronic inflammation and inflammatory bowel disease (IBD) 
 
Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative 
colitis (UC).  Both are severe chronic inflammatory disorders, together affecting 
approximately 0.2% of the human population [10]. UC is an inflammation of the 
mucosa of the colon and rectum, and is characterised by ulcers and abscesses 
primarily confined to the mucosal and, to a lesser degree, the sub mucosal 
compartments [11].  Crohn’s disease, by contrast, causes inflammation of the full 
thickness of the bowel wall and may involve any part of the digestive tract. Both 
conditions usually involve severe diarrhoea, pain, fatigue and weight loss [12].  
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Despite intense study in the last ten years, the aetiology and pathogenesis of these 
diseases remains unclear.  
 
Studies investigating IBD have implicated immune, environmental and genetic 
factors in the pathogenesis of IBD, with a combination of these factors resulting in 
the induction of inflammation, followed by the development of mucosal lesions [13].  
For instance, disruption of T lymphocyte regulatory functions and impairment of the 
mucosal immune response to normal bacterial flora has been shown to play a crucial 
role in the pathogenesis of chronic intestinal inflammation [14, 15].  It has also been 
suggested that a loss of regulatory mechanisms and a breakdown of oral tolerance to 
luminal antigens further contributes to the pathology seen in IBD [14, 16]. In support 
of this, IBD patients demonstrate abnormal T-cell responsiveness against indigenous 
microbiota suggesting that commensals may initiate and/or perpetuate the intestinal 
inflammation [17]. Indeed, recent genome-wide association studies have confirmed 
that microbial components play a role in the development of Crohn's disease and UC, 
with many patients displaying mutations in genes encoding recognition, processing 
and killing of microorganisms and the regulation of immune processes in the colon 
[18]. 
 
1.1.3 Cancer in the Gastrointestinal (GI) tract 
 
The GI tract has a higher incidence of cancer development and cancer-related 
mortality than any other organ system in the body [19]. The development of 
colorectal cancer (CRC) can be viewed as an ordered process in which three main 
phases are identified: initiation, promotion and progression, reflective of the genetic 
alterations which drive the progressive transformation of normal healthy cells into 
their malignant counterparts.  The inactivation of a variety of tumour suppressor 
genes with the simultaneous activation of oncogenes gives a selective growth 
advantage to intestinal epithelial cells that are subsequently no longer bound by the 
normal cell cycle checkpoints and restraints. Thus the transformation from normal 
healthy colonic epithelia to adenomatous polyp occurs.  The process from adenoma 
to carcinoma usually takes decades and the transition from carcinoma to metastatic 
CRC takes an additional 2–3 years [20].   A schematic of the morphological changes 
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that occur in CRC along with the genetic alterations thought to be involved in 
neoplastic progression is shown in Figure 1.1.3.1. 
 
  
Normal colon cells 
Late adenoma 
Colon carcinoma 
Metastatic carcinoma 
APC/ -catenin 
K-Ras, 18q LOH 
Figure 1.1.3.1. Sequential genetic alterations, corresponding with well-defined 
morphologic changes, in the development of colon cancer. Loss of APC occurs 
early in the development of adenomas, while progression from early to late 
adenoma is associated with mutation of Ras and LOH of chromosome 18q. 
Inactivation of p53 favours the progression to a malignant carcinoma.  
Early adenoma 
p53 
Other genetic 
alterations? 
5 
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Over the years, numerous investigations have uncovered several critical genes and 
pathways that are important in the initiation and progression of CRC. These include 
mutations in the Wingless (Wnt), Ras-mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol 3-kinase (PI3K) signalling pathways, transforming growth 
factor beta (TGF-β), p53 and DNA mismatch-repair pathways [21].  Together these 
mutations culminate in the acquisition of what are referred to as the hallmarks of 
cancer - sustained proliferative signalling, evasion of growth suppressors, resistance 
to cell death, replicative immortality, induction of angiogenesis, and activation of 
invasion and metastasis [22].  Underlying these hallmarks are genomic instability 
and inflammation [23].  In addition, IBD patients have an increased risk of colorectal 
cancer, estimated to be between 4-20 fold relative to non-sufferers, with the risk 
being directly related to the duration and anatomic extent of the inflammation [24].  
Furthermore, the mortality in patients diagnosed with colorectal cancer in the setting 
of IBD is higher than for sporadic colorectal cancer [25], suggesting the 
inflammatory processes characteristic of these diseases predisposes to aggressive 
neoplasia. 
 
1.2 Fas (CD95) and Fas ligand (FasL/CD95L) 
1.2.1 Fas (CD95) 
 
Fas, also known as CD95, is a membrane receptor belonging to the tumour necrosis 
factor (TNF) receptor superfamily.  It is a 45-52 kDa, highly glycosylated type 1 
membrane protein with six antiparallel, amphipathic -helices arranged in a fold 
[26], The Fas receptor has a tertiary protein structure common to all members of the 
TNF receptor (TNFR) superfamily (Figure 1.2.1.1a).  All members have several 
cysteine-rich motifs (CRD) in the extracellular N-terminal domain. These motifs fold 
independently to the rest of the protein, and are stabilised by extensive intrachain 
disulphide bonding. Receptor-ligand interactions are believed to occur via these 
CRDs [27].  In addition, the Fas receptor and TNFR 1 share significant homology 
within their intracellular C terminal domains, both containing an 80-amino acid 
region called the death domain (DD).  Fas has been shown to be predominately 
located at the cell surface, where it pre-associates into signalling incompetent, 
homodimers [28]. 
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The human Fas gene is a single copy gene that has been mapped to chromosome 
10q23 and consists of nine exons (25 bp to >1.44 kb) that are separated by eight 
introns (152 bp to - 12 kb), spanning 25 kb [29].  Fas is constitutively expressed on a 
wide variety of cell types, and is particularly abundant on T and B cells, monocytes, 
neutrophils, eosinophils, macrophages, epithelial and endothelial cells [30].   It is 
also constitutively expressed by intestinal epithelial cells.  In addition, Fas 
expression can also be induced in some cells types in an NF-κB- and p53- dependant 
manner [31, 32].   
 
1.2.2 Fas Ligand (CD95 ligand) 
 
The cognate ligand for the Fas receptor, is Fas ligand (FasL/CD95L). FasL is 
synthesised as a 281 amino acid type II trans-membrane protein (Figure 1.2.1.1b).  
The C terminus contains the specific receptor binding domain which mediates the 
selective binding to the cysteine rich CRD domains of the Fas receptor.  The 
intracellular N terminal domain of FasL contains highly conserved proline residues 
as well as several potential tyrosine phosphorylation sites which are likely to 
influence FasL protein sorting to secretory lysosomes [33]. 
 
The human FasL gene was mapped on chromosome 1q23 and consists of ∼8.0 kb 
split into four exons [34].  NF-κB, Sp1 and EGR response elements have all been 
identified in the FasL promoter region [35] [36, 37].  In contrast to the ubiquitous 
expression of Fas, the expression of FasL is much more limited with only a few cell 
types constitutively expressing appreciable levels of FasL such as natural killer (NK) 
cells and cytotoxic T lymphocytes.  FasL is also constitutively expressed in some 
tissues such as the eye, the testis and in some neurons where it is thought to mediate 
immune privilege [38, 39].  The expression of FasL is inducible in some cells such as 
CD4+ T helper 1 cells with expression requiring activation with antigen [40] [41].  
The expression of FasL can also be induced upon cellular stress in some cells and 
this is thought to be dependent on JNK activation [42]. 
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In addition to their membrane bound versions, both Fas and FasL exist as soluble 
proteins, sFas and sFasL, respectively [43, 44]. Although the functions of these 
soluble counterparts is still unclear, there is evidence to suggest that both sFas and 
sFasL can act as decoys, binding to either membrane bound FasL or Fas, 
respectively, inhibiting Fas-mediated signalling [45].  However, sFasL has also been 
shown to induce apoptosis on Fas bearing cells, although the biological activity of 
sFasL is thought to be much lower than that of mFasL [46]. 
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Figure 1.2.1.1 The structure of the Fas and FasL proteins 
a) The mature human Fas protein consists of 319 amino acids. The N-terminal 
extracellular oligomerization domain is responsible for the FasL-independent 
oligomerization of the receptor. There are three cysteine-rich domains.  A 
cytoplasmic death domain is crucial for apoptotic signalling. The last 15 amino 
acids constitute a C-terminal inhibitory domain.  
b) FasL is a highly conserved transmembrane protein. The extracellular domain 
contains the self-assembly (SA) and receptor binding (RB) domain; whilst the 
intracellular domain contains motifs important for signalling including the 
proline-rich domain (PRD). 
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1.2.3 Fas-mediated apoptosis 
Fas activation requires the association of trimeric FasL–Fas (FasL3–Fas3) complexes 
[47] which reorganises and aggregates signalling-incompetent pre-assembled Fas 
complexes, leading to the formation of a high stability, ‘supramolecular’, signalling-
competent complex [48]. Formation of the supramolecule along with other 
intermediate steps such as actin reorganization [49], and association with membrane 
rafts [50], allows for the recruitment of the adaptor molecule, Fas-associated death 
domain (FADD), via DD–DD interactions. FADD also contains a death effector 
domain (DED), which in turn recruits pro-caspase-8 (FLICE) and/or pro-caspase-10 
to the Fas receptor via DED-DED interactions.  The resulting multimeric protein 
complex is called the death-inducing signalling complex (DISC), and forms within 
seconds of receptor engagement [51] (Figure 1.2.3.1).  At the DISC, the initiator 
caspase, pro-caspase-8 (and/or -10), is activated. Caspases are cysteine proteases that 
cleave their substrates at aspartic acid residues [52]. Synthesized as inactive 
zymogens called pro-caspases, initiator caspases (e.g. caspases-8 and -9) require 
dimerization for activation [53].  Executioner caspases (Caspases-3, -6 and -7) are 
produced as inactive pro-caspase dimers that must be cleaved by initiator caspases. 
In type I cells, sufficient levels of caspase-8 are activated at the DISC, leading to the 
cleavage and activation of executioner caspases.  [54].  Once activated, a single 
executioner caspase can cleave and activate other executioner caspases, leading to an  
FasL 
Fas 
FADD 
Procaspase-8 
Caspase-8 
Caspase cascade 
(executioners) 
Caspase 
mediated 
proteolysis 
of protein 
targets 
Apoptosis 
Figure 1.2.3.1  The extrinsic and intrinsic pathways of apoptosis 
a) The extrinsic pathway 
When cell surface Fas engages with Fas ligand, several proteins are recruited to the 
intracellular death domain of Fas to form the death-inducing signalling complex 
(DISC).  This results in the proteolytic processing  and autoactivation of pro-caspase 
8.  In type I cells, this activated ‘initiator’ caspase, then activates a number of 
intracellular executioner caspases.  This caspase cascade leads to the caspase-
mediated proteolysis of specific protein targets. b) The intrinsic pathway 
In type II cells, caspase-8 mediated cleavage of Bid to tBid leads to its translocation 
to the mitochondria, eventually leading to the release of caspase C from the 
mitochondrial intermembrane space.  This leads to the formation of the apoptosome 
within which pro-caspase 9 is activated. Caspase 9 subsequently activates the 
initiator caspases resulting in cell death. 
tBid     Bid 
Bax, Bak 
Pro-
Caspase-9 
Apaf-1 
Caspase-9 
Cytochrome C 
b) The intrinsic 
pathway 
a) The extrinsic 
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Mitochondria 
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ATP 
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accelerated feedback loop of caspase activation (Figure 1.2.3.1a). 
In other cells, an insufficient amount of caspase 8 is activated at the DISC to allow 
for the direct induction of cell death. In these type II cells, caspase-8 must first 
activate the mitochondrial or ‘intrinsic’ apoptotic pathway [55].  This mitochondrial 
or ‘intrinsic’ apoptotic pathway is activated by caspase-8-mediated cleavage of the 
Bcl-2 family member, Bid. Truncated Bid translocates to the mitochondria, where it 
can induce both the oligomerization of pro-apoptotic Bax and/or Bak in the 
membrane and the release of pro-apoptotic molecules, including cytochrome C, from 
the mitochondrial intermembrane space. Cytochrome C can then associate with the 
scaffolding protein Apaf-1, dATP and pro-caspase-9 to form a high-molecular mass 
complex called the Apoptosome [56]. Within the Apoptosome, pro-caspase-9 is 
activated.  Caspase-9 then activates caspase-3, resulting in cell death [56] (Figure 
1.2.3.1b). 
Type I and II cells differ in their content of intracellular inhibitor of apoptosis 
proteins (IAPs), which block executioner caspase function unless suppressed by 
proteins released from the mitochondria [57]. Members of the Bcl-2 family, which 
includes both positive regulators such as Bax, Bak, and Bid and anti-apoptotic 
molecules such as Bcl-2 and Bcl-xL, also vary between type I and type II cells [24]. 
Expression of either Bcl-2 or Bcl-xL renders Type II cells resistant to Fas-mediated 
apoptosis. Type I cells however, cannot overcome the production of the large 
amounts of caspase-8 produced at the DISC, and are therefore not protected from 
Fas-mediated apoptosis even by the expression of very high levels of Bcl-2 or Bcl-xL 
[58]. 
Both the intrinsic and extrinsic pathways of apoptosis culminate in the activation of 
the end stage caspases which ultimately cause the morphological and biochemical 
changes seen in apoptotic cells [59].  These include degradation of chromosomal 
DNA, chromatin condensation, cytoskeletal reorganisation, and finally 
phosphatidylserine externalization which allows for phagocytic recognition and 
uptake of the apoptotic cells [60]. 
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1.2.4 The physiological and pathological functions of the Fas/FasL apoptotic 
signalling pathway 
 
Characterisation of lpr and gld mice which exhibit lymphadenopathy and 
splenomegaly revealed mutations in Fas and FasL, respectively [61, 62], with the 
defects in these mice mutants providing some of the first evidence for a role for 
Fas/FasL signalling in the immune system. These mutations are loss of function 
mutations, resulting in impaired Fas-mediated apoptosis. Activation-induced cell 
death (AICD) is the primary homeostatic mechanism used by the immune system to 
control T cell responses in the peripheral lymphoid organs, restoring normal cell 
number following T cell expansion in response to infection [63].   Fas-mediated 
apoptosis has been shown to play a critical role in AICD. Fas-mediated apoptosis is 
also critical in the clonal deletion of auto reactive T cells [64].   Furthermore, 
following target cell recognition, FasL is upregulated on cytotoxic CD4+ T cells, 
which subsequently binds to Fas on the target cell thus executing the specific killing 
of virally infected or transformed cells [65].   
The Fas/FasL system also plays an important role in immune privilege with some 
tissues, such as the eye and the testes constitutively expressing Fas ligand [66-68].  
Constitutive expression of FasL in such tissues has been shown to trigger apoptosis 
of activated Fas-bearing inflammatory cells entering these sites, thereby protecting 
these tissues from a potentially disastrous inflammatory immune response [38]. 
 
Whereas the Fas/FasL apoptotic system normally contributes to the killing of virally 
infected, damaged or excess cells, abnormally increased levels of Fas-mediated 
apoptosis has been implicated as a cause of certain immunopathological disorders.  
For instance, Fas-mediated apoptosis has been implicated, alongside perforin, in the 
destruction of insulin-producing cells and the development of diabetes [69-71].  
Insufficient levels of Fas-mediated apoptosis have also been implicated as a cause of 
disease with the Fas/FasL system being involved in the pathogenesis of autoimmune 
lymphoproliferative syndrome (ALPS). A rare disorder of disrupted lymphocyte 
homeostasis, clinical manifestations of ALPS vary, but typically include abnormal 
enlargement of organs and lymph nodes within the first two years of life.  Patients 
also have an increased number of double-negative T cells (CD4-/CD8-) [21].  Since 
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these features are shared with lpr and gld mice, mutations in either Fas or FasL genes 
were suspected to play a role in the development of ALPS, with subsequent studies 
confirming this. [16, 72-74].  Mapping these mutations to the FasL and Fas genes 
suggests that the resultant mutant transcripts may either be unable to bind Fas or 
transduce the apoptotic signal. Systemic lupus erythematosus (SLE) is an 
autoimmune disease that can affect different organs including skin, heart, lungs, 
blood vessels, liver, kidneys, joints and the nervous system. SLE is characterised by 
malregulation of T and B cells causing the production of excessive auto-antibodies 
and the formation of immune complexes against nuclear antigens [75, 76].  The 
elimination of auto reactive T or B cells is impaired in SLE patients [17, 77], 
suggesting that the Fas/FasL signalling system may also play a role in this disease. 
Evidence suggests that an single nucleotide polymorphism in the enhancer region of 
the Fas gene promoter prevents the binding of the SP-1 transcription factor, which in 
turn leads to diminished Fas expression, which may contribute to the reduced ability 
of SLE patients to clear auto reactive T and B cells [13, 78-80]. 
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1.3 The non-apoptotic functions of Fas 
Although most extensively studied for its role as a mediator of cell death, Fas has 
been found to mediate a variety of non-apoptotic functions.   These include 
proliferation, migration and inflammation (Figure 1.3.1).   
  
Apoptosis 
Migration 
Proliferation 
Inflammation 
FasL 
Fas 
Figure 1.3.1 Signals emanating from Fas-ligation 
Upon FasL ligation, the best characterised response is apoptosis  in the Fas-bearing 
cell.  However ligation of Fas has also been shown to lead to a variety of other 
cellular consequences including inflammation, migration and proliferation. 
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1.3.1 Proliferation 
 
One of the first examples of a non-apoptotic function for Fas was the discovery that 
Fas could stimulate the proliferation of anti-CD3-activated human peripheral blood T 
cells.  Activation of T cells requires two main signals with a lack of secondary co-
stimulation resulting in Fas-mediated apoptotic cell death. However, despite a lack of 
secondary co-stimulation, T cell receptor (TCR)/CD3-stimulated memory T cells do 
not undergo apoptosis but instead proliferate more rapidly as a consequence of Fas 
ligation. This suggests that the physiological response of CD4
+
 T cells to Fas ligation 
is determined by previous antigenic history and availability of co-stimulatory 
molecules [81].  Moreover, the outcome of Fas ligation on naïve T cells was found to 
depend largely on the ‘dose of agonist’, with a complete block of activation 
occurring at high doses of Fas agonist, while lower concentrations of Fas agonist had 
co-stimulatory  activity [82].  Taken together, these data suggest that the expression 
levels of FasL present on antigen presenting cells (APCs) regulate the immune 
response, with initial low levels positively co-stimulating naïve T cells and increased 
FasL expression later on resulting in immune response termination by inducing 
apoptosis in pre-activated T cells.  
A variety of non-immunological cells, including B cells and fibroblasts, have also 
been shown to respond to Fas stimulation with enhanced proliferation.  Moreover, in 
the liver, although in vivo administration of an anti-Fas antibody caused massive 
hepatic apoptosis resulting in hepatic failure [83], partial hepatectomy prevented the 
systemic lethal effect, with Fas engagement actually accelerating the regenerative 
response [84].  These data indicate that liver damage stimulates a Fas-mediated 
protective regenerative response which may be harnessed to promote regeneration 
and healing. 
 
1.3.2 Migration 
 
Several studies have suggested that signalling through Fas can promote cell 
migration [85-88].   In multiple cancer cell types resistant to Fas-mediated apoptosis, 
urokinase plasminogen activator (uPA) was found to be required for Fas ligand-
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induced motility and invasiveness [85].  After binding to its receptor, uPA cleaves 
plasminogen forming plasmin, which can cleave and activate matrix 
metalloproteinases (MMP), specifically MMP2 and MMP9, in a tyrosine kinase-
dependant manner, resulting in the cleavage of further proteins such as collagen [89].  
3811}. uPA is absolutely required for intravasion [90] and it has been recognized 
that uPA can also induce increased motility in tumour cells [91].  In vivo, mice that 
lack FasL specifically in neutrophils and macrophages exhibit a reduced infiltration 
of neutrophils and macrophages to the spinal cord following transfection injury. 
Furthermore, FasL treatment of these cells lead to increased invasion using an in 
vitro transmigration assay, which was abolished upon pharmacological inhibition of 
MMP-2 and 9 [93, 94]. 
Tyrosine kinase activation by Fas in colorectal cancer cells has also been shown to 
result in the rapid actin-driven formation of cell protrusions, a process that is 
essential for tumour cell invasion [93]. Thus, it appears that Fas activation can 
promote tumour cell invasion through distinct pathways. 
Fas ligation has been shown to promote neurite outgrowth and branching [95, 96] 
and following in vivo sciatic nerve injury, acceleration of nerve regeneration [95].  
Fas signalling may also mediate neuronal branching [97]. Moreover, since potent 
immunosuppressive drugs, which completely prevent autoimmunity, fail to prevent 
neurological defects from developing in lpr mice, may suggest that 
neurodegeneration in the lpr mouse is a direct result of limited Fas expression on 
neuronal cells, highlighting the importance of the Fas/FasL system in the nervous 
system [98, 99]. 
1.3.3 Inflammation 
 
Fas ligation has also been shown to induce the production of a number of 
proinflammatory cytokines, such as IL-8, IL-6, IL-1β and monocyte chemoattractant 
protein-1 (MCP-1), by a variety of non-lymphoid cells [100-102] [103, 104], [105], 
[106], as well as by lymphoid cells [104, 107]. Fas-induced cytokine production has 
been shown to involve the direct activation of NFB, and the p38 JNK, ERK, MAPK 
signalling pathways.  Recently, studies have suggested that myeloid differentiation 
primary response 88 (MyD88) may also play a role in Fas-mediated inflammation 
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(Figure 1.3.3.1).  The Fas-induced chemokine (C-X-C motif) ligand 1 (CXCL-1) 
production in alveolar epithelial cells was shown to be dependent on MyD88, with 
Fas-induced chemokine production decreased in MyD88 deficient macrophages 
[108]. In addition, numerous allograft studies have demonstrated that over-
expression of FasL can trigger neutrophil recruitment, ultimately leading to graft 
rejection [109-111]. 
Fas/FasL-mediated inflammation has been implicated in the pathogenesis of several 
diseases that have an underlying inflammatory component such as acute respiratory 
distress syndrome [108], cystic fibrosis [112], arthritis [104, 113] and cancer [114]. 
Moreover, many chronic inflammatory diseases are attenuated in mice lacking Fas or 
FasL [113, 115, 116].  For example, in models of pulmonary inflammation, lpr mice 
exhibit reduced cytokine secretion and neutrophil influx, together with a reduction in 
epithelial cell apoptosis and tissue damage [117] [118]. 
  
Figure 1.3.3.1.  Signalling pathways involved in Fas-mediated inflammation 
Ligation of Fas has been shown to promote inflammation via the activation of p38, 
ERK, and JNK MAPK signalling pathways as well as activation of NFκB.  MyD88 
may interact directly with Fas, independently of FADD, resulting in activation of the 
JNK and ERK MAPK signalling pathways.  Alternatively, in the absence of Fas 
ligation, FADD may interact with MyD88 in the cytoplasm potentially reducing the 
stability of its interaction with IRAK1, thus limiting MyD88-dependant signalling. 
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1.4 Fas signalling in the intestine 
Despite being constitutively expressed in the intestine, the physiological role of Fas 
in the colon is unclear. Fas has been shown to be constitutively expressed at the 
basolateral side of all epithelial cells in the colon [119, 120], while FasL is 
predominantly shown to be found in a few scattered lamina propria cells and Paneth 
cells [121].  Despite being best characterised for its role in apoptosis, there are no 
differences in morphology or apoptotic cell counts in the gut mucosa of lpr and gld 
mice relative to WT mice [122]. Indeed Fas-induced apoptosis was demonstrated to 
be impaired in active UC [123], suggesting that Fas signalling may actually be 
protective in the colon.  Consistent with this, the colonic epithelium from
 
lpr mice 
infected with Citrobacter rodentium (C. rodentium) was found to be more damaged 
and hyperplastic in comparison to control mice [124].  Taken together, it is therefore 
unlikely that the Fas/FasL system is involved in the physiological turnover of the gut 
epithelium.   
Recent evidence suggests that Fas/FasL signalling in the intestine may play a crucial 
role in the host response to pathogens and in particular, pathogen clearance.  
Bacterial pathogens have been shown to antagonize death receptor-induced apoptosis 
of infected cells in the intestine [124, 125].  NleB is an effector protein of the Type 
III secretion system, a syringe-like apparatus that delivers bacterial effector proteins 
directly into the host cell cytoplasm [126].  NleB was recently shown to bind to and 
modify the death domain of FADD [125] and in doing so, prevent DISC formation, 
thereby suppressing caspase activation and subsequent cell death [124].   
Infection can also induce inflammation in the host in order to promote the rapid 
recruitment of immune cells to combat potential pathogens and Fas ligation on 
intestinal cancer cells has been shown to enhance immune cell recruitment through 
the production of cytokines and chemokines.  For example, Fas signalling increases 
CXCL-1 chemokine production in alveolar epithelial cells that leads to enhanced 
neutrophil infiltration [108].   Furthermore, lpr mice exhibit reduced airway 
epithelial cell apoptosis, cytokine secretion, neutrophil influx, and tissue damage in 
models of pulmonary inflammation [116].  Similar results have been obtained using 
small interfering RNA (siRNA) targeted against Fas [127], suggesting that Fas-
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mediated inflammatory signalling may be important for effective pathogen clearance 
and host defence in mucosal tissues. 
 
1.5 Fas signalling in colon cancer 
Numerous studies have shown that the expression of FasL is upregulated in cancers 
of the gastrointestinal tract and this is thought to be an early event during neoplastic 
transformation [128-130]. The upregulation of FasL is associated with a poor clinical 
prognosis and resistance to chemotherapy [131].  By upregulating FasL, tumours are 
thought to be able to mount a counter attack against Fas-bearing tumour infiltrating 
lymphocytes, in effect potentially affording tumours the same immune privilege that 
is seen in areas such as the eye and the testis [132].  In support of this model, 
apoptosis of tumour infiltrating lymphocytes was increased within FasL-expressing 
areas of oesophageal, gastric and colonic tumours [133-135], while areas of human 
colon cancers expressing increased FasL exhibit reduced lymphocyte infiltration 
[136]. Moreover, subcutaneously injected colon cancer cells with reduced FasL 
expression exhibited reduced tumorigenicity, increased infiltration of TILs and an 
enhanced anti-tumour immune response in vivo [132, 137] providing functional 
evidence in favour of a role for FasL in colorectal cancer.  
Signalling through Fas by FasL has also been shown to mediate migration and 
invasion of tumour cells, and to play an important role in tumour recurrence 
following treatment of colorectal liver metastases. FasL is more frequently expressed 
in liver metastases than in primary colon carcinomas [138] [139], with FasL 
signalling shown to lead to the accelerated outgrowth of micro metastases [140] 
[141]. These data indicate that tumour-expressed FasL may also be important in the 
colonization of colon cancer cells in tissues distant to the original neoplastic site 
such as the liver [142].  
Despite extensive studies demonstrating a role for FasL in tumorigenesis, allograft 
studies, whereby cells were engineered to over-express FasL, demonstrated that FasL 
triggered extensive neutrophil recruitment and allograft destruction.  These 
neutrophil recruitment studies indicated that by recruiting tumouricidal neutrophils, 
tumour-derived FasL expression may potentially mediate tumour rejection [143-
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145].  A caveat to this conclusion is however necessary, since all studies used cells 
that were engineered to overexpress FasL, which is rarely reflective of the 
physiological situation.  
In contrast to the wealth of investigations into the role of FasL in tumorigenesis, 
there are relatively few studies focusing on Fas and its role in neoplasia.  The 
carcinogen, azoxymethane (AOM) can be used in combination with the 
inflammatory agent, dextran sodium sulphate (DSS) to induce colon cancer in rodent 
models [146]. An investigation into the potential role of Fas signalling in the 
intestine using the AOM/DSS mouse model demonstrated that deletion of intestinal 
cancer cell-expressed Fas resulted in a greater number of colonic tumours relative to 
mice with wild type intestinal cancer cells [147], perhaps suggesting that Fas acts as 
a tumour suppressor in this tissue.  However, since DSS was used to induce colitis in 
this investigation, the ensuing inflammation may have itself promoted colon 
carcinogenesis and therefore effectively negated a potentially protective effect of a 
reduction of tumour-expressed Fas.  Indeed another investigation suggested that Fas 
acts as a tumour promoter in the colon, with Fas deficiency leading to an increase in 
tumour burden relative to control mice with normal Fas expression levels [148]. 
Thus, the role of the Fas/FasL system in the intestine is unclear and warrants further 
characterisation. 
 
1.6 Innate immunity 
1.6.1 Pathogen Recognition Receptors  
 
The innate immune system constitutes the first line of host defence against infection 
and so plays a crucial role in the early recognition and initiation of a 
proinflammatory response to invading pathogens.  The innate immune response 
relies on recognition of evolutionarily conserved signature molecular structures on 
pathogens, termed pathogen-associated molecular patterns (PAMPs).  PAMPs are 
recognised by a limited number of germ line-encoded pattern recognition receptors 
(PRRs).  Several families of PRRs, including the membrane associated Toll-Like 
receptors (TLRs), the cytosolic NOD-like receptors (NLRs) and the RIG-I-like 
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receptors (RLRs), are known to play a crucial role in host defence (Figure 1.6.1.1).  
TLRs ligate and respond to PAMPS present on the cell surface or in host endosomes; 
NLRs recognise microbial molecules in the host cytoplasm whilst the RLRs promote 
a response to viral RNA strands present in the host. In addition, recent studies have 
suggested that human caspase 4, and the mouse homologue, caspase 11, play an 
important role in LPS-induced mortality [149] . 
PAMPs are essential invariant functional components of microorganisms not usually 
present in the host cell and are therefore distinguishable from “self”.  Major PAMPs 
are microbial nucleic acids, including DNA (e.g. unmethylated CpG motifs), double-
stranded RNA (dsRNA), single-stranded RNA (ssRNA), as well as lipoproteins, 
surface glycoproteins, and membrane components such as peptidoglycans, 
lipotechoic acid, lipopolysaccharide (LPS) and Flagellin.  PRRs can also recognize 
host factors as “danger” signals when they are present in aberrant locations or in 
abnormal molecular complexes such as heat shock proteins (HSP), and high-mobility 
group box protein 1 (HMGB1), and these are known as danger associated molecular 
patterns (DAMPs) [150, 151]. 
Following PAMP or DAMP recognition, PRRs activate a multitude of intracellular 
signalling pathways, including the MAPK signalling pathways, as well as activating 
transcription factors such as NF-κB. This ultimately results in the activation of gene 
expression and the synthesis of a broad range of molecules, including cytokines, 
chemokines, cell adhesion molecules and immunoreceptors, which together 
orchestrate the early host response to infection [152]  (Figure 3.6.1.1). 
  
Figure 1.6.1.1 Examples of known PRRs and their function.  
Members of each PRR family member specified above detect specific PAMPs 
from various pathogens as indicated. Upon recognition of each PAMP, the PRRs 
initiate a downstream signalling cascade leading to the eventual activation of 
transcription factors which in turn induce expression of the appropriate immune 
response genes.  
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1.6.2 The Toll-Like Receptors 
 
There are thirteen known mammalian TLR genes, eleven of which are expressed in 
humans.  TLRs vary in their distribution between the plasma and endosomal 
membranes; TLRs 1, 2, 4-6 are located at the plasma membrane whilst TLRs 3 and 
7-10 are found endosomally.  Cell surface TLRs mainly recognize microbial 
membrane components such as lipids and lipoproteins. For example, TLR4 
recognizes bacterial LPS and there is evidence to suggest the existence of viral 
ligands for TLR4 [153].  TLR2, along with either TLR1 or TLR6, recognizes a wide 
variety of PAMPs including lipoproteins, peptidoglycans, lipotechoic acids and 
zymosan.  TLR5 recognizes bacterial Flagellin.  Intracellular TLRs include TLR3 
and TLRs 7-10.  TLR3 recognizes viral dsRNA, small interfering RNAs and self-
RNAs derived from damaged cells whilst TLR7 is predominantly expressed in 
plasmacytoid DCs (pDCs) and recognizes ssRNA from viruses. Human TLR8 
responds to viral and bacterial RNA whilst TLR9 recognizes bacterial and viral DNA 
that is rich in unmethylated CpG-DNA motifs. Intracellular TLR10 has recently been 
shown to collaborate with TLR2 to recognize ligands from Listeria Monocytogenes 
[154]. A table showing the location of TLRs and their identified ligands is shown in 
Table 1. 
 
The TLRs are type I integral membrane receptors, containing an N-terminal ligand 
recognition domain, a single trans-membrane helix, and a C-terminal cytoplasmic 
signalling domain [155], known as Toll IL-1 Receptor (TIR) domains due to the fact 
that they share homology with the signalling domains of IL-1R family members 
[156].  The transmembrane domains of the TLRs each contain a typical stretch of 
approximately 20 uncharged, mostly hydrophobic, residues. The N-terminal ligand 
recognition ectodomains (ECDs) of TLRs are glycoproteins composed of 550–800 
amino acid residues [155].  PAMPs bind to the receptor ECD and induce the 
dimerization of the TIR domains, forming a scaffold for downstream signal 
transducers.  Cell-surface TLRs are monomeric but form active homo- or 
heterodimers when exposed to PAMPs.   
  
Receptor Location Ligand Ligand origin 
TLR1 Cell surface 
Multiple triacyl 
lipopeptides 
Bacteria 
TLR2 Cell surface 
multiple glycolipids 
multiple lipoproteins 
HSP70 
zymosan 
Bacteria 
Bacteria 
Host 
Fungi 
TLR3 
Cell 
compartment 
Double-stranded RNA Viruses 
TLR4 Cell surface 
lipopolysaccharide 
heat shock proteins 
fibrinogen 
Gram-negative bacteria 
Bacterial and host cells 
Host 
TLR5 Cell surface Flagellin Bacteria 
TLR6 Cell surface 
multiple diacyl 
lipopeptides 
Mycoplasma 
TLR7 
Cell 
compartment 
Single stranded RNA RNA Viruses 
TLR8 
Cell 
compartment 
Single stranded RNA  RNA Viruses 
TLR9 
Cell 
compartment 
Unmethylated CpG 
Olidodeoxynucleotide 
DNA   
Bacteria, DNA Viruses 
TLR10 
Cell 
surface/cell 
compartment 
?/L.monocytogenes 
ligand? 
?/bacteria 
Table 1 TLRs and their ligands 
Intracellular location of each TLR with their known respective ligands and the 
origin of each ligand. 
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Heterodimerisation between TLRs or the association with co-receptors such as CD14 
or CD36 increases the diversity of molecules that can be recognized by TLRs [157, 
158].  Whilst the majority of TLRs traffic directly to the cell surface after their 
synthesis, TLRs7–9 are synthesized as stable preformed dimers [159, 160]. 
Irrespective of the mode of dimerization, ligand-activation of TLRs brings the 
sequences at the C terminus of the two ECDs into close proximity which is 
imperative for downstream signalling. 
1.6.3 TLR signalling pathways 
There are 2 main adaptor proteins that bind to TLRs and facilitate signal 
transduction.  These are known as Myeloid Differentiation factor 88 (MyD88), and 
TIR-domain-containing adapter-inducing interferon-beta (TRIF). Signal transduction 
via MyD88 or TRIF can also be mediated by the bridging adaptor proteins, MyD88-
adapter-like (MAL) or TRIF-related adaptor molecule (TRAM) respectively (Figure 
1.6.3.1). MAL is a sorting adaptor that recruits MyD88 to cell surface TLRs such as 
TLR2 and TLR4. However, a recent study demonstrated that MAL also participates 
in signalling through endosomal TLRs such as TLR9 [161].  TRAM is selectively 
recruited to TLR4, but not TLR3, to link between TRIF and TLR4 whilst TLR3 
directly interacts with TRIF.   
MyD88 is a modular protein containing a death domain (DD) that is connected to a 
TIR domain by an intermediate domain. During MyD88-mediated TLR signal 
transduction, MyD88 assembles with the DD-containing IL-1R-associated kinase 
(IRAK) family, four of which are found in vertebrates:  IRAK1, IRAK2, IRAKM 
(also known as IRAK3) and IRAK4.  In vitro, the MyD88 DD forms a 
heterogeneous mixture of dimers and higher-order oligomers but in the presence of 
IRAK4, these assemble into a discrete heterocomplex, coined the Myddosome [162], 
the composition of which is thought to depend on the cellular context [163].  IRAK4 
phosphorylates IRAK1, which is also recruited to the complex, leading to its 
activation.  IRAK1 then dissociates from the complex and interacts with TNF 
receptor associated factor -6 (TRAF6).  TRAF6 is the activator of the canonical NF-
κB pathway (Hayden and Ghosh, 2004). TRAF6 becomes ubiquitinated at residue 
K63 and this modification allows TRAF6 to activate the next component in the 
pathway, which is most likely to be TGF-β activated kinase-1 (TAK1) (Sun et al., 
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2004). TAK-1 then activates the inhibitory κB (IκB) kinase complex leading to 
activation of NF-κB, and upstream kinases for the p38 and JNK MAPK signalling 
pathways, leading to the production of a number of cytokine and chemokines (Figure 
1.6.3.1). 
  
IRAK 4 IRAK 1 
NFκB 
ISRE3 ISRE7 
MAL 
TRAF 6 
   Iκβα 
   p65    p50 
   Iκβα degradation 
  RIP1 
  FADD 
Caspase 8 
TRAF 3 
IRAK1 
TLR5 
TLR6 TLR1 TLR2 
MyD88 
TLR4 TLR4 
LPS 
LPS 
TLR7  
or 
TLR8 
TLR9 
Flagellin 
Endosome 
TLR3 
dsRNA 
Iκκα 
Iκκβ 
Iκκγ 
NEMO 
   p65    p50 
TLR4 
Iκκε Iκκε 
TBK1 
IRF7 IRF3 
IRF7 IRF3 
TLR3 
NF-κB 
RAC 1 
PI3K 
   AKT 
Cell 
survival 
INFLAMMATION 
Cytokines and chemokines 
ANTIVIRAL 
IMMUNE 
RESPONSE 
Figure 1.6.3.1  Signal transduction of TLRs following ligand recognition.  
Following ligand recognition, each TLR initiates a downstream signalling cascade 
using adaptor molecules. All TLRs signal through MyD88 with the exception of 
TLR3 which requires TRIF. TLR4 and TLR5 may also signal through TRIF with the 
using TRAM. Recruitment of MyD88 to the TLR receptor initiates downstream 
activation of TRAF6, which in turn, activates NF-κB resulting in the transcription of 
inflammatory cytokines. Alternatively, if TLR4 is trafficked to the endosome upon 
ligand recognition, it recruits TRAM, which recruits TRIF. TLR3 also recruits TRIF 
upon ligand binding. This initiates downstream activation of TRAF3 and 
subsequently activates the IRF transcription factors which induces production of the 
anti-viral interferon genes. TLR-mediated MyD88 signalling can also lead to the 
activation of the PI3K cell survival pathway whilst TLR-mediated TRIF signalling 
has been shown to activate the apoptotic pathway. 
MyD88 
MAL 
MyD88 
MyD88 
MyD88 
MAL 
MyD88 
TRIF 
TRAM 
TRIF 
TRIF 
TRIF 
TRAM 
Type I 
IFNs 
APOPTOSIS 
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MyD88 is required by all TLRs for signal transduction except for TLR3, which uses 
the alternative adaptor protein, TRIF (Figure 1.6.3.1).  TLR3 has an alanine rather 
than a proline in the TIR domain BB loop which is unique to human TLRs and gives 
TLR3 its specificity for TRIF-dependant ligation and signalling.   Mutation of this 
one residue in TLR3 to proline causes a switch in adaptor protein specificity from 
TRIF to MyD88 resulting in attenuated IRF3-dependant signalling and enhanced 
NFκB activation [164].   Relative to MyD88, TRIF has a more complex 
multimodular structure of 712 amino acids. The α-helical N-terminal domain of 
TRIF is followed by a proline-rich region with binding sites for the downstream 
effector proteins TRAF2 and TANK-binding kinase 1 (TBK1).  The TIR domain and 
a receptor-interacting protein (RIP) homotypic interaction motif (RHIM) domain 
constitute the C terminus of TRIF [165-167]. The TIR domain of TRIF binds to 
TLR3. It can also bind to TLR4–TRAM leading to the binding of TBK1 and TRAF3, 
and ultimately the activation of IRF3 and/or IRF7. This pathway results in IRF1-
dependent type I interferon production via a mechanism involving the activation of 
IRF3.  TRIF can also activate NFκB by activating TRAF6 [166].   
Recently, it has been shown that TLR5 also utilises TRIF, at least in intestinal cancer 
cells, in a process that requires internalisation of TLR5 into endosomes [168].  
However, it is likely that TRIF mediated TLR5-induced responses are associated 
with regulating NFκB and MAPK activation rather than IRF-3 activation and IFN-β 
expression in order to mediate TLR5-dependent inflammatory responses.  Uniquely, 
TLR4 can activate both the MyD88 dependant and TRIF dependant (Myd88-
independent) signalling pathways with the LPS-induced production of 
proinflammatory cytokines such as TNF-α or IL-6 requiring both MyD88- and 
TRIF-dependent pathways [169, 170].  LPS is also capable of activating MyD88-
independant signalling in order to produce interferons [171]. 
Due to their integral role as sentinels of the innate immune response, TLR-mediated 
inflammation is of paramount importance in resolving infection and mediating tissue 
healing.  In addition to playing a key role in host defence against danger, activation 
of TLRs has been linked to the pathogenesis of many inflammatory and autoimmune 
diseases including rheumatoid arthritis (RA), sepsis, systemic lupus erythematosus 
(SLE), inflammatory bowel disease (IBD) and type I diabetes.   For example, TLR-
mediated microbial recognition in the intestine is important in the development of 
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chronic enterocolitis [172] and aberrant that the MyD88 dependant TLR-mediated 
signalling is thought to be responsible for the development of the atherosclerosis 
[173, 174].   In addition, in patients with SLE, the normally limited numbers of auto-
reactive B and T cells that are present in healthy individuals are expanded, producing 
large quantities of autoantibodies, directed especially against nuclear antigens such 
as those that act as TLR7 and TLR9 ligands [175].  Single nucleotide polymorphisms 
in the genes encoding TLRs have also been shown to confer a greater risk of 
developing infectious diseases.  For example, the relatively common D299G 
polymorphism in the TLR4 receptor increases the risk of Gram negative infections 
[176], and is associated with an increased incidence of systemic inflammatory 
syndrome [177].   
1.6.4 TLR expression and function in the intestine 
 
In the intestine, although all TLRs are expressed at the mRNA level, the expression 
of only TLRs 1-5 and 9 has been confirmed at the protein level by a number of 
different visualisation techniques.  TLR2 and TLR4 are known to be expressed at 
low levels in intestinal epithelial cells [178-180], while TLR3 expression is abundant 
in both the small and large intestine [181].  TLR5 expression is predominantly 
restricted to the colon [182, 183].  Intestinal epithelial cells are structurally and 
functionally polarised with an apical surface facing the intestinal lumen and a 
basolateral face facing the underlying basement membrane and there is evidence that 
TLRs are expressed in a spatially restricted fashion in the GI tract (Figure 1.6.4.1).  
For example, TLR2 and TLR4 were shown to be expressed on the basolateral surface 
of the ileal crypts [184]  whilst TLR9 has been found to be apically expressed in the 
murine colon [185].  Furthermore, in vitro, polarised intestinal cancer cells respond 
differently depending on whether they are exposed to apical or basolateral 
CpGODN, demonstrating that TLR function, as well as expression, can be polarised 
[186].   Although studies using polarised human  
 
  
Figure 1.6.4.1 TLR expression in intestinal epithelial cells 
TLRs are expressed in a spatially restricted fashion in IECs. The expression of 
TLR4, TLR5 has been shown on the basolateral surfaces of IECs whilst TLR2 and 
TLR9 are expressed on both the basolateral and apical surface of this cell type.  
Polarized expression of TLRs at either the apical or basolateral membrane may 
contribute to the discrimination between commensal and pathogen microbial 
signals. For example, signalling through apical TLR9 promotes the inhibition of 
NF-κB signalling in IECs, whereas TLR signalling from the basolateral pole 
promotes NF-κB activation.  
 
Adapted from ‘Intestinal epithelial cells: regulators of barrier function and immune 
homeostasis.’  Peterson and Artis, Nature Reviews Immunology 14, 141–153 
(2014) 
TLR2 
(apical) 
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intestinal cancer cells indicated that TLR5 is expressed only on the basolateral 
surface of the intestine, recent studies have indicated that functional TLR5 is also 
present on the apical surface of the murine ileum and is capable of inducing the 
production of CXCL-1, an IL-8 homolog, in response to commensal derived 
Flagellin [183, 187].   
The recognition of microbial products by TLRs leads to the induction of a variety of 
signalling pathways that regulate the host inflammatory response that is initiated 
upon pathogenic invasion.  For example, studies have shown that intestinal cancer 
cells stimulation with Flagellin leads to the TLR5-mediated production of IL-8 and 
macrophage inflammatory protein-3 alpha (MIP3α), proinflammatory cytokines that 
are important in driving both the innate and adaptive immune responses to 
pathogenic organisms in the colon [188, 189].  However, given the constant presence 
of the commensal flora, intestinal cancer cells must be maintained in a state of 
immune tolerance.  The expression of negative regulators of PRR signalling such as 
single Ig IL-1R-related molecule (SIGIRR) (also known as Tir8), Toll interacting 
protein (TOLLIP), peroxisome proliferator-activated receptor-γ (PPARγ) and 
interleukin-1 receptor-associated kinase monocytes/macrophages (IRAKM) by 
intestinal cancer cells, is critical in controlling the homeostasis and innate immune 
responses of the colon to enteric microflora.  The mechanism of TLR inhibition 
varies between these proteins.  For instance, SIGGIR, as an orphan receptor, binds to 
and therefore inhibits, TLR signalling by virtue of its TIR-domain [130].  By 
contrast, the mechanism by which TOLLIP down regulates TLR signalling is 
thought to be mediated by ubiquitination of the TLR4–CD14 complex [131].  
Commensal signalling through TLRs has been shown to result in the upregulation of 
TLR inhibitory proteins such as PPARγ [190] and recent evidence has demonstrated 
a role for the hypo responsiveness afforded by TLR inhibition in host defence. The 
exaggerated inflammatory, antimicrobial and proliferative responses driven by the 
IL-1 receptor reported in SIGIRR deficient mice rapidly deplete the intestinal 
microbial community.  This reduction in commensal gut microflora leads to a 
reduced ability to outcompete invading pathogens for space and nutrients, making 
the mice extremely susceptible to infection by C. rodentium and other intestinal 
bacterial pathogens.  Thus, by sacrificing maximal innate responsiveness by 
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intestinal cancer cells to commensal bacteria, resistance against bacterial pathogens 
is promoted in the intestine [191].   
In the GI tract, TLR signalling also regulates barrier function.  For example, TLR2 
activation has been shown to result in the reorganisation of Z01, a protein required 
for tight junction formation [192].  Treatment of intestinal cancer cells with TLR 
ligands in vitro resulted in increased transepithelial resistance, a measure of the 
strength of the tight junctions between intestinal cancer cells, suggestive of an 
increase in barrier function.  Furthermore, recent data have demonstrated that sensing 
of commensal bacteria by TLRs is important for the actual spatial segregation of the 
microbiota [193, 194] with studies showing that TLR signalling from Paneth cells is 
vital for the secretion of antimicrobial peptides and lectins that prevent the invasion 
of pathogenic bacteria.  Therefore, host intestinal cancer cells respond directly to the 
commensal microbiota through TLRs and enhance barrier function in a number of 
ways.  In support of this, intestinal cancer cells-specific deletion of TLR4 and NOD1 
or MyD88 impairs immunity to bacterial infections [195, 196].  Furthermore, 
although the majority of microbially-regulated genes involved in immune responses 
and barrier function are not dependent on the expression of MyD88 [197], MyD88 
deficient mice demonstrate impaired barrier function [198] indicating the importance 
of MyD88 dependant signalling in the colon.  MyD88 deficiency in some mouse 
strains also significantly alters the composition of the microbiota in a way that 
predisposes the conventionally raised host to viral infections.  It has been speculated 
that MyD88-dependant increases in the expression of the antimicrobial genes, Reg β 
and Reg γ, contribute to the clustering of specific bacterial communities which are 
responsible for protection against viral infections [197]. In addition, TLR5 knockout 
(KO) mice develop spontaneous colitis and also metabolic abnormalities on some 
murine genetic backgrounds [199, 200]. Microbiota transfer from diseased TLR5KO 
mice into GF wild type mice reproduced the observed metabolic disease phenotype 
strongly suggesting that the microbiota are responsible for the increased insulin 
resistance and adiposity observed upon TLR5 deficiency [200].  This phenomenon is 
not restricted to TLR5, as TLR2KO mice have been reported to suffer a similar 
phenotype [201].   
Ligation of TLRs on intestinal epithelial cells thus promotes the expression of 
antimicrobial peptides and regulates barrier function.  Furthermore, TLR signalling 
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on intestinal cancer cells is vital for the development of the gastrointestinal immune 
system.  In addition, TLR signalling can directly influence the commensal 
community which may have important consequences both in the prevention of 
pathogenic infection and also in the induction of disease in the colon and elsewhere. 
 
1.6.5 TLR signalling in the intestine in disease 
Given that TLRs induce the secretion of proinflammatory cytokines, dysregulation of 
TLR mediated signalling can lead to acute and chronic intestinal inflammation in the 
bowel, symptoms of which are characteristic of inflammatory bowel disease (IBD).  
Under healthy conditions, expression of the TLR 4 receptor complex is generally low 
in the intestinal mucosa [202-204], but is significantly upregulated in either 
nonactive and/or active human IBD colitis [204-206].  Additionally, the T-cell-
derived cytokines, such as interferon gamma (IFNγ) and tumour necrosis factor 
alpha (TNF-α), which have been shown to play significant pathophysiological roles 
in IBD, upregulate intestinal epithelial TLR4 expression in vitro [203, 207]
, 
suggesting that changes in the commensal composition in A genetically susceptible 
host may therefore result in aberrant TLR4 hyper responsiveness of the intestinal 
mucosa [199].
 
Patients with IBD are at increased risk of developing colon cancer and the risk is 
proportional to the degree of inflammation [208]. Consistent with a role for TLRs in 
the development of colitis-associated cancer (CAC), TLR4KO mice are protected 
against tumour development in the colon induced by the carcinogen azoxymethane 
(AOM) followed by dextran sodium sulphate (DSS) administration [209], a 
commonly used mouse model of CAC. Furthermore, it was shown that TLR4 
expression by intestinal cancer cells, rather than haematopoietic cells, was required 
for malignant transformation [210].  In support of this, increased TLR signalling by 
intestinal cancer cells was shown to increase the risk of inflammation-associated 
neoplasia [211, 212]. Moreover, SIGIRR KO mice develop increased inflammatory 
responses to AOM and DSS, and are more susceptible to CAC [211, 212]. As this 
phenotype can be rescued by the transgenic intestinal cancer cells expression of 
SIGIRR, the cancer phenotype of these mice was thought to result from dysregulated 
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TLR signalling in epithelial cells [211]. Furthermore, implanted TLR5-expressing 
colonic cancer cells stimulated by Flagellin, induced anti-tumour immunity and 
decreased tumour size, whereas knockdown of TLR5 expression resulted in 
increased tumour size [213].  Together, these studies suggest that intestinal cancer 
cells-mediated TLR signalling leads to increased inflammation, potentially 
promoting the development of inflammation-associated neoplasia in the intestine. 
The effect of decreased PRR signalling on tumour number and size in the Min mouse 
model has been studied by crossing Apc
Min/+
 mice with MyD88-deficient (MyD88
-/-
) 
mice. Although the overall incidence of intestinal tumours was similar in Apc
Min/+
 
mice and MyD88
-/-
/Apc
Min/+
 mice, the tumours were significantly smaller in the 
absence of MyD88 [214], suggesting that intestinal PRR signalling may contribute to 
the development of sporadic colon cancer [215]. 
There are also many reports suggesting that tumours are supported by the host 
through the recruitment of inflammatory cells that are generally immunosuppressive, 
including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), 
which can dampen the otherwise the proinflammatory immune response [216].  In 
support of this, TLR4 activation on colonic tumour cells has been shown to have a 
protective effect against anti-tumour cytotoxic T cells and NK cells resulting in 
increased tumour burden [217]. 
 
1.7 Crosstalk between the Fas and TLR signalling pathways  
Recent studies have provided evidence of a link between the Fas and TLR signalling 
pathways. Although Fas-mediated activation has been reported to directly activate 
key transcription factors and signalling pathways in order to induce the secretion of 
pro-inflammatory cytokines [218-221], several lines of evidence suggest that MyD88 
may play a role in Fas-mediated inflammation. For example, it was found that in 
macrophages, Fas-induced chemokine release was abrogated in the absence of 
MyD88.  Furthermore, in vivo, disrupting MyD88 signalling led to attenuated 
neutrophil in response to the murine agonistic Fas antibody, Jo-2 [222].  In addition, 
MyD88 silencing in vitro has also been shown to result in the attenuation of 
chemokine (C-X-C motif) ligand 1(CXCL-1) release from alveolar epithelial cells in 
38 
 
response to Jo-2 in vivo confirmatory studies demonstrating that MyD88-null mice 
are protected from Fas-induced acute lung injury [108].   
In support of Fas playing a role in TLR-mediated inflammation, peritoneal 
macrophages from lpr or gld mice have been shown to have a diminished ability to 
produce IL-6 in response to LPS [104].  These lpr mice exhibit suppressed LPS- and 
IL-1- induced NF-κB activation and cytokine expression suggesting that Fas ligation 
enhances IL-R1/TLR4 signalling to promote macrophage-mediated inflammation.   
Moreover, interruption of Fas ligation was shown to suppress IL-1R1 and TLR4-
induced IκBlα degradation in primary macrophages [104], suggesting that Fas 
ligation is able to modulate macrophage cytokine production by activation of NFκB.   
Further evidence for a role of Fas in TLR-mediated inflammation came from studies 
that suggested that FADD can interact with MyD88 and in doing so, suppress TLR-
mediated cytokine production.  In the absence of Fas signalling, FADD was shown 
to be present in the cytoplasm of macrophages bound to MyD88, potentially 
blocking/limiting MyD88 signalling [104, 223].  Following activation of Fas, FADD 
is recruited to the DISC which may sequester FADD away from MyD88, thereby 
promoting TLR-mediated inflammation (Figure 1.3.3.1).   Despite this compelling 
evidence, to the best of my knowledge, no study has directly investigated the 
crosstalk between the Fas and TLR signalling pathways in intestinal cancer cells. 
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1.8 Aims 
Therefore the aims of this study were to: 
1. Investigate the role of Fas signalling in intestinal inflammation and in 
particular the crosstalk between Fas and the TLR signalling pathways in 
intestinal cancer cells (Chapters 3 and 4). 
 
2. Given that chronic inflammation in important in cancer and that ligation 
of Fas can lead to the production of inflammatory cytokines and 
chemokines, I sought to investigate the role of Fas in colon cancer 
(Chapter 5). 
 
3. Furthermore, given the studies showing potential crosstalk between Fas 
and TLR4 in macrophages, and the studies showing that TLR4 
antagonism is beneficial in colon cancer, I sought to assess whether a 
reduction in tumour-expressed Fas has the potential to increase the 
efficacy of TLR4 antagonism (Chapter 5). 
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2. Material and Methods 
2.1   Materials  
All reagents were stored and prepared according to the manufacturer’s guidelines. 
 
2.1.1 Bacterial strains 
Escherichia coli strain K12 was obtained from the Alimentary Pharmabiotic Centre 
(University College Cork, Ireland).  Listeria monocytogenes strain EGD (serotype 
1/2a) was a gift from Professor C Hill (University College Cork).  Salmonella 
typhimurium strain SJW1103 (wild type) was a gift from Professor P. O’Toole.  
 
2.1.2 Cell lines and tissue 
HT29, HCT116, CT26, SW480, Jurkat T, HL-60 and THP-1 cells were obtained 
from the American Type Culture Collection (MD, USA).  Tissue from C57BL/6 
TLR2, 4 and 5 knockout (KO) and WT mice was kindly provided by the Alimentary 
Pharmabiotic Centre (University College Cork) whilst tissue from C57BL/6 MyD88 
and TRIF KO mice was obtained from P. Fallon Trinity College (Dublin, Ireland).  
These mice were originally generated by the Yale School of Medicine (TLR5 KO) or 
the Shizuo Akira laboratories (TLR2, TLR4, MyD88 and TRIF KO).  Briefly, the 
tlr2 [224], tlr4 [225], tlr5 [226], myd88 [161], and trif [170] genes were disrupted by 
homologous recombination replacing part or whole of the open reading frame of the 
relevant gene in E14.1 embryonic stem (ES) cells. ES cell clones were selected in the 
presence of neomycin and ganciclovir.  ES cell lines containing a mutant allele were 
microinjected into C57BL/6 blastocysts and heterozygous mice were intercrossed to 
produce TLR2, 4, 5 or TRIF or MyD88-deficient mice.  Mutant mice were born at 
the expected Mendelian ratio, were heatlhy and did not show any obvious clinical or 
behavioural abnormalities.  Northern blot analysis was performed to confirm that the 
mutations inserted inactivated the relevant genes. 
 
Tissue from Swiss Webster wild-type (WT) and germ-free (GF) mice was kindly 
provided by the Alimentary Pharmabiotic Centre (University College Cork).  GF 
mice were generated, colonized for 49 days, and tissue obtained.   
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2.1.3 Mice 
Six week old female Balb/C mice were obtained from Harlan (Oxon, UK) and 
maintained in the animal facility of University College Cork.  Standard housing and 
environmental conditions were maintained (temperature 21°C, 12 hrs light and 12 
hrs darkness with 50% humidity). Animals were fed sterile standard pellet diet and 
water ad libitum. Animal husbandry and experimental procedures were approved by 
the University College Cork Animal Experimentation Ethics Committee (AEEC). 
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2.1.4 Reagents 
2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one hydrochloride (LY294002) 
L9908 (Sigma Aldrich, Dublin, Ireland) 
4-[5-(4-Fluorophenyl)-2-[4-(methylsμlfonyl)phenyl]-1H-imidazol-4-yl]pyridine 
(SB203580) S8307 (Sigma Aldrich) 
2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide (TPCA-1) 
T1452 (Sigma Aldrich) 
Agarose A9414 (Sigma Aldrich) 
AgeI R0552S (New England Biosciences, MA, USA) 
Bovine Serum Albumin A9418 (Sigma Aldrich) 
BCA Protein Assay Reagents A and B 23223 and 23224 (Thermo Scientific, IL, 
USA) 
Brain-heart infusion broth 53286 (Sigma Aldrich) 
Dulbecco's Modified Eagle Medium D5796 (Sigma Aldrich) 
CCL-2 571402 (Biolegend, CA, USA) 
Collagenase Dispase solution 10269638001 (Roche Diagnostics, Basel, Switzerland) 
Crystal Violet Dye C3886 (Sigma Aldrich) 
Dimethyl sulphoxide D2650 (Sigma Aldrich) 
DPX mounting medium 44581 (Sigma Aldrich) 
EcoRI R0101S (New England Biosciences) 
Eosin 45260 (Sigma Aldrich) 
Ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate 
(TAK242) tlrl-cli95 (Invivogen, Toulouse, France) 
Ultra-pure FL-AST tlrl-epstfla (Flagellin) (Invivogen) 
Donkey serum D9663 (Sigma Aldrich) 
Gentamycin sulphate salt G1264 (Sigma Aldrich) 
Normal Goat serum X0907 (DAKO Diagnostics) 
Human recombinant IL-8 14-8089-63 (eBioscience, CA, USA) 
Heat-inactivated foetal calf serum F2442 (Sigma Aldrich) 
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Haematoxylin 51260 (Sigma Aldrich) 
Immobilon Western Chemiluminiscent HRP substrate WBLUF0500 (Merck 
Millipore, MA, USA) 
Ultra-pure LPS tlrl-pb5lps (Invivogen) 
Anti-fade fluorescent mounting media GM-304 (Dako)   
Luria-Bertani broth L3152 (Sigma Aldrich) 
Pam3CSK4 tlrl-pms (Invivogen) 
Penicillin/Streptomycin P4333 (Sigma Aldrich) 
Peptidoglycan – S. aureus tlrl-pgnsa (Invivogen) 
Phorbol 12-myristate 13-acetate (PMA) P1585 (Sigma Aldrich) 
Phosphate Buffered Saline D8662 (Sigma Aldrich) 
Polyinosinic-polycytidylic acid sodium salt tlrl-pic (Invivogen) 
Polyoxyethylene(20)sorbitan monolaurate (TWEEN) P1379 (Sigma Aldrich) 
Polybrene sc-134220 (Santa Cruz, Heidelberg, Germany) 
Protease inhibitor cocktail I 539131 (Merck Millipore) 
Puromycin P8833 (Sigma Aldrich) 
Oligodeoxynucleotide 2006 tlrl-2006 (Invivogen) 
Oligodeoxynucleotide 1826 tlrl-1826 (Invivogen) 
Tet-pLKO-puro plasmid #21915 (Addgene, MA, USA) 
Red cell lysis buffer R7757 (Sigma Aldrich) 
Resazurin powder R7017 (Sigma Aldrich) 
Tumour necrosis factor alpha 300-01A (PeproTech, NJ, USA) 
Triton X T8787 (Sigma Aldrich) 
Staurosporine from Streptomyces sp. S5921 (Sigma Aldrich) 
Xho1 R0146S (New England Biosciences) 
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Table 2   Antibodies used 
Target Dilution/
Conc. 
Species raised 
against 
Clone Host Source 
Fas 50μg/ml Human CH-11 Mouse Millipore 
Fas 100μg/ml Murine Jo-2 Rabbit BD Biosciences 
Fas 1 in 1000 Human C-20 Rabbit Santa Cruz 
Fas 1 in 500 Murine X-20 Rabbit Santa Cruz 
FasL 1 in 1000 Murine Ab15285 Rabbit Abcam, Cambridge 
UK 
TLR4 1 in 500 Human H-80 Rabbit Santa Cruz 
TLR5 1 in 500 Human  H-127 Rabbit Santa Cruz 
TLR2 1 in 1000 Human N/A Rabbit Novus 
TLR9 1 in 1000 Human N/A Rabbit Novus 
IGFR-β1 1 in 1000 Human C-20 Rabbit Santa Cruz 
TNFR-1 1 in 1000 Human C-20 Rabbit Santa Cruz 
β actin 1 in 5000 Human N/A Rabbit Sigma Aldrich 
FADD 1 in 200 Human H-181 Rabbit Sigma Aldrich 
MyD88 1 in 200 Human N/A Rabbit Santa Cruz 
IRAKm 1 in 500 Human N/A Rabbit Abbomax, CA USA 
SIGIRR 1 in 500 Human N/A Rabbit Pro-Sci, CA USA 
Lactoferrin 1 in 200 Murine N-20 Goat Santa Cruz 
F4/80 1 in 1000 Murine N/A Rabbit Santa Cruz 
FLAG 1 in 200 Human F1804 Rabbit Sigma Aldrich 
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Table 3 Oligonucleotide Primers and Universal probe Library probes 
 
Gene Name Forward Reverse UPL probe # 
TOLLIP caacctcgtcatgtcctacg gctggtacactgttggcatc 38 
SIGIRR tgaaagacgggcttccatt gacaggttggccttgacc 75 
PPARγ gacaggaaagacaacagac
aaatc 
ggggtgatgtgtttgaacttg 7 
IRAKm agagctctgcgctgttctg gctgcttgaaagtctctctgc 26 
CXCL-1 tcctgcatcccccatagtta tcctgcatcccccatagtta 52 
 
Table 4 Applied Biosystems® TaqMan® Probes 
 
Gene Name Probe 
Fas Hs00236330_m1 
FasL Mm01292781_m1 
TNFα Hs00174128_m1 
IL-8 Hs00174103_ml 
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2.2 Methods  
2.2.1 Cell culture 
 
Cells were cultured in 75cm
2
 flasks at 37°C in 5 % C02 in DMEM supplemented 
with 10% FBS and 10,000 units/ml penicillin, 10mg/ml streptomycin.  Cells were 
routinely grown to 70-80% confluence in T150 cell culture flasks before bi-weekly 
passaging.  Passaging involved washing cells with pre-warmed PBS and subsequent 
incubation with 3 ml EDTA to detach cells from the flask wall.  
2.2.2 Western blotting 
 
Cells were seeded at 1x10
5
 cells/ml into 6 well plates and then cultured until 60% 
confluent.  Cells were then treated as specified in the figure legends.  Following 
treatment cells were washed with ice-cold PBS and then lysed on ice for 1 hr with 
100ml of lysis buffer containing 50 mM Tris-HCl (pH 8.0), supplemented with 1X 
protease inhibitor cocktail (Merck Millipore, USA).   Cells were then scraped and 
transferred to a 1.5ml eppendorf.  Lysates were centrifuged at 14600 rpm at 4°C for 
10 mins.  The resulting cell debris was discarded and lysate was stored at -20°C. 
Protein standards were prepared using Bovine Serum Albumin (BSA) (Thermo 
Scientific, IL, USA) (0, 2.5, 5, 7.5, 10, 15, 20μg/ml) and added to a 96 well plate.  
2μl of each sample was added to the plate followed by 38μl of dH20.  Both standards 
and samples were analysed in triplicate.  160μl of BCA Protein Assay Reagent 
(Thermo -Scientific) was added to each well, the plate agitated and then left at 37°C 
for 30 mins before reading at 595nm on a spectrophotometer.   
The appropriate amount of cell supernatant containing 50µg of protein was mixed 
with 5 x PAGE loading buffer (125mM Tris, 2% SDS, 20% Glycerol, 2.5% beta 
mercaptoethanol) and lysis buffer (containing 50 mM Tris-HCl (pH 8.0) to a final 
volume of 20μl.  Samples were boiled for 5 mins before loading onto a separating 
and stacking SDS gel.  A 19-180 kilo Dalton (kDa) molecular weight marker (Sigma 
Aldrich) was run alongside the samples.  Proteins were separated by electrophoresis 
at 40mA and then transferred overnight onto an Immobilon –P polyvinylidene 
diflouride membrane at 40V and 4°C using a wet transfer method.  The following 
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morning, membranes were stained with Ponceau to check for transfer of proteins.  
Ponceau was washed with distilled water and PBS-0.1% TWEEN before membranes 
were blocked using 5 % (w/v) milk powder in PBS-0.1% TWEEN (hereafter referred 
to as blocking buffer) for 1 hr with rocking.  Membranes were washed for 5 mins in 
PBS-0.1% TWEEN before the appropriate primary antibody was added diluted in 
blocking buffer and stored overnight at 4°C.  Membranes were washed 3 times with 
PBS-0.1% TWEEN for 10 mins at a time, and then incubated for 1 hr at room 
temperature with the appropriate secondary antibody.  Finally, membranes were 
washed 3 times with PBS-0.1% TWEEN for 5 mins at a time before detection using 
an Immobilon Western Chemiluminiscent HRP substrate according to 
manufacturer’s instructions.  Protein bands were analysed using ImageJ (National 
Institutes of Health, Bethesda, MA, USA, http://imagej.nih.gov/ij/, 1997-2012.).   
Changes in protein expression were determined after normalising the band intensity 
of each lane to that of β-actin. 
 
2.2.3 RNA extraction 
 
Cells were lysed with 250μl of RNA lysis buffer and RNA extracted using the 
Bioline ISOLATE kit according to the manufacturer’s instructions.  Resultant RNA 
was quantified using a Nano drop. 
 
2.2.4 cDNA preparation and quantitative real-time polymerase chain reaction 
(qRTPCR) 
 
10 µl of total RNA was used as the template for cDNA synthesis using a 
commercially available cDNA synthesis kit according to the manufacturer’s 
instructions (Bioline, UK).  This was added to 1μl of Oligo (Dt), and 1μl of 10Mm 
dNTP and heated to 65°C for 10 mins.  Following 2 mins on ice, 4μl of 5x Reverse 
Transcriptase Buffer, 1μl of RNase inhibitor, 0.25μl of Reverse Transcriptase, and 
2.75μl of DEPC treated water was added to each sample before incubation at 37°C 
for 30 mins.  The reaction was terminated by a final incubation at 70°C for 15 mins 
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and chilling samples on ice.  2μl of cDNA template was amplified in a 25μl total 
reaction volume as per Applied Biosystems standard PCR protocol using appropriate 
probes and TaqMan Gene Expression Master Mix (Applied Biosystems, UK).  
Thermal cycling was performed in a machine (Applied Biosystems), with general 
conditions as follows:  50 °C for 2 mins; 95 °C for 10 mins; 60 cycles at 95 °C and 
60 °C for 1 min.  The results were analysed using the ΔΔ ct method and the gene of 
interest was normalized to the corresponding GAPDH results.  Data were expressed 
as fold induction relative to untreated. 
 
2.2.5 Resazurin Assay  
 
Resazurin powder (Sigma Aldrich) was hydrated with PBS under sterile conditions 
to make a 10 x stock solution (440μM).  The solution was filter sterilized using a 
0.22µm filter and stored in a foiled covered container at 4°C until use.  Media was 
aspirated off the 6 well plates and each well was washed once with PBS.  2ml of pre-
warmed 1x Resazurin solution was added to each well before measuring 
fluorescence at 535-590nm on a GenIOS fluorometer.  Fluorescence readings were 
taken at a variety of time points (5-55 mins) to create a standard curve of 
fluorescence against time.  Readings were subsequently taken during the log phase 
of the reaction. 
 
2.2.6 Caspase 3/7 Assay 
 
Cells were seeded overnight in black flat-bottomed 96-well plates at a density of 
20,000 cells/well, treated with CH-11 for 1hr and subsequently with 100ng/ml 
Flagellin or 100ng/ml LPS for 24 hr, or were treated with each agonist separately.  
Apo-ONE caspase-3/7 reagent was added and following 1 hr incubation, 
fluorescence (485 excitation, 530 emission) was measured using a GENios 
Microplate Reader (Tecan Group Ltd, Männedorf, Switzerland). Jurkat T cells were 
treated with 200ng/ml CH-11 as a positive control.  Changes in caspase 3/7 
activation were normalised relative to untreated cells.  
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2.2.7 Immunohistochemistry 
 
Formalin fixed and paraffin embedded murine colonic sections were deparaffinized 
and rehydrated using Xylene and an ethanol gradient (100%, 95%, 70% ethanol and 
then water).   The sections were then boiled with sodium citrate (pH 8) in order to 
induce epitope retrieval.  Sections were washed in Tris Saline solution (1% Tris 
Saline (0.05M) and 0.001% Saponin) hereafter known as wash solution, and blocked 
in 3% hydrogen peroxide.  Following a further wash in 1% normal goat serum 
(NGS) or normal rabbit serum (NRS) Wash solution, a blocking step in 5% NXS 
Tris Saline and a final wash, sections were incubated with primary antibody in 1% 
NXS Tris Buffer over night at 4°C.  The following morning, sections were washed 
with wash solution before incubation for 45 mins at room temperature with 0.5% 
biotinylated anti-Rabbit IgG or anti-goat IgG (Vector Laboratories, Inc CA, USA).  
A five minute wash step followed, after which the sections were incubated with ABC 
Elite complex (Vector Laboratories) for 45 mins at room temperature.  Sections were 
then washed and DAB substrate added (Vector Laboratories) according to 
manufacturer’s instructions.  Finally sections were washed in tap water, 
counterstained with Mayer’s haematoxylin (Sigma Aldrich), washed in tap water 
again before being mounted with crystal mount (Sigma Aldrich).  The specificity of 
the reaction was proven by staining with a normal rabbit IgG or normal goat IgG 
isotype control.  
 
2.2.7 Enzyme Linked Immunoassay (ELISA) 
 
IL-8 levels were quantified using the Human IL-8 ELISA Ready-SET-Go!® kit 
(eBiosciences, San Diego, USA) according to manufacturer’s instructions. 
 
2.2.8 Immunofluorescence  
 
Cells were seeded at 1x10
5
cell/ml onto EZ slides (Millipore) before fixing in 
methanol the following day.  Cells were permeabilised using 0.2% Triton X-100 
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before blocking in 10% normal donkey serum.  The slide was incubated with 
primary antibody overnight in 1.5% normal donkey serum at 4°C.  The following 
day, the slide was incubated in the appropriate secondary antibody diluted in normal 
donkey serum for 1 hr before counterstaining with DAPI and mounting with anti-
fade fluorescent mounting media.  Specificity of the reaction was proven by 
incubating with only primary or only secondary antibody.   
 
2.2.9 Cloning 
 
The pLKO-Tet-On vector was transformed into competent E.coli cells and streaked 
onto an ampicillin selective (50μg/ml) plate.  Following 24 hr incubation at 37°C, 
colonies were expanded, maxi-prepped and DNA purified using the Qiagen Maxi 
Plus Plasmid kit. The purified plasmid was digested with AgeI and EcoRI for 1 hr  
The digested plasmid was run on a 2% agarose gel to confirm excision of the 
‘stuffer’ fragment and subsequently gel purified using the QIAquick Gel Extraction 
Kit.  Oligomer sequences for shRNA against Fas were reconstituted and used in the 
subsequent ligation reaction with the pLKO-Tet-On purified plasmid at a final 
concentration of 0.1nml/μl. Stb13 cells were transformed with 4μl of ligation 
product, incubated on ice for 30 mins followed by heat shock for 45 seconds at 42°C.  
Cells were put on ice for 2 mins and 250μl of super optimal broth (SOC) media was 
added to each vial.  The SOC innoculum was left shaking at 225rpm at 37°C for 1 hr 
and 100μl of was spread onto prewarmed agar plates containing 50μg/ml 
carbenicillin. Stb13 cells were also transformed with the pUC19 control plasmid to 
confirm transformation efficiency.  After 48 hrs incubation at 37°C, colonies were 
grown in LB broth overnight containing 50μg/ml ampicillin and the following day 
mini-prepped using the Qiagen Miniprep kit.  The purified plasmids were digested 
with XhoI for 1 hr before running the digestion products on a 2% agarose gel. 
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2.2.10 Viability  
 
100μl of cell suspension was added to 900μl of Trypan Blue and 20μl was 
transferred to a haemocytometer. The number of stained cells was counted, in 
addition to the total number of cells and percentage viability assessed. 
 
2.2.11 Coimmunoprecipitation 
 
Initial optimisation experiments were performed by transfecting HCT116 cells with 
either 0.5, 1 or 2μg HA-tagged MyD88 constructs or with 1, 2 or 5 μg of FLAG-
tagged FADD constructs and protein expression detected by Western blotting.  The 
coimmunoprecipitation reaction was subsequently optimised by co-transfecting 
HCT116 cells with 2μg HA-tagged MyD88 and 5 μg FLAG-tagged FADD 
constructs. 25μl of anti-HA or anti FLAG was added to 100μl protein A agarose 
beads and incubated overnight at 4
o
C with agitation. Protein A agarose beads 
complexed with the relevant antibody was added to lysate and incubated at room 
temperature for 2 hrs.  The agarose bead/Ab complex was washed x2 with TBS and 
x2 with RIPA buffer. Lysate-agarose bead suspension was then washed x1 in 500μl 
water, with 100μl Laemmli buffer added. Samples were then heated to 95oC for 
5mins and run on a 15% SDS PAGE gel, transferred to PVDF membrane and 
immunoblotted with the relevant antibody. 
 
2.2.12 dHL-60 migration assay 
 
HL-60 cells were cultured in 75cm
2
 flasks with 1.3% DMSO for 5 days.  dHL-60 
cells were then seeded at 1.5x10
6
 cells/ml in the upper chamber of a 5μm pore size 
transwell.  750μl of supernatant derived from either untreated HT29scr shRNA or 
HT29
Fas shRNA
 cells, or from cells treated for 24 hrs with CH-11, Flagellin or LPS, 
was added to the lower chamber. 
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In order to control for dHL-60 cells migrating to LPS, Flagellin or CH-11 in the 
media, media alone or media conditioned with CH-11, Flagellin, LPS was added to 
the lower chamber. 20nM hrIL-8 was added in media to the lower chamber as a 
positive control. After 2 hrs cells that had migrated through the insert were 
immobilized onto a glass slide, fixed and stained by H&E.  Cells from 10 fields of 
view (x40) from each slide were counted and averaged.  
 
2.2.13 THP-1 derived macrophage migration assay 
 
THP-1 cells were seeded at 2x10
5
 cells/ml into the upper chamber of a 5μm pore size 
transwell in 10% FCS RPMI containing 10μM PMA.  750μl of 10% FCS RPMI was 
added to the bottom chamber of the transwell.  72 hrs later, the media in the bottom 
chamber was replaced with supernatants from SW480 cells, either untreated, or 
stimulated with CH-11, Flagellin, or LPS.  In order to control for THP-1 derived 
macrophages migrating to LPS, Flagellin or CH-11 in the media, media alone or 
media conditioned with CH-11, Flagellin, LPS was added to the lower chamber. 
54nM CCL2 was added in media to the lower chamber as a positive control.  After 6 
hrs incubation at 37
o
C, the insert was cut out of the upper chamber, washed twice in 
PBS and fixed in ice cold methanol for 5 mins. Inserts were then stained in 0.1% 
crystal violet in 0.1M borate pH 9.0 and 2% ethanol for 20 mins. Inserts were then 
washed 3 x 5 mins in PBS and placed into a 24 well plate containing 200μl of acetic 
acid to elute the stain.  Absorbance was read at 570nm. 
2.2.14 Generation of Fas 
Low/negative 
intestinal cancer cells 
 
Cells were transfected with lentiviral particles containing target-specific shRNA 
against Fas (sc-29311-V (human) or sc-29312-V (murine)) or control lentiviral 
particles containing scrambled shRNA (sc-108080) (Santa Cruz Biotechnology), 
according to the manufacturers’ instructions.  Cells were seeded in 12-well plates at 
a concentration of 7.5x10
3
 cells/ml.   Cells were infected 24hrs later with lentiviral 
particles in the presence of 4µg/ml polybrene, and cultured in selection medium 
containing 6-8μg puromycin until resistant clones could be identified.  Resistant 
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clones were selected by limiting dilution.   Knockdown of Fas expression was 
determined by Western blotting and functional analysis.  
2.2.15 Bacterial cell culture and infection 
 
L. monocytogenes was grown to the logarithmic growth phase in brain–heart 
infusion broth at 37°C shaking at 200 rpm, while S. typhimurium were grown in 
Luria–Bertani broth.  Bacteria were diluted in PBS for infection at multiplicity of 
infection (MOI) of 10:1. Intestinal cancer cells were seeded overnight at 
5x10
5
cells/ml and cultured with L. monocytogenes or S. typhimurium for 3hr   
Supernatant was removed and replaced with gentamycin-containing media 
(50ng/ml), and 24 hrs later cell culture supernatant was harvested.   SW480 cells 
were seeded overnight at 5x10
5 
cells/ml, stimulated for 1 hr with CH11(100ng/ml) 
and cultured with E. coli K-12 strain (10:1,bacteria:cells) for 8hrs.  Cells were lysed 
for subsequent RT-PCR analysis. 
2.3 In vivo studies 
For the initial in vivo study, female Balb/c mice were injected with either CT26
scr 
shRNA#1
 (n=4) or CT26
Fas shRNA#1
 cells (n=4) and tumour growth monitored over a 
period of 21 days.  A separate control group were injected with PBS only (n=3)  
The subsequent investigation compared two CT26
FasshRNA
 groups each with one 
control CT26
Scr shRNA
 group.  Data from the initial investigation indicated that the 
mean survival time (calculated as number of days to tumour growth) of the control 
group is 21 days (day at which the experiment was terminated) whilst mice injected 
with CT26
FasshRNA
 cells developed tumours after 9 days.  In order to reject the null 
hypothesis that the survival curves from the CT26
FasshRNA
 and CT26
Scr shRNA
 –derived 
tumours are the same with probability 0.800, 6 mice per CT26
FasshRNA
 and CT26
Scr 
shRNA
 group were required (n=6).  The type I error associated with this test is 0.05.  A 
separate control group were injected with PBS only (n=2). 
 
 
54 
 
2.3.1 Treatment groups and ear marking 
Mice were weight matched and divided randomly into groups.   Mice were ear 
clipped for identification purposes. 
 
2.3.2 Monitoring body weight 
 
Mice were weighed thrice weekly to monitor changes in body weight and for 
calculation of the appropriate dose of TAK242. 
 
2.3.3 Tumour formation 
 
Mice were subcutaneously injected into the right flank with CT26 cells suspended in 
100μl of PBS. Tumour formation was monitored thrice weekly by palpation at the 
site of injection.  The width (w) and length (l) of the tumours was measured using 
Vernier calipers and the mean tumour volume calculated using the formula: 
 ½ (l x w
2
). 
 
2.3.4 Drug administration  
 
TAK242 was administered at 1mg/kg bi-weekly in 100μl of sterile PBS to mice via 
intraperitoneal injection.  Alternate sides of the abdomen were injected to prevent 
inflammation by repeated injection at one site and no adverse effects were observed 
upon injection.  Assessments of the level of suffering of the animals under study was 
undertaken by way of a distress scoring sheet taking into account appearance, food 
and water intake, behaviour and any clinical indication of distress.  No side effects 
were noted in those mice administered with TAK242.   
 
2.3.5 Tumour sampling  
 
Following euthanasia by CO2 inhalation and cervical dislocation, tumours were 
excised from mice and dissected for subsequent analysis using a clockface dissection 
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method.  This method ensured that all stored tissue incorporated tumour tissue from 
the core to the leading tumour edge. Tissue was stored in liquid nitrogen for Western 
blotting and formalin for immunohistochemistry.  In addition, tissue was placed in 
an eppendorf containing 1 ml of a working solution of collagenase/dispase in PBS on 
ice.  
 
2.3.6 Single cell suspension of tumour cells 
 
Tumours in collagenase/dispase solution were incubated at 37
o
C for 1hr with 
shaking.  Tumour tissue was placed into a petri dish, 10ml of serum free DMEM 
added and cells were then passed through a cell strainer.  Cells were pelleted, washed 
in PBS and resuspended in 2ml of Red Cell Lysis Buffer. Following incubation at 
room temperature for 10 mins, 10% FCS DMEM media was added to stop the lysis 
reaction. Finally, a cell count was performed to obtain a final concentration of 1.x 
10
6
cells/ml. 
 
2.3.7 Flow cytometry 
200,000 cells per tumour sample were re-suspended in 200μl of cell staining buffer 
and samples were incubated with monoclonal antibodies against CD4 (T helper), 
CD8 (Cytotoxic T cells), CD49b (Natural killer cells), SIGLEC-F (eosinophils), 
LY6G+ (neutrophils), and F4/80 (macrophages) for 30 minutes on ice in the dark.  
Cells were then washed twice with 2 ml of cell staining buffer and centrifuged at 350 
x g for 5 minutes before being resuspended 0.5ml of cell staining buffer.   2.5ug/ml 
of ViViD viability staining solution was added per million cells and sample 
incubated on ice for 15 minutes in the dark. 
 
Debris was excluded from flow cytometric analysis by excluding those events with 
low forward scatter (FSC) and high side scatter (SSC) properties.  Singlets were 
defined by having a similar height (FSC-H) and area (FSC-A) measurement in the 
forward scatter. Live cells were identified (ViViD
neg
) and subsequently cell 
populations were assessed using the fluorescently tagged markers with Accuri C6 
Flow Cytometer System and CFlow commercial software. 
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2.4 Statistical analysis 
 
Experiments were performed a minimum of three times in triplicate. Results were 
statistically evaluated using One-way Anova with Tukeys post-test, or by students 
paired t test.  Values of p < 0.001 are indicated by three asterisks (***). Values of p 
< 0.01 are indicated by two asterisks (**). Values of p < 0.05 are indicated by one 
asterisk (*).  
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Chapter 3  
 
TLR 4 and TLR 5 upregulate Fas and FasL 
expression in intestinal cancer cells in vitro and 
in vivo 
  
58 
 
3.1 Introduction 
The gastrointestinal tract, along with other mucosal surfaces of the body, such as the 
airways, skin, and reproductive tract are continuously exposed to innocuous 
environmental antigens and commensal microorganisms that live in a mutually 
beneficial relationship with their mammalian hosts.  In fact the adult human intestine 
is home to an estimated 10
14
 commensal bacteria [227] and the microbial 
colonisation of the colon has been found to essential for the development and 
function of the gut associated lymphoid tissue (GALT).  For example, commensal 
bacteria have been shown to offer protection against tissue injury, as well as 
promoting angiogenesis [228-230] and essential for the maintenance of intestinal 
barrier function [231, 232].  In addition, commensals also aid in digestion, as well as 
in the absorption and storage of nutrients [6, 233, 234].   Mammalian intestinal 
epithelial cells (IECs) have therefore evolved to be broadly immunologically 
hyporesponsive to the commensal bacteria to which they are constantly exposed.  
They do this by a variety of mechanisms such as the limited and restricted 
localisation of expression of pathogen recognition receptors (PRR) (reviewed in 
[235]) as well as the upregulation of negative regulators of PRR signalling such as 
Single Ig IL-1-related receptor (SIGIRR) [236]. 
As crucial innate immune sensors in the intestine, studies of the family of PRRs 
known as the Toll-like Receptors (TLRs) have shown that the characteristic signal 
transduction pathways downstream of these receptors in intestinal cancer cells have 
both inflammatory and homeostatic roles following binding of their cognate ligands 
[237].  In the healthy colon, basal activation of TLRs, along with other PRRs, by the 
commensal bacteria, maintains barrier function and the crosstalk between intestinal 
cancer cells, intestinal microbes and local immune cells is a fundamental feature of 
intestinal homeostasis.  Colonisation of the colon, however, carries the risk of 
infection and inflammation if epithelial or immune cell homeostasis is disrupted and 
so TLR signalling in the intestine is necessarily tightly controlled [235]. 
Fas (CD95/APO-1) is a member of the tumour necrosis factor (TNF) superfamily. 
Members of this family function in a plethora of different cellular responses, 
including cellular differentiation, proliferation, and migration.  Fas is best known, 
however, for its role in apoptosis which is triggered upon binding of its cognate 
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ligand, FasL.  Fas receptor engagement induces the formation of a death-inducing 
signalling complex, resulting in the cleavage and activation of pro-caspase-8. 
Caspase-8, in turn, activates a caspase cascade, culminating in the apoptotic death of 
the Fas-bearing cell.  Fas is ubiquitously expressed throughout the human body, but 
is particularly abundant activated mature lymphocytes, in the liver, heart, brain, and 
colon tissues.  Studies have shown that Fas is constitutively expressed within the 
cytoplasm and at the basolateral surface of every colonic epithelial cell [238] 
irrespective of its location and early studies suggested that the Fas/FasL system was 
involved in the regulation of normal apoptotic cell turnover in epithelial crypts [119]. 
More recently, however, using mice deficient for Fas specifically in intestinal cancer 
cells, Fas has been shown to have a potentially cytoprotective role in a DSS model of 
experimental colitis, a result which is more suggestive of a protective rather than 
pro-apoptotic role in the intestine [147].  Indeed Fas has been shown to activate non-
apoptotic signalling pathways in intestinal cancer cells such as JNK activation [239] 
suggesting that the non-apoptotic outcomes of Fas signalling may predominate in the 
intestine. 
Fas expression is often modulated in diseases and pathological conditions.  For 
instance, Fas is upregulated in Parkinson’s disease [240] and is downregulated in 
many cancers [241, 242].  Moreover, expression of its ligand, FasL, has been shown 
to be increased in many cancers including that of the colon [128, 243].  Thus, 
dysregulation of the Fas/FasL system may contribute to pathologies of the colon. 
Given that IECs constitutively express Fas and FasL, expression levels of which are 
often altered in pathological circumstances, the mechanism by which expression of 
these proteins is regulated was investigated.  Studies have shown that activation of 
TLRs on macrophages can lead to an upregulation Fas expression [244-246], 
suggesting that stimulation of TLRs on intestinal cancer cells may also affect Fas 
and FasL expression.  To date, however, no studies have investigated the potential of 
TLR ligands to modulate Fas and FasL expression in the colonic epithelia. 
AIM – The aim of this chapter was to examine the effect of TLR ligands on the 
expression of Fas and FasL in human intestinal cancer cells. 
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3.2 Results 
3.2.1 SW480, HCT116 and HT29 human intestinal cancer cells express TLR2, 4, 
5 and TLR9 
 
To investigate if TLR ligands are capable of upregulating Fas and/or FasL 
expression in intestinal cancer cells, basal TLR expression was examined.  SW480 
human intestinal cancer cells have been previously shown to express TLRs 1-9 
[247].   As shown in Figure 3.2.1.1 a and b, expression of TLR4 and TLR5 was 
confirmed by immunofluorescence and Western blotting.  Expression of TLRs 4 and 
5 was also detected in two other cell lines examined, HCT116 and HT29.  Moreover, 
all three cell lines were shown to express TLRs 2 and 9 (Figure 3.2.1.1b). 
 
3.2.2 Fas and FasL are expressed in SW480 and HT29 human intestinal cancer 
cells 
 
The basal level of Fas and FasL expression in SW480 cells was investigated.  As 
shown in Figure 3.2.2.1, SW480 cells express a basal level of both Fas and FasL 
throughout the cytoplasm.  HT29 cells were also confirmed to express Fas and FasL 
(Figure 3.2.2.1b). 
  
TLR4 
TLR5 
Figure 3.2.1.1 Colonic epithelial cells express TLR4 and TLR5.  (a) SW480 
cells were seeded at 1x105cells/ml onto sterile coverslips.  24 hrs later, cells were 
fixed and immunofluorescently stained with anti-TLR4 or anti-TLR5 antibodies.  
Cells were counterstained with DAPI. Scale bar = 100μM.  (b) Cell lysates were 
separated by SDS-PAGE and probed with anti-TLR 2,4,5 or 9 antibodies.  β actin 
was used as a loading control.  
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Figure 3.2.2.1 SW480 and HT29 cells express Fas and FasL.  (a) SW480 cells or 
(b) HT29 cells were seeded at a concentration of 1x105cells/ml onto sterile 
coverslips. 24 hours later, cells were fixed and immunofluorescently stained with 
anti-Fas or anti-FasL specific antibodies.  Cells were counterstained with DAPI. 
Scale bar = 100μM. 
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3.2.3 Ligands for TLRs 4 and 5, but not TLR2 or TLR9, increase the expression 
of Fas and FasL in intestinal cancer cells  
 
In order to investigate a role for TLRs in the expression of Fas and FasL, SW480 
cells were treated with increasing concentrations of TLR ligands and changes in 
expression of Fas and FasL were examined  (Figure 3.2.3.1a).  Stimulation of cells 
with the TLR5 ligand, Flagellin, resulted in a significant increase in Fas (p<0.01) 
and FasL (p<0.01) mRNA expression (Figure 3.2.3.1a).  This was confirmed at the 
protein level by Western blotting (Figure 3.2.3.1b) with densitometric analysis also 
showing a significant increase in both Fas (p<0.01) and FasL (p<0.01) (Figure 
3.2.3.1c). 
Stimulation of SW480 cells with the TLR4 ligand, LPS also leads to an increase in 
expression of Fas and FasL both at the mRNA (Figure 3.2.3.2a) and protein (Figure 
3.2.3.2b) level.  Densitometric analysis confirmed that the upregulation of Fas 
(p<0.05) and FasL (p>0.01) expression upon LPS stimulation was significant (Figure 
3.2.3.2c). 
In contrast, Pam3CSK4, a TLR2 ligand, had no effect on the expression level of Fas 
and FasL in SW480 cells (Figure 3.2.3.3a).  In addition, treatment of SW480 cells 
with peptidoglycan (PGN), another TLR 2 ligand, failed to alter Fas expression 
(Figure 3.2.3.3b).  Similarly, transfection of SW480 cells with CpGDNA, a TLR9 
ligand, had no effect on Fas and FasL expression (Figure 3.2.3.3c).   
In order to verify that SW480 cells were capable of responding to TLR2 and TLR9 
ligands, SW480 cells were stimulated with Pam3CSK4 and CpGDNA and the 
expression levels of other proteins examined.  Stimulation of SW480 cells with 
Pam3CSK4 increased the expression of the gap-junction protein, Connexin-43 
(Cx43) (Figure 3.2.3.3d) while expression of the Wnt-signalling protein Frizzled5 
(Fzd5) was increased by TLR9 stimulation (Figure 3.2.3.3e).  These genes were 
selected as they have been previously shown to be activated by Pam3CSK4 and CpG 
DNA respectively, in intestinal cancer cells [185, 248].  Furthermore, despite failing 
to induce Fas and FasL in SW480 cells, peptidoglycan (PGN) induced a significant 
increase (p<0.01) in IL-8 secretion by these cells (Figure 3.2.3.3f). 
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Figure 3.2.3.1 Stimulation of SW480 cells with Flagellin upregulates Fas and 
FasL expression.  (a) SW480 cells were treated with increasing concentrations of 
Flagellin for 24 hrs.  Total RNA was extracted and Fas and FasL mRNA levels 
were measured by real-time RT-PCR. (b) Cell lysates were separated by SDS-
PAGE and probed with anti-Fas, anti-FasL or anti-β-actin specific antibodies.  
(c) Semi-quantitative analysis of Fas and FasL expression was determined by 
densitometry and normalised to β actin from 3 independent experiments. Values are 
plotted as Mean S.E.M.  (**p<0.01, *p<0.05 as compared to untreated control; one 
way ANOVA, Tukeys post hoc t-test). 
E
x
p
re
ss
io
n
 F
a
s 
re
la
ti
v
e 
to
 u
n
t 
40kDa 
42kDa 
Fas  
FasL  
β actin 
0
10
20
** 
** 
  Flagellin (10ng/ml)
 
   
  -                 +                -                +        
  
Fas FasL 
0.0
2.5
5.0
0
1
2
3
0      0.1    1      5     10      20
  
0      0.1    1      5     10      20  Flagellin 
(ng/ml) 
 
 
 
  
** 
* * 
** 
** 
** 
** 
F
o
ld
 c
h
a
n
g
e 
m
R
N
A
  
E
x
p
re
ss
io
n
 F
a
sL
 r
e
la
ti
v
e 
to
 u
n
t 
a) 
b) 
c) 
64 
42kDa 
LPS (ng/ml)         0           25        50       75        100       125
  
F
o
ld
 c
h
a
n
g
e 
m
R
N
A
  
0.0
2.5
5.0
7.5
10.0
12.5
48kDa 
40kDa 
Fas  
FasL  
β actin 
 LPS (100ng/ml)
    
 
 
  
  -                 +                -                +        
0
1
2
3
0
1
2
** 
*** 
*** * * 
0      25     50    75   100  125    0     25     50    75    100  125
  
 LPS  
(ng/ml)
 
 
 
  
Figure 3.2.3.2 Stimulation of SW480 cells with LPS upregulates Fas and FasL 
expression.  (a) SW480 cells were treated with increasing concentrations of LPS 
for 24 hrs.   Total RNA was extracted and Fas and FasL mRNA levels were 
measured by real-time RT-PCR.  (b) Cell lysates were separated by SDS-PAGE and 
probed with anti-Fas, anti-FasL or anti-β-actin specific antibodies. (c) Semi-
quantitative analysis of Fas and FasL expression was determined by densitometry 
and normalised to β actin from 3 independent experiments. Values are plotted as 
Mean S.E.M.  (***p>0.001, **p<0.01, *p<0.05 as compared to untreated control; 
one way ANOVA, Tukeys post hoc t-test). 
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Figure 3.2.3.3 Fas and FasL expression in SW480 cells is unaffected by 
stimulation with TLR2 and TLR9 ligands.  SW480 cells were treated with 
increasing concentrations of (a) Pam3CSK4 (b) PGN, and (c) CpG for 24 hrs.  Cell 
lysates were separated by SDS-PAGE and probed with anti-Fas, anti-FasL or anti-
β-actin specific antibodies.  SW480 cells were treated with (d) Pam3CSK4 or (e) 
CpG DNA for 8 hrs, total RNA was extracted, and Cx43 and Fxd5 mRNA levels 
were measured by real-time RT-PCR.  (f) SW480 cells were stimulated with PGN 
for 24 hrs and IL-8 levels measured by ELISA. Values are plotted as Mean S.E.M.  
(**p<0.01 as compared to untreated control; one way ANOVA, Tukeys post hoc t-
test). 
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3.2.4 The increase in expression of Fas and FasL in intestinal cancer cells in 
response to Flagellin occurs in an NFκB-, and PI3Kinase -dependant manner. 
 
TLR4 and TLR5 activate downstream signalling pathways such as the NFκB, the 
MAP kinase and the PI3K/Akt pathways.  In order to investigate which pathway was 
responsible for the upregulation of Fas and FasL by Flagellin, SW480 cells were pre-
treated with inhibitors of NF-B, PI3K, or p38 MAP kinase signalling pathways 
prior to stimulation with Flagellin.  TPCA-1, an IKKβ inhibitor, reduced Flagellin-
induced upregulation of both Fas (p<0.05) and FasL (p<0.05) expression (Figure 
3.2.4.1a and b). Pre-treatment of cells with LY294002, a PI3K inhibitor, also 
significantly prevented Flagellin-induced Fas (p<0.001) and FasL (p<0.01) 
expression (Figure 3.2.4.1a and c).  In contrast, pre-treatment of SW480 cells with 
SB208530, a p38 MAPK inhibitor did not alter the ability of SW480 to upregulate 
Fas or FasL in response to Flagellin (Figure 3.2.4.1a). 
 
3.2.5 The increase in expression of FasL on intestinal cancer cells in response to 
LPS occurs in a p38 MAP kinase-dependant manner. 
 
Similarly, SW480 cells were pre-treated with inhibitors of NF-B, PI3K, or p38 
MAP kinase signalling pathway prior to stimulation with LPS.  In contrast to the 
results seen with Flagellin, pre-treatment with the P13K inhibitor, LY294002 had no 
effect on the ability of LPS to upregulate FasL (Figure 3.2.5.1a and b).  The p38 
MAPK inhibitor, SB208530, prevented LPS-induced FasL upregulation (p<0.01) 
(Figure 3.2.5.1a and c) but did not prevent the induction of Fas by LPS.  Pre-
treatment of SW480 cells with TPCA-1 did not alter the ability of SW480 to 
upregulate Fas or FasL in response to LPS (Figure 3.2.5.1a). 
  
Figure 3.2.4.1  Pre-treatment with an NFκB inhibitor or a PI3K inhibitor 
prevents the upregulation of Fas and FasL by Flagellin. (a) SW480 cells were 
pre-treated with TPCA-1 or LY294002 for one hr prior to stimulation with 
10ng/ml Flagellin for 24 hrs. Cell lysates were separated by SDS-PAGE and 
probed with anti-Fas, anti-FasL or anti-β-actin specific antibodies. Semi-
quantitative analysis of Fas and FasL expression was determined by densitometry 
and normalised to β actin from 3 independent experiments for (b) TPCA-1 and (c) 
LY294002.  Values are plotted as Mean S.E.M.  (***p<0.001, *p<0.05 as 
compared to untreated control; one way ANOVA, Tukeys post hoc t-test). 
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Figure 3.2.5.1  Pre-treatment with a PI3K inhibitor prevents the 
upregulation of Fas by LPS whilst pre-treatment with a p38 kinase inhibitor 
LPS-induced FasL expression.  (a) SW480 cells were pre-treated with 
LY294002 or  SB208530  for one hr prior to stimulation with 100ng/ml LPS for 
24 hrs. Cell lysates were separated by SDS-PAGE and probed with anti-Fas, anti-
FasL or anti-β-actin specific antibodies.  Semi-quantitative analysis of Fas and 
FasL expression was determined by densitometry and normalised to β actin from 
3 independent experiments for (b) LY294002 and (c) SB208530. Values are 
plotted as Mean S.E.M.  (***p<0.001, **p<0.01, **p<0.05 as compared to 
untreated control; one way ANOVA, Tukeys post hoc t-test). 
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3.2.6 Fas and FasL expression is reduced in the colons of germ-free, TLR4 and 
TLR5 knockout mice. 
 
In order to determine the in vivo relevance of the induction of Fas and FasL 
expression by TLR4 and TLR5 ligands, colonic tissue from conventionally reared 
mice was assessed for Fas and FasL expression.  Initially, a number of different 
concentrations of anti-Fas and anti-FasL antibodies were used in order to determine 
the optimum concentration to best visualise the expression levels of these proteins in 
the colon tissue (Figure 3.2.6.1 a and b).  An isotype control was included in order to 
validate the specificity of the staining (Figure 3.2.6.1c).  
Fas and FasL were found to be expressed throughout the colonic epithelia of 
conventionally reared mice, from the basal to the apical face, in a uniform manner 
(Figure 3.2.6.1 and b).  In contrast, expression of Fas and FasL was reduced in the 
colonic epithelium of germ-free (GF) mice, as assessed by both 
immunohistochemistry (IHC) (Figure 3.2.6.2a) and Western blotting (Figure 
3.2.6.2b and c), consistent with the lack of exposure of the intestinal cancer cells to 
commensal flora and thus TLR ligation.  Conventionalisation of GF mice, however, 
restored Fas and FasL expression to levels to that seen in conventionally reared 
animals (Figure 3.2.6.2a), suggesting that Fas and FasL expression is, at least 
partially, dependent on colonisation of the colon by commensal bacteria. 
Since both LPS and Flagellin upregulated Fas and FasL in intestinal cancer cells in 
vitro, the expression levels of Fas and FasL in the distal colon of TLR4 and TLR5 
knock out (KO) mice were examined by IHC.  In contrast to the 
immunohistochemical staining pattern observed in wild type (WT) mice, colonic 
tissue from both TLR4KO and TLR5KO mice demonstrated a marked reduction in 
expression of both Fas and FasL (Figure 3.2.6.3a). This reduction in expression of 
Fas and FasL in TLR4KO colonic tissue was confirmed by Western blotting (Figure 
3.2.6.3b and c).  Unfortunately, whole cell lysate from TLR5 tissue was not available 
for Western blotting.   Consistent with the in vitro findings, Fas and FasL expression 
was unchanged in the IECs of TLR2KO mice, although it appeared somewhat 
reduced in the Western blot (Figure 3.2.6.3a and b).  Whole cell lysate from colon 
tissue contains a mixed population of cells, including absorptive and secretory cells, 
as well as a plethora of cells of a lymphoid origin, each of which may vary in their 
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expression of Fas and FasL.  Furthermore, it is impossible to quantify these different 
cell types within the lysate.  In contrast, immunohistochemical staining and 
subsequent microscopy affords visualisation at the single cell level, allowing for cell 
type identification. This may explain the discrepancy between expression levels 
observed using the two techniques when comparing colonic tissue from WT and 
TLR2KO mice. 
In order to investigate whether the reduction of expression of Fas and FasL in the 
colon of TLR4 and TLR5KO mice was specific, colon tissue was 
immunohistochemically stained for other proteins such as the Insulin Growth 
Receptor 1β, IGFR-1β.  As can be seen in Figure 3.2.6.4a, IGFR-1β is uniformly 
expressed throughout the epithelial cells of the colon and this is unchanged in the 
colon tissue from TLR4 and TLR5KO mice.  TNFR-1 is another member of the 
death receptor family and so its expression was also examined in the colon of TLR4 
and TLR5KO mice relative to WT.  Expression of TNFR-1 was found to be 
restricted to the apical surface of the colon in the wild type tissue and this pattern of 
expression was unchanged in the TLR4 and TLR5KO tissue (Figure 3.2.6.4b). 
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Figure 3.2.6.1  Optimisation of anti-Fas and anti-FasL antibodies for colon 
tissue immunohistochemistry.  Paraffin-embedded colon tissue sections were 
rehydrated and heat-induced antigen retrieval performed.  A range of dilutions of 
(a) anti-Fas (X20) and (b) FasL (ab15285) was used to immunohistochemically 
stain the tissue.  Brown indicates positive staining. (c) Staining with a normal 
rabbit IgG isotype control, (sc-2027) was performed as a negative control.  Scale 
bar = 100μM.   
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Figure 3.2.6.2  Expression of Fas and FasL is reduced in the colon tissue of 
germ-free mice relative to WT and conventionalised mice. (a) Paraffin-
embedded colon tissue sections from WT, GF and GF-conventionalised for 49 
days were rehydrated and immunohistochemically stained for Fas and FasL.  
Scale bar = 100μM.  (b) Protein was extracted from colonic tissue and changes in 
Fas, FasL and β actin detected by Western blotting. (c) Semi-quantitative analysis 
of Fas and FasL expression was determined by densitometry and normalised to β 
actin from 3 independent experiments.  Values are plotted as Mean S.E.M.  
(***p<0.001, as compared to wildtype tissue, one way ANOVA, Tukeys post hoc 
t-test). 
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Figure 3.2.6.3  Expression of Fas and FasL is reduced in the colon tissue of 
TLR4 and TLR5KO mice relative to WT mice.  (a) Paraffin-embedded colon 
tissue sections from WT, TLR2KO, TLR4KO and TLR5KO mice were rehydrated 
and immunohistochemically stained for Fas and FasL. Scale bar = 100μM.  Data 
shown are representative of colonic tissue obtained from 5 mice per group. (b) 
Protein was extracted from colonic tissue and changes in Fas, FasL and β actin 
detected by Western blotting.   Data shown are representative of tissue from 5 mice. 
(c) Semi-quantitative analysis of Fas and FasL expression was determined by 
densitometry and normalised to β actin from 3 independent experiments.  Values are 
plotted as Mean S.E.M.  (***p<0.001, as compared to wildtype tissue, one way 
ANOVA, Tukeys post hoc t-test). 
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Figure 3.2.6.4  Expression of  IGFR-β1 and TNFR-1 remains unchanged in 
the distal colon of TLR4 and TLR5KO mice relative to WT mice. Paraffin-
embedded distal colon tissue sections from wildtype, TLR4 KO and TLR5 KO 
mice were rehydrated and immunohistochemically stained for (a) IGFR-β1 or (b) 
TNFR-1. Scale bar = 100μM.  
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3.2.7 Expression levels of Fas and FasL is altered in other tissues from TLR4 
and TLR5KO mice. 
 
In order to further investigate the possible extent of alterations in Fas and FasL 
expression in TLR 4 and 5KO mice, tissue was assessed from other organs.  As can 
be seen in Figure 3.2.7.1a, Fas is expressed throughout the cytoplasm in the WT lung 
tissue, and this is greatly reduced in the TLR4 and TLR5KO tissue.  FasL is also 
expressed throughout the cytoplasm of the lung epithelium and its expression is 
markedly reduced in the epithelium of the TLR5KO lung tissue.  In the TLR4KO 
tissue, FasL expression appears to be completely abrogated.  In the spleen, FasL is 
expressed in the dense white pulp and, to a lesser extent, in the surrounding fibrous 
red pulp (Figure 3.2.7.1b and d).  Given the important role of FasL in immunity, this 
finding is in agreement with the literature as the white pulp is populated by T 
lymphocytes, which express high levels of FasL upon stimulation [249].  Expression 
levels of FasL in the TLR5 KO spleen tissue are reduced relative to the WT spleen.  
Fas is expressed primarily in the white pulp in the WT tissue [250] and this is also 
reduced in the TLR5KO tissue.   
Since the tissues examined in this study to date were either highly immunogenic (i.e. 
the spleen) or colonised by commensal bacterial flora (i.e. the colon and the lung), I 
next examined expression levels of Fas and FasL in other tissues such as the kidney 
and the brain.   FasL and Fas were found to be primarily expressed in the renal 
tubules of the kidney in WT tissue (Figure 3.2.7.2a and c), which is in agreement 
with the published literature [251].  Neither Fas nor FasL expression was affected 
upon TLR4 or TLR5KO in the kidney tissue.  Neuronal cells of the cerebellum were 
also found to express relatively high levels of Fas and FasL and this was unchanged 
in TLR4 and TLR5KO mice (Figure 3.2.7.2b).  These results suggest that the 
potential of TLR4 and TLR5 to regulate Fas and FasL expression may be tissue 
specific and/or dependant on the presence of commensal flora. 
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Figure 3.2.7.1  Expression of Fas and FasL is reduced in the lung epithelium 
and spleen of TLR4 and TLR5KO mice relative to WT mice. Paraffin-
embedded (a) lung and (b) spleen tissue sections from WT, TLR4KO and 
TLR5KO mice were rehydrated and immunohistochemically stained for Fas and 
FasL. Standard H and E protocol was used to stain (c) lung and (d) spleen tissue, 
rp = red pulp; wp = white pulp; a = arteriole. Scale bar = 100μM. 
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Figure 3.2.7.2  Expression of Fas and FasL remains unchanged in the kidney 
and cerebellum of TLR4 and TLR5KO mice relative to WT mice. Paraffin-
embedded (a) kidney and (b) cerebellum tissue sections from wildtype, TLR4 
KO and TLR5KO mice were rehydrated immunohistochemically stained for Fas 
and FasL.  Standard H and E protocol was used to stain (c) kidney and (d) 
cerebellum tissue, g = glomerulus, rt = renal tubule; ia = interlobular artery. Scale 
bar = 100μM 
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3.2.8 The altered Fas and FasL expression in TLR4 and TLR5KO mice may be 
due to differences in adaptor proteins  
 
The findings so far are suggestive of a level of specificity in the ability of TLR 
ligands to upregulate Fas and FasL in the intestine. One possible explanation for this 
specificity may be differences between the signalling pathways activated by the 
TLRs. Whilst all four TLRs examined in this study (TLR2, 4, 5 and 9) utilise the 
TLR adaptor protein, myeloid differentiation primary response gene (MyD88), only 
TLRs 4 [180] and 5 [252] utilise the adaptor molecule, TIR-domain-containing 
adapter-inducing interferon-β (TRIF). This utilisation of TRIF by TLR5 was shown 
specifically in intestinal cancer cells [253]. Therefore Fas and FasL expression in 
TRIF and MyD88 knockout tissue was examined. Expression of both Fas and FasL 
protein was significantly reduced in TRIF KO tissue, as assessed by both 
immunohistochemistry (Figure 3.2.8.1a) and Western blotting (Figure 3.2.8.1 b and 
c). Expression was also reduced, albeit to a lesser extent, in MyD88 KO tissue. 
These findings indicate that signalling through TRIF by ligands for TLRs 4 and 5, 
but not TLRs 2 or 9, may be responsible for the induction of Fas and FasL 
expression in intestinal cancer cells.    
  
MyD88 KO  TRIF KO Wild Type 
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FasL 
Figure 3.2.8.1.  Expression of  Fas and FasL is reduced in the distal colon of  
MyD88 and TRIF KO mice relative to WT mice.  (a)  Paraffin-embedded 
distal colon tissue sections from WT, TRIF KO and MyD88 KO mice were 
rehydrated and immunohistochemically stained for Fas and FasL.  Scale bar = 
100μM. (b) Protein was extracted from colonic tissue and changes in Fas, FasL 
and β actin detected by Western blotting.  Data shown are representative of 
tissue from 5 mice.  (c) Semi-quantitative analysis of Fas and FasL expression 
was determined by densitometry and normalised to β actin from 3 independent 
experiments *** p<0.001, Values are shown as Mean ± SEM. 
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3.3 Discussion 
I have shown that stimulation through TLRs 4 and 5 either by their cognate ligands 
or by commensal flora increases expression of Fas and FasL in vitro and in vivo in 
tissues that are either immunogenic or are exposed to a commensal bacterial 
population, i.e. the colon, the lung and the spleen.  It was also shown that this 
regulation of expression is specific to Fas and FasL and may be mediated by the 
TLR adapter protein, TRIF, in the colon. 
The regulation of Fas and FasL has been most extensively studied in T cells of the 
adaptive immune system, where expression of both receptor and ligand are 
upregulated upon T cell receptor crosslinking [254].  Recently, studies have 
characterised the role of Fas and FasL in cells of the innate immune system and 
upregulation of Fas by TLR 2, 3, 4, 7 and 9 ligands has been reported in 
macrophages [244-246].   To the best of my knowledge, no report has demonstrated 
an upregulation of Fas and FasL by PAMPs in intestinal cancer cells.  Treatment of 
SW480 cells with LPS and Flagellin led to an upregulation of Fas and FasL 
expression.  To determine whether TLR4 and TLR5 were specific in their ability to 
upregulate Fas and FasL expression in intestinal cancer cells, SW480 cells were 
stimulated with ligands for a number of other TLRs including TLRs 2, 3 and 9. 
Despite being generally responsive to TLR2 and 9 ligands, the expression levels of 
Fas and FasL were unaltered upon Pam3CSK4 and CpG-ODN stimulation of SW480 
cells.  Thus ligands for TLRs 2, 4, 5 and 9 were used in further investigations.  A 
recent study found that CpG-ODN is capable of downregulating FasL expression on 
HepG2 cells, a hepatocellular carcinoma cell line [255].  This group also found that 
treatment with CpG-ODN down-regulated the expression of Fas in human Jurkat 
cells.  These observations are in contrast to the lack of response in intestinal cancer 
cells seen here.  CpG-ODNs are short synthetic single-stranded DNA molecules 
possessing a partially or completely phosphorothioated (PS) backbone and contain 
unmethylated CpG motifs.  There are three major classes of stimulatory CpG-ODNs 
which differ in their structure and ability to activate different cell types [256-258].  
intestinal cancer cells have previously been shown to be responsive to CpG ODN 
2006 [185], a class B CpG-ODN, which is the molecule used in this study to 
stimulate intestinal cancer cells.  In contrast, Zheng., et al used the C-class CPG-
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ODN M362 on liver-derived and immune cell lines [255]; differences which may 
explain the contrasting observations in terms of Fas and FasL expression. 
TLRs are capable of initiating a wide variety of signalling cascades including the 
activation of NF-κB and of the p38 MAP kinase signalling pathways [259, 260].  It 
has been demonstrated here that the NF-κB and P13Kinase pathways are important 
for Flagellin-driven upregulation of Fas and FasL expression whilst FasL expression 
regulation initiated by LPS stimulation involves the activation of the p38 MAPK 
pathway.  The FasL promoter region has been shown to have two distinct NFκB 
binding sites and NFκB has been shown to directly regulate FasL expression [35].  
Recently, 3 NFκB sites have also been found in the Fas promoter region which, 
when methylated, lead to the reduced binding of this transcription factor [261].  
Additionally, NF-κB has been implicated in the induction of Fas expression by TNF-
α stimulation [31, 262].  The PI3K pathway also has been shown to be important in 
the regulation of FasL expression.  For example, phosphorylation of MADS box 
transcription enhancer factor 2 by Extracellular-signal-regulated kinase 5 enhances 
its transcriptional activity downstream of PI3K activation, although in fibroblasts 
this led to a downregulation of FasL expression [263].  Furthermore, consistent with 
the data presented here demonstrating that the p38 kinase inhibitor, SB208530, 
prevented LPS-induced FasL expression in intestinal cancer cells, transcription 
factors important for FasL expression have been shown to be phosphorylated and 
subsequently activated by p38 [264-266].  Thus, a number of diverse signalling 
pathways upstream of a myriad of transcription factors are responsible for the 
regulation of Fas and FasL expression, some of which may be cell or tissue-specific.  
My results indicated that in intestinal cancer cells, multiple pathways exist that are 
capable of regulating Fas and FasL expression. 
GF mice showed markedly reduced Fas and FasL in the distal colon which supports 
the hypothesis that TLR signalling regulates the expression of Fas and FasL in the 
colon.  Conventionalisation for 49 days however effectively reversed or ‘rescued’ the 
expression levels back to those seen in WT tissue suggesting that pathogen 
associated molecular pattern (PAMP) signalling through TLRs is responsible for this 
alteration.   
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Consistent with this, Fas and FasL expression was also reduced in the epithelial cells 
of the colon of TLR4 and TLR5KO mice.  Since there was no change in TLR2 
knockout mice, this suggests a level of specificity to the ability of TLRs to regulate 
Fas and FasL expression in the colon.  These results are in contrast to a report that 
has shown that TLR2 is capable of increasing Fas expression on macrophages [246], 
which serves to again indicate the importance of cell lineage for this phenomena.    
The lung epithelia, like the colon, forms a mucosal surface primed for pathogen 
entry by both expressing PRRs, and being constantly exposed to PAMPS [267].  
Furthermore, the lung also has a commensal microbiota with which it interacts for 
homeostatic and protective purposes [268].   Consistent with this, a reduction in 
expression of Fas and FasL was evident in lung tissue from TLR4 and TLR5KO 
mice relative to WT mice. 
Within the intestine, immune cells are distributed amongst the GALT.  The M cells 
contained in such tissue constantly sample the luminal microenvironment of the gut.  
A recent study has shown that antigens administered orally via the bacterial poly-
component vaccine Immunovac-VP-4, which contains a wide panel of PAMPs not 
only led to an increased population of rapid effector cells of mucosal immunity in 
GALT [269] but also a concurrent increase in the spleen, the organ in which they are 
activated  [270, 271].  These findings therefore confirm that there is an interchange 
of lymphocytes between the GALT and the spleen.  Furthermore, it is thought that 
dendritic cells present in the lamina propria are actually able to open the tight 
junctions between epithelial cells in order to send dendrites outside the epithelium 
and therefore are able to directly sample bacteria [272].  Being migratory, DCs can 
then transport pathogens to the mesenteric lymph node and the spleen for the 
induction of systemic immune responses.  The trafficking of immune cells from 
mucosal surfaces is therefore a likely way in which PAMPs are able to alter 
expression levels of Fas and FasL in resident cell populations of the spleen.   
Unlike the lung or colon, the kidney is rarely exposed to bacterial or viral PAMPs 
and although TLRs are expressed by renal cells, their activation remains largely 
limited to the action of danger associated molecular pattern (DAMPS) rather than 
exogenous PAMPS.   Indeed, it is the high levels of endogenous TLR ligands such as 
High-mobility group box 1 (HMGB1) reported in the injured kidney that are likely to 
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be responsible for chronic kidney disease [273, 274].  In this study, kidney tissue 
from TLR4 and TLR5 KO mice showed unaltered expression levels of Fas and FasL 
consistent with the kidney being a relatively sterile environment.   
The blood brain barrier (BBB), the major structure responsible for transporting 
molecules and cells selectively into the central nervous system (CNS), maintains 
relative immune deficiency inside this compartment [275].  Furthermore, endothelial 
cells of the BBB express FasL [276], which significantly limits the extravasation of 
Fas-bearing inflammatory cells thus suppressing the immune response in the CNS.  
Given this immune privilege, it is likely that the expression of Fas and FasL is 
regulated in the brain by means other than TLR ligation which would explain why 
expression was unchanged in brain tissue from TLR4 and TLR5KO mice relative to 
WT. 
The differential use of TLR adaptor proteins helps to explain the distinct pathways 
activated by TLRs and this, too, is likely to be tissue specific.  Upon TLR ligation, 
signalling cascades are activated via Toll/IL-1 receptor (TIR) domain-containing 
adaptors, such as MyD88, TIR-domain containing adapter protein (TIRAP), and Mal 
so eliciting inflammatory responses.  It is well known that TLR4 utilizes a 
combination of both Mal/TIRAP-MyD88 (MyD88-dependent pathway) and TRAM-
TRIF (MyD88-independent pathway) to transduce its signal.   Recently, TLR5 has 
also been shown to utilise TRIF in intestinal cancer cells [277].  Interestingly, this 
group showed that impaired TRIF expression reduced TLR5-induced NFκB and 
MAPK activation in response to Flagellin, an observation that supports the finding 
here that inhibition of NFκB prevented Flagellin induced upregulation of Fas and 
FasL.  Convincingly, expression of Fas and FasL was greatly reduced in TRIF KO 
mice, with only a modest reduction observed in MyD88 KO mice.  In contrast, 
neither TLR2 nor TLR9 have been reported to use TRIF, consistent with a failure of 
TLR2 and TLR9 ligands to upregulate Fas and FasL.  Furthermore, a recent study 
examining the respective importance of TRIF-dependant versus MyD88-dependant 
gene expression in intestinal cancer cells revealed that the number of TRIF-
dependent genes far exceeded the number of genes regulated by MyD88 [278].  This 
suggests that the specificity of TLR-induced upregulation of Fas and FasL in 
intestinal cancer cells may be due to the ability of TLRs 4 and 5 to utilise TRIF. 
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In conclusion, this chapter has contributed evidence for an unappreciated role of 
TLRs 4 and 5 in the regulation of Fas and FasL expression in the intestine. These 
finding are significant as they demonstrate a hitherto unknown link between Fas and 
FasL expression and the presence of commensal flora in the intestine.   
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Chapter 4  
Fas as a modulator of intestinal TLR-mediated 
inflammation. 
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4.1 Introduction 
Communication between the normal gut flora and the underlying intestinal 
epithelium has an essential role in promoting homeostasis and epithelial integrity in 
the intestinal mucosa.  Intestinal epithelial cells (IECs) express a comprehensive 
panel of pathogen recognition receptors (PRRs) by which they are able to respond to 
luminal bacteria.  These include the toll-like receptors (TLRs), nucleotide-binding 
oligomerization domain-like (NOD-like) receptors, the retinoic acid-inducible gene 
1-like (RIG-I) receptors, the RNA helicases and the C-type Lectins.  The recognition 
of pathogen activated molecular patterns (PAMPs) by TLRs on the cell surface or 
the endosomal surface of intestinal cancer cells leads to a swift immunological 
response via the production of pro-inflammatory and immune molecules produced in 
a variety of different ways such as the MAPK and p38 ERKs signalling pathways 
and the activation of transcription factors such as NFκB.  For example, studies have 
shown that Flagellin activates TLR5 on intestinal cancer cells leading to the 
secretion of a number of pro-inflammatory cytokines and chemokines from intestinal 
cancer cells such as IL-8 and MIP3α.  These are important in driving both the innate 
[188] and adaptive immune responses in the colon to enteropathogenic organisms 
[189].  Similarly, despite generally having relatively low expression levels of TLR4, 
intestinal cancer cells have been found to have a functionally active response to LPS 
resulting in NFκB activation and resulting in the induction of pro inflammatory 
cytokines [178, 180].  In this way, the detection of PAMPs by PRRs is thought to 
lead to clearance of gut infecting pathogens and the resolution of infection.  If 
pathogens cannot be eliminated, chronic inflammation may occur and aberrant PRR 
signalling is thought to be a central contributor to the pathophysiology of 
inflammatory bowel disease (IBD).  Indeed genetic-association studies have 
demonstrated a link between PRR genes, including NOD2, NLRP3 and a number of 
TLR genes with IBD susceptibility [235, 279]. 
Signals from commensal bacteria are also mediated via intestinal cancer cell PRRs 
and they have been shown to contribute to epithelial homeostasis and repair [228].  
Mice that are deficient in the TLR adaptor protein, MyD88, exhibit enhanced 
apoptosis of epithelial cells and diminished epithelial cell proliferation in response to 
dextran sodium sulphate (DSS) relative to DSS-treated wild-type (WT) mice [280], 
indicating that signalling through MyD88 in IECs is protective in the colon.  
88 
 
Similarly, loss of TLR2 has been shown to lead to an exacerbation of intestinal 
inflammation in DSS colitis which is associated with high morbidity and mortality 
[281].  Intestinal cancer cell-derived PRR signalling has been shown to lead to the 
expression of cytoprotective heat-shock proteins, epidermal growth factor receptor 
ligands [228] [282], and Trefoil Factor 3 [283] as well as promoting tight junction 
formation [192, 284], all of which are important in epithelial integrity and 
homeostasis.  Microbial sensing by PRRs on IECs also drives the recruitment of 
stromal and myeloid cells to the intestinal mucosa, thereby facilitating regeneration 
of the epithelium after injury [285, 286]. Studies have also shown that the intestinal 
microbiota have a considerable effect on the development of the gastrointestinal 
tract.  Germ-free (GF) mice have a reduced intestinal surface area in comparison to 
conventional mice; are impaired in brush border differentiation, and have reduced 
villus thickness [287].  These defects have been attributed to the reduced cell 
regeneration and a longer cell cycle of the crypt cells in GF mice relative to 
conventionalised animals [288]. Furthermore, new-born mammals have been found 
to have a functionally and structurally immature gastrointestinal (GI) tract that is 
only matured upon colonisation [289].  These data indicate that bacterial signalling 
through PRRs is essential for GI development and homeostasis. 
Given the constant presence of the commensal flora, intestinal cancer cells must 
therefore be maintained in a state of immune tolerance.  The expression of negative 
regulators of PRR signalling such as single Ig IL-1R-related molecule (SIGIRR) 
(also known as Tir8) and Toll interacting protein (TOLLIP), peroxisome 
proliferator-activated receptor-γ (PPARγ) and interleukin-1 receptor-associated 
kinase monocytes/macrophages (IRAKM) by intestinal cancer cells, is critical in 
controlling the homeostasis and innate immune responses of the colon to enteric 
microflora.   Commensal bacteria have been shown to upregulate the expression of 
TLR inhibitory proteins on intestinal cancer cells and intestinal cancer cells deficient 
in SIGIRR are more susceptible to commensal-dependent intestinal inflammation 
[290].  This indicates that the intrinsic expression of TLR inhibitory proteins by 
intestinal cancer cells in response to commensal bacteria regulates the 
communication between commensal bacteria and the host immune system [291].   
Fas (APO-1/CD95) is a membrane receptor also expressed in the intestinal 
epithelium and studies have shown that Fas is constitutively expressed within the 
89 
 
cytoplasm and at the basolateral surface of every colonic epithelial cell [238] 
irrespective of location.   Engagement of Fas with its ligand, FasL, has been well 
characterised in terms of apoptosis. Fas associated death domain, FADD, is recruited 
to the receptor and the death inducing signalling complex (DISC) is formed.  The 
DISC activates the initiator protease, caspase-8, which triggers activation of the 
effector proteases, caspase-3 and -7, that drive the cellular changes characteristic of 
apoptosis. Since expression of FasL is highly limited in the intestine [238], the 
Fas/FasL system is unlikely to play a role in epithelial regeneration.   In ulcerative 
colitis (UC), although the number of Fas-positive cells in the intestine is increased, 
investigations have shown that Fas-mediated apoptosis is inhibited rather than 
increased, and it is now the augmented immune cell infiltrate that is considered to be 
the major cause of the clinical characteristics of IBD [123, 292]. 
In contrast to its role in mediating cell death, Fas has been shown to also activate 
non-apoptotic signalling pathways in a number of different cell types including 
macrophages, neuronal cells and intestinal cancer cells [101, 104, 221] with Fas 
ligation shown to induce the production of a number of pro inflammatory cytokines 
including IL-8, IL-6 and MCP-1 in intestinal cancer cells [221, 293].  The role of Fas 
in inflammation has also been assessed using lpr mice, which lack a functional Fas 
receptor and thus cannot be activated by FasL.  In models of pulmonary 
inflammation, lpr mice exhibit reduced cytokine secretion and neutrophil influx, 
together with a reduction in epithelial cell apoptosis and tissue damage [117] [118]. 
Although Fas has been reported to directly activate key transcription factors in order 
to induce the secretion of pro-inflammatory cytokines [218-221], several lines of 
evidence suggest a level of crosstalk exists between the Fas and the TLR signalling 
pathways [104, 108, 222, 223].  Peritoneal macrophages from lpr or gld (FasL 
deficient) mice have been shown to have a diminished ability to produce IL-6 in 
response to LPS [104].  These lpr mice exhibit suppressed LPS and IL-1 induced 
NF-κB activation and cytokine expression suggesting that Fas ligation enhances IL-
R1/TLR4 signalling to promote macrophage-mediated inflammation.   Furthermore, 
interruption of Fas ligation was shown to suppress IL-1R1 and TLR4-induced IκBlα 
degradation in primary macrophages [104], thus suggesting that Fas ligation is able 
to modulate macrophage cytokine production by activation of NFκB.   
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Cross talk between Fas and TLR signalling has also recently been investigated in 
alveolar epithelial cells where investigators determined that Fas-induced 
inflammation occurred in a MyD88-dependant manner [222].  However, to the best 
of my knowledge, no study has directly investigated the crosstalk between these 
pathways in intestinal cancer cells. 
AIM:  The aim of this chapter was to determine if crosstalk exists between the Fas 
and TLR signalling pathways in intestinal cancer cells. 
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4.2 Results 
4.2.1 Stimulation with agonistic Fas antibody and TLR4 or TLR5 ligands alters 
intestinal cancer cell-mediated cytokine production. 
 
In the previous chapter, I demonstrated that TLR4 and 5 activation leads to the 
upregulation of expression of both Fas and FasL in intestinal cancer cells.  As both 
TLR and Fas receptor engagement have been shown to independently induce the 
production of inflammatory cytokines in intestinal cancer cells, I next examined the 
response of these cells to simultaneous stimulation of Fas and TLR4 or TLR5.  
SW480 cells were pre-treated with the agonistic Fas antibody, CH-11, prior to 
stimulation with either LPS or Flagellin. Cytokine gene expression was initially 
analysed by qRT-PCR.    
Treatment of SW480 cells with CH-11 resulted in a ~ 3 fold increase in TNFα 
production over untreated levels. Whilst LPS treatment led to a ~5 fold induction in 
TNFα transcription, stimulation of SW480 cells with CH-11 followed LPS resulted 
in a greater fold TNFα induction relative to LPS alone (p<0.01) (Figure 4.2.1.1a).  
Flagellin also induced a ~5 fold increase in TNFα production in SW480 cells and 
transcription of TNFα was augmented when cells were pre-treated with CH-11 
followed by Flagellin treatment, relative to Flagellin treatment alone (p>0.001).  
Treatment of SW480 cells with CH-11 resulted in a ~5 fold increase in IL-8 relative 
to untreated levels (Figure 4.2.1.1b).  Whilst LPS treatment led to a ~8 fold induction 
in IL-8 transcription, stimulation of SW480 cells with CH-11 followed by LPS 
resulted in a greater fold increase in IL-8 production relative to LPS alone (p<0.001).  
Similarly, whilst a three-fold increase in IL-8 was seen upon Flagellin treatment, 
stimulation with CH-11 with subsequent Flagellin stimulation augmented IL-8 
transcription levels relative to Flagellin stimulation alone (p<0.05).   
The augmented production of IL-8 in SW480 cells was confirmed by ELISA (Figure 
4.2.1.2).  In contrast to the mRNA data, CH-11 stimulation alone failed to induce IL-
8 protein secretion in SW480 cells over 3 separate experiments, indicating a possible 
post-transcriptional level of regulation of this cytokine.   LPS stimulation led to a 
175pg/ml production of IL-8, whilst pre-stimulation with CH-11 augmented this to 
240pg/ml, a statistically significant increase (p<0.05) relative to LPS alone.  
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Flagellin stimulation resulted in a modest increase in basal IL-8 secretion levels 
although these were also augmented upon CH-11 pre-treatment.  To confirm that the 
augmented IL-8 production observed upon Fas and TLR ligation was not specific to 
SW480 cells, HT29 and HCT116 intestinal cancer cells were treated in the same 
manner.  In contrast to the limited response of SW480 cells to CH-11, IL-8 
production was increased by CH-11 alone in both HT29 and HCT116 cell lines to 
~260 and ~150 pg/ml respectively (Figure 4.2.1.3a).  Pre-treatment with CH-11 
followed by LPS led to a three-fold increase in IL-8 protein production relative to 
LPS alone (p<0.05).   Similarly, CH-11 pre-treatment followed by Flagellin 
stimulation resulted in a similar 3.5 fold increase in IL-8 production over Flagellin 
alone (p<0.05).  Like HT29 cells, HCT116 cells doubled their basal expression of 
IL-8 in response to CH-11 (Figure 4.2.1.3b) and although LPS or Flagellin treatment 
alone failed to induce expression of IL-8 over untreated levels, pre-treatment with 
CH-11 led to a five-fold increase in IL-8 cells over Flagellin treatment alone 
(p<0.001). 
 
4.2.2 Stimulation of SW480 cells with agonistic Fas antibody and E. coli K12 
augments cytokine production. 
 
In order to investigate the physiological significance of the augmented TLR-induced 
cytokine production upon Fas stimulation, SW480 cells were pre-stimulated with 
CH-11 prior to infection with the gram negative bacterium, E.coli strain K12, which 
would be expected to stimulate cells through TLR4.  Pre-stimulation with CH-11 
followed by E.coli K12 infection increased TNFα mRNA levels relative to E.coli 
K12 infection alone (p<0.001) (Figure 4.2.2.1a).  IL-8 mRNA production was also 
augmented with CH-11 pre-stimulation relative to E. coli K12 treatment alone 
(Figure 4.2.2.1b), indicating that Fas receptor ligation modulates IL-8 and TNFα 
production in response to E. coli K12 in intestinal cancer cells. 
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Figure 4.2.1.1 Pre-treatment of SW480 cells with CH-11 and TLR4 or TLR5 
ligands modulates cytokine production.  (a&b) SW480 cells were treated with 
200ng/ml agonistic Fas antibody (CH-11) for 1hr followed by stimulation with 
100ng/ml LPS or 100ng/ml Flagellin for 8 hrs.  Changes in TNFα and IL-8 were 
detected by qRT-PCR. Statistical analysis was performed and statistical change 
determined comparing either LPS or Flagellin stimulation alone to LPS+CH-11 or 
Flagellin+CH-11. Values are plotted as Mean ± S.E.M. n=3.   ***p<0.001, 
**p<0.01, *p<0.05; one way ANOVA, Tukeys post hoc t-test. 
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Figure 4.2.1.2 Pre-treatment of SW480 cells with CH-11 and TLR4 or TLR5 
ligands augments IL-8 protein production.  SW480 cells were treated with 
200ng/ml agonistic Fas antibody (CH-11) for 1hr followed by stimulation with 
100ng/ml LPS or 100ng/ml flagellin for 24 hrs. Supernatents were harvested and 
IL-8 protein concentration determined by ELISA.  Statistical analysis was 
performed and statistical change determined comparing either LPS or Flagellin 
stimulation alone to LPS+CH-11 or Flagellin+CH-11. Values are plotted as Mean 
± S.E.M. n=3. *p<0.05; one way ANOVA, Tukeys post hoc t-test. 
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Figure 4.2.1.3 The augmentation of TLR4 and 5-induced IL-8 production by  
CH-11 also occurs in HT29 and HC116 cells. (a) HT29 cells and  (b) HCT116 
cells were treated with 200ng/ml agonistic Fas antibody (CH-11) for 1hr followed 
by stimulation with 100ng/ml LPS or 100ng/ml Flagellin for 24 hrs.  Supernatents 
were harvested and IL-8 protein concentration determined by ELISA. Statistical 
analysis was performed and statistical change determined comparing either LPS 
or flagellin stimulation alone to LPS+CH-11 or Flagellin+CH-11. Values are 
plotted as Mean ± S.E.M. n=3. ***p<0.001, **p<0.05; one way ANOVA, Tukeys 
post hoc t-test. 
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Figure 4.2.2.1 Stimulation of SW480 cells with CH-11 followed by infection 
by E.coli K12 results in augmented cytokine production.  (a&b) SW480 cells 
were treated with 200ng/ml agonistic Fas antibody (CH-11) for 1hr followed by 
stimulation with E.coli K12 10:1 (bacteria:cells) for 12 hrs and changes in TNFα 
and IL-8 were detected by qRT-PCR. Values are plotted as Mean ± S.E.M. n=3. 
***p<0.001, as compared to E. coli infection only; one way ANOVA, Tukeys post 
hoc t-test. 
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4.2.3 The augmented cytokine production observed following stimulation of 
intestinal cancer cells with CH-11 and TLR4 or TLR5 ligands is independent of 
cell death. 
 
The Fas/FasL system is best characterised in terms of its role in apoptosis, with some 
reports showing that cytokine expression occurs concomitantly with apoptotic cell 
death (Joshi, Kalvakolanu et al. 2003). Moreover, TLRs have been shown to induce 
apoptosis in certain cell types; for instance TLR5 stimulation can induce apoptosis in 
intestinal cancer cells (Zheng, Ouaaz et al. 2001). In order to determine if the 
augmented cytokine production observed occurred concomitantly with, or was 
independent of, Fas-mediated apoptosis, cells were stimulated with CH-11 and/or 
LPS or Flagellin, and cell viability and proliferation assessed.  
Treatment of  SW480 cells with LPS, Flagellin or CH-11 alone, or in combination, 
did not alter cell viability or cell proliferation relative to untreated cells (Figure 5 a 
and b). In contrast, cells treated with staurosporine, a natural product isolated from 
Streptomyces staurosporeus that is known to induce apoptosis, resulted in 
substantially reduced cell viability (reduced by 75%) and proliferation (reduced by 
50%) relative to untreated cells (Figure 4.2.3.1 a and b).  Since caspase activation is 
essential for Fas-mediated apoptosis induction, caspase 3/7 activity was also 
assessed.  Caspase 3/7 activity was not increased upon LPS, Flagellin or CH-11 
treatment either alone or in combination (Figure 4.2.3.1c), whilst a four-fold 
induction in caspase 3/7 activity with staurosporine treatment was observed in these 
cells.  In contrast, Jurkat T cells, known to be sensitive to Fas-mediated apoptosis, 
demonstrated a 6 fold increase in caspase 3/7 activity following CH-11 stimulation 
relative to untreated control (Figure 4.2.3.1d), indicating that CH-11 is able to induce 
caspase 3/7 activity in sensitive cells. 
In order to confirm that these results were not cell line specific, cell proliferation and 
caspase 3/7 activity was also measured in HT29 cells following treatment with LPS, 
Flagellin or CH-11 either alone or in combination.  As observed in the SW480 cell 
line, cell proliferation was not affected by any of the treatments in HT29 cells 
(Figure 4.2.3.2a), whilst staurosporine treatment reduced proliferation by 90% 
relative to untreated cells.  Similar to SW480 cells, HT29 cells did not exhibit 
increased caspase 3/7 activity in response to treatment with CH-11, LPS or Flagellin, 
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whereas staurosporine induced a 3 fold increase in caspase 3/7 activity (Figure 
4.2.3.2b). 
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Figure 4.2.3.1 Treatment of SW480 cells with CH-11, TLR4 and/or TLR5 
ligands does not alter cell viability, proliferation or caspase 3/7 activation.  (a) 
SW480 cells were treated with 200ng/ml agonistic Fas antibody (CH-11) for 1hr 
followed by stimulation with 100ng/ml LPS or 100ng/ml Flagellin for 8 hrs.  
Staurosporine treatment was added as a positive control.  Trypan blue exclusion 
was used to determine viability. (b) Resazurin reduction was used to measure cell 
proliferation and (c) caspase activation was measured fluorescently. (d) Jurkat T 
cells were treated with 200ng/ml CH-11 as a positive control for caspase 3/7 
activation in response to Fas activation. 
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Figure 4.2.3.2 Treatment of HT29 cells with CH-11, TLR 4 and/or TLR5 
ligands does not alter proliferation or caspase 3/7 activation.  (a) HT29 cells 
were treated with 200ng/ml agonistic Fas antibody (CH-11) for 1hr followed by 
stimulation with 100ng/ml LPS or 100ng/ml Flagellin for 8 hrs.  Staurosporine 
treatment was included as a positive control. Resazurin reduction was used to 
measure cell proliferation and (b) caspase 3/7 activation was measured 
fluorescently.  
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4.2.4 Stimulation of intestinal cancer cells with agonistic anti-Fas reduces the 
expression of TLR inhibitory proteins. 
 
TLR signalling is regulated by an extensive array of TLR inhibitory proteins.  In 
order to investigate the mechanism by which TLR4 and TLR5-induced cytokine 
production is augmented by Fas activation, the expression levels of a panel of TLR 
inhibitory proteins was assessed in SW480 cells following LPS or Flagellin 
treatment either alone or when pre-treated with CH-11.  
Stimulation of SW480 cells with CH-11 reduced the transcription of both TOLLIP 
and SIGIRR (p<0.05) as compared to untreated cells (Figure 4.2.4.1a). This reduced 
expression was maintained when cells were subsequently treated with LPS or 
Flagellin.  In contrast, the expression levels of two other TLR inhibitors, PPARγ and 
IRAKM, were unaffected by CH-11 stimulation in SW480 cells (Figure 4.2.4.1b).  
The change in protein levels of SIGIRR but not IRAKm was confirmed by Western 
blotting (Figure 4.2.4.1c and d).  These findings suggest that the augmentation in 
TLR4- and TLR5- induced cytokine production by Fas may be due to its ability to 
downregulate expression of key TLR inhibitory proteins. 
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Figure 4.2.4.1 Fas activation reduces the expression of key TLR inhibitory 
proteins in IECs. (a and b) SW480 cells were treated with 200ng/ml agonistic 
anti-Fas antibody (CH-11) for 1hr followed by stimulation with 100ng/ml LPS or 
100ng/ml Flagellin for 4 hrs.  Changes in inhibitory proteins were detected by 
qRT-PCR. (c and d) Cells were treated with CH-11 as above for 24 hrs and 
changes in protein expression were detected by Western blotting and quantified by 
densitometry.  Results shown are representative of three independent experiments. 
Statistical analysis was performed using one-way Anova, Tukeys post hoc t-test  
(a and b) and paired students t test (c and d) and statistical change determined 
compared to untreated control.  Values are shown as Mean ± SEM, n=3. * p<0.05, 
** p<0.01 and *** p<0.001. 
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4.2.5   FADD associates with MyD88 in intestinal cancer cells. 
 
Previous studies in macrophages have shown that, in the absence of Fas signalling, 
the Fas adaptor protein, FADD, is present in the cytoplasm bound to the TLR 
adaptor protein, MyD88, and this interaction suppresses MyD88-dependant cytokine 
production [104, 223].  Engagement of Fas was shown to prevent this interaction, 
releasing MyD88 and thereby promoting TLR-mediated inflammation.  Whilst I 
have shown that downregulation of TLR inhibitory proteins is one potential 
mechanism whereby stimulation of Fas augments TLR4- and TLR5- induced TNFα 
and IL-8 production in intestinal cancer cells, I also examined whether FADD and 
MyD88 interacted in intestinal cancer cells as this may be an additional mechanism 
underlying the augmentation in cytokine production. Plasmids encoding Flag-tagged 
FADD and HA-tagged MyD88 (Flag-FADD and MyD88-HA respectively) were 
over-expressed in HCT116 cells.  Expression was confirmed by Western blotting 
(Figure 4.2.5.1 a and b).  Next, the co-immunoprecipitation technique was optimised.    
HCT116 cells were transfected with either Flag-tagged FADD or HA-tagged MyD88 
or co-transfected with both constructs.  Following immunoprecipitation with either 
anti-FLAG or anti-HA, I was able to confirm immunoprecipitation of Flag-FADD 
(Figure 4.2.5.1c) and MyD88-HA (Figure 4.2.5.1d) by Western blotting respectively.  
Upon co-transfection with Flag-tagged FADD or HA-tagged MyD88, HA-tagged 
MYD88 was seen to co-immunoprecipitate with Flag-tagged FADD (Figure 4.2.5.2), 
thus indicating an association between the two adaptor proteins in intestinal cancer 
cells. 
  
MyD88-HA 
Figure 4.2.5.1  Optimisation of coimmunoprecipitation experiment in 
HCT116 cells. (a) HCT116 cells were transfected with either 0.5-2μg HA-tagged 
MyD88 or (b) 1-5μg FLAG-tagged FADD constructs. Cell lysates were separated 
by SDS-PAGE and probed with anti-HA, anti-FADD or anti- β actin specific 
antibodies as indicated. (c & d) Cells were transfected with 2μg MyD88-HA, 5μg 
FLAG-FADD or co-transfected with both constructs. Immunoprecipitation (IP) 
was performed with anti-FLAG or anti-HA antibodies.  The immunoprecipitates 
were subjected to immunobloting (IB) with anti-HA or anti-FADD specific 
antibodies as indicated. 
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Figure 4.5.5.2  FADD associates with MyD88 in intestinal epithelial cells.  
Cells were transfected with 2μg MyD88-HA, 5μg FLAG-FADD or co-transfected 
with both constructs. Immunoprecipitation (IP) was performed with anti-HA 
antibody.  The immunoprecipitate was subjected to immunobloting (IB) with an 
anti-FADD specific antibody. 
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4.2.6 Suppression of Fas expression limits the ability of HT29 cells to respond to 
CH-11 
 
In order to further investigate the potential crosstalk between Fas and TLR4 and 5 in 
intestinal cancer cells, stable cell lines with reduced Fas expression were generated 
using lentiviral particles designed to target the human Fas gene, HT29
Fas shRNA 
cells.  
In parallel, HT29 cells were lentivirally transfected with plasmids with a scrambled 
sequence showing no homology to any known mammalian gene, HT29
scr shRNA 
cells.  
As can be seen in Figure 4.2.6.1a, two distinct HT29 clones transfected with shRNA 
against Fas, (hereafter referred to as HT29
Fas shRNA
 cells #1 and #2) were identified, 
showing a reduction in Fas expression (p<0.001) relative to HT29
scr shRNA
 cells by 
Western blot.  To further characterise knock down of Fas expression, a functional 
assay was performed.  CH-11 treatment led to a 3 fold increase in IL-8 production in 
HT29
scr shRNA 
cells (Figure 4.2.6.1b).  In contrast, neither HT29
Fas shRNA#1
 or HT29
Fas 
shRNA#2
 cells were able to upregulate IL-8 production upon CH-11 stimulation 
(p<0.001) (Figure 4.2.6.1c). 
Fas is a member of the death receptor superfamily, of which TRAIL and TNF are 
other members.  In order to assess the relative specificity of knock down, the 
expression levels of these receptors was examined by Western blotting.  As can be 
seen in Figure 4.2.6.1d, the expression of TRAIL R-1 and TNFR-1 is unaltered in 
HT29 
Fas shRNA#1
 cells relative to HT29
scr shRNA 
cells. 
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Figure 4.2.6.1  Fas expression was reduced in HT29 cells using lentiviral 
particles expressing short hairpin RNA targeted against Fas. (a) HT29 cells 
were transfected with Fas or scrambled control shRNA lentiviral particles in the 
presence of polybrene. Following selection, stable clones were generated and 
knockdown of Fas expression was determined by Western blotting and quantified 
by densitometry. (b) Changes in IL-8 production was assessed by ELISA.   
(c) Total cellular lysates from HT29 cells were separated by SDS-PAGE, and 
probed with the specified antibodies. Values are plotted as Mean ± S.E.M. n=3. 
***p<0.001, as compared to HT29scr shRNA; one way ANOVA, Tukeys post hoc t-
test. 
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4.2.7 Suppression of Fas expression limits the ability of intestinal cancer cells to 
respond to TLR4 & TLR5 ligands. 
 
In order to characterise the effect of reducing Fas expression on the response of 
intestinal cancer cells to TLR ligands, HT29
scr shRNA
, HT29
Fas shRNA#1
 and HT29
Fas 
shRNA#2
 cells were stimulated with LPS and Flagellin.  In contrast to the 3 fold 
induction of IL-8 protein production seen upon LPS stimulation of HT29
scr shRNA 
cells, neither HT29
Fas shRNA #1
 nor HT29
Fas shRNA #2
 cells were able to increase 
expression of IL-8 in response to LPS (p<0.001) (Figure 4.2.7.1).  Furthermore, 
whilst HT29
scr shRNA
 cells upregulated IL-8 production in response to Flagellin, 
neither HT29
Fas shRNA #1 
nor HT29
Fas shRNA #2
 cells were able to increase expression of 
IL-8 in response to Flagellin (p<0.001).   
To determine whether IL-8 secretion in response to other TLR ligands was also 
affected by Fas suppression, cells were stimulated with the TLR2 ligand, 
Pam3CSK4, and the TLR9 ligand, CpG DNA.  HT29
scr shRNA
 cells secreted IL-8 in 
response to stimulation with CpG DNA, and this response was unaffected by a 
reduction in Fas expression (Figure 4.2.7.1a).   HT29 cells were unable to secrete IL-
8 in response to Pam3CSK4 irrespective of Fas expression levels.   In contrast, both 
HT29
Fas shRNA#1
 and HT29
Fas shRNA #2
 cells were able to produce IL-8 to a level 
comparable to that secreted by HT29
scr shRNA
 cells in response to TNFα, a known 
inducer of IL-8. 
These results were confirmed in CT26 murine intestinal cancer cells. Fas was stably 
suppressed in these cells by shRNA (CT26
Fas shRNA
) (Figure 4.2.7.1b). As murine 
cells do not produce IL-8, the induction of CXCL-1, a murine IL-8 homolog, was 
determined. Consistent with suppression of Fas expression, the CT26
Fas shRNA
 cells 
failed to upregulate CXCL-1 in response to Jo-2 (a murine agonistic anti-Fas Ab) 
(Figure 4.2.7.1c). The ability of LPS to induce CXCL-1 in CT26
Fas shRNA
 was also 
reduced to basal levels consistent with the findings in HT29 cells.  CT26 cells do not 
express TLR5 [294] and therefore I was unable to assess their response to Flagellin. 
 
In order to confirm that the abrogation in the ability of  HT29
Fas shRNA#1
 and HT29
Fas 
shRNA #2
 cells to respond to LPS and Flagellin was not due to any reduction in 
expression of other proteins following shRNA transfection, the expression levels of 
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TLR4, 5, 2 and 9 were assessed by Western blotting.  The expression level of these 
receptors was unchanged between HT29
scr shRNA, 
HT29
Fas shRNA#1
 and HT29
Fas
 
shRNA #2
 
cells (Figure 4.2.7.2). 
  
Figure 4.2.7.1  Suppression of Fas expression limits the ability of IECs to 
respond to TLR4 and TLR5 ligands. (a) HT29scr shRNA  and HT29Fas shRNA clones 
were treated with either 200ng/ml agonistic anti-Fas antibody (CH-11), 100ng/ml 
Flagellin, 100ng/ml LPS, 5μM CpG, 10μM Pam3CSK4, or 100ng/ml TNFα for 24 
hrs.  Cell supernatants were collected and IL-8 protein production determined by 
ELISA. (b) CT26 cells were transfected with Fas shRNA lentiviral particles and 
stable clones generated.  Knockdown of Fas expression was determined by Western 
blotting and quantified by densitometry. (c) CT26scr shRNA  and CT26Fas shRNA clones 
were treated with either 50ng/ml agonistic Fas antibody (JO-2), 100ng/ml flagellin, 
100ng/ml LPS, 1mg/ml Poly I:C or 100ng/ml TNF α for 4 hrs. Changes in CXCL-1 
mRNA were detected by qRT-PCR.  Values are plotted as Mean ± S.E.M. n=3. 
***p<0.001, **p<0.01 as compared to HT29/CT26scr shRNA; one way ANOVA, 
Tukeys post hoc t-test. 
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Figure 4.2.7.2  Suppression of Fas expression does not alter expression of 
TLR2, 4, 5, or 9.   Total cellular lysates from HT29 cells were separated by SDS-
PAGE, and probed with the specified antibodies.  Lysates were probed using β 
actin as a loading control.   
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4.2.8 Fas is required for the IL-8 response of HT29 cells to intestinal pathogens 
Listeria monocytogenes (L. Monocytogenes) and Salmonella typhimurium 
(S.typhimurium). 
 
Given that pre-stimulation with CH-11 followed by E.coli K12 treatment led to 
enhanced IL-8 production in SW480 cells, I next investigated whether attenuating 
Fas expression would alter the response of intestinal cancer cells to intestinal 
pathogens. Following S.typhimurium infection, the production of IL-8 by HT29
scr 
shRNA 
cells doubled relative to uninfected levels (Figure 4.2.8.1).  In contrast, both 
HT29
Fas shRNA#1
 and HT29
Fas shRNA#2
 demonstrated a reduced capability to produce IL-
8 in response to S.typhimurium infection. 
Given that the intestinal cancer cells response to the TLR5 ligand Flagellin was also 
attenuated upon suppression of Fas expression, the ability of HT29 cells to respond 
to L Monocytogenes, a Flagellin-expressing bacterium was also assessed.  HT29
scr 
shRNA
 cells upregulated IL-8 production in response to infection with this bacterium 
whilst neither HT29
Fas shRNA#1
 nor HT29
Fas shRNA#2
 cells were able to produce IL-8 in 
response L. Monocytogenes infection (p<0.001 as compared to HT29
scr shRNA 
cells) 
(Figure 4.2.8.2). 
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Figure 4.2.8.1  Fas is required for the induction of IL-8 in response to S. 
typhimurium infection in HT29 cells. Confluent HT29 cells were treated with 
Salmonella typhimurium  for 3 hrs followed by treatment with gentamycin 
(50ng/ml). Bacteria were diluted in PBS for infection at multiplicity of infection 
(MOI) of 10:1.  IL-8 protein levels in cell culture supernatants were measured 
after 24hrs by ELISA.  Values are plotted as Mean ± S.E.M. n = 3. 
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Figure 4.2.8.2  Fas is required for the induction of IL-8 in response to L. 
monocytogenes infection in HT29 cells.  Confluent HT29 cells were treated 
with Listeria monocytogenes  for 3 hrs followed by treatment with gentamycin 
(50ng/ml). Bacteria were diluted in PBS for infection at multiplicity of 
infection (MOI) of 10:1.  IL-8 protein levels in cell culture supernatants were 
measured after 24hrs by ELISA.  Values are plotted as Mean ± S.E.M.  n=3.  
***p<0.001, as compared to HT29scr shRNA; one way ANOVA, Tukeys post hoc 
t-test. 
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4.3 Discussion 
In this chapter I have demonstrated that extensive cross-talk exists between the Fas 
and TLR signalling pathways in intestinal cancer cells in terms of cytokine induction 
in response to bacterial infection.   Firstly, co-stimulation with an agonistic Fas 
antibody, CH-11, in combination with either TLR4 or TLR5 ligands increases 
expression of TNFα, IL-8 and CXCL-1 over and above the TLR ligand alone.  This 
cytokine production was independent of alterations in viability, proliferation and 
caspase 3/7 activation suggesting that increased cytokine production occurs 
independently of Fas-mediated apoptosis. The downregulation in the expression of a 
number of key negative regulators of TLR signalling by Fas ligation may partly 
responsible for the altered cytokine production in intestinal cancer cells.  Finally, 
suppression of Fas expression led to a reduction in the ability of intestinal cancer 
cells to respond to TLR4 and TLR5 ligands, despite these cells still expressing TLR4 
and TLR5.  Moreover, HT29
Fas shRNA
 cells exhibited a reduced ability to express IL-8 
upon bacterial infection with either L. monocytogenes or S. typhimurium suggesting 
a possible physiological consequence for cross talk between Fas and TLR signalling 
in intestinal cancer cells. 
Allograft studies provided some of the first evidence that the FasL/Fas signalling 
pathway could trigger inflammation (Kang, Schneider et al. 1997; Turvey, Gonzalez-
Nicolini et al. 2000). Ectopic over-expression of FasL in pancreatic and liver cells, 
resulted in extensive neutrophil recruitment and ultimately, graft rejection in a 
number of cases [110, 295].  Consistent with a pro-inflammatory function for Fas, I 
have shown that stimulation of intestinal cancer cells with CH-11 induced the 
production of IL-8 and TNFα.  There have been many other reports demonstrating 
that activation of Fas signalling can lead to the expression and release of 
inflammatory factors in vitro and in vivo, both in lymphoid [107, 218, 220, 296] and 
non-lymphoid tissue [108, 219, 297].  Similar to the data presented here, Fas 
stimulation has been shown to lead to the production of IL-8 in a number of cell 
types including synoviocytes, bronchiolar epithelial cells, and astrocytes [100-102]. 
A number of other cytokines and chemokines have also been shown to be induced by 
Fas ligation including interleukin-6 (IL-6) from astrogliomal cells [103, 104], IL-1β 
from dendritic cells [105], MCP-1 (monocyte chemoattractant protein-1) from 
pancreatic cells [106], with macrophages reported to secrete all of these cytokines 
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and more [104, 107].  In terms of the ability of Fas to induce inflammation in 
epithelial cells, HT29 intestinal cancer cells have been shown to produce IL-8, IL-6 
and MCP-1 following engagement of Fas [221, 293].  The data presented here not 
only support these findings, demonstrating that intestinal cancer cells respond to the 
agonistic Fas antibody by secreting TNFα, IL-8 and CXCL-1, but also build on the 
role of Fas in inflammation by demonstrating that co-stimulation with the TLR4 
ligand, LPS, or the TLR5 ligand, Flagellin, leads to an augmentation in production of 
these pro-inflammatory factors. Although Fas has been shown to modulate TLR4-
mediated cytokine production in macrophages [104, 298] and endothelial cells [223], 
to the best of my knowledge, the data presented here is the first time Fas has been 
shown to modulate TLR4 signalling in intestinal cancer cells.  Furthermore, it is the 
first time that Fas has been shown to augment TLR5-driven production of 
inflammatory mediators in any cell type, demonstrating a hitherto unappreciated 
crosstalk between TLR and Fas signalling in intestinal cancer cells. 
Moreover, I have shown that not only does Fas activation augment cytokine 
synthesis by commercially purchased TLR ligands, but that it also enhances IL-8 
secretion by the live bacterium, E. coli K12.  A recent study has shown that Flagellin 
from an avirulent bacterial strain such as E.coli K12 can induce secretion of IL-8 in 
intestinal cancer cells to a comparable level as that from the virulent strain, E. coli 
O83:H1 [183].  The data presented here not only confirm that the non-pathogenic, 
E.coli K12 strain is capable of inducing a pro-inflammatory response in SW480 
cells, but that this is augmented upon Fas receptor pre-stimulation, thus indicating a 
physiological role for Fas in the immune response to bacterial infection. 
IL-8 and CXCL-1 are potent chemotactic factors important for neutrophil migration.  
Expression of IL-8 has been shown to be upregulated from intestinal cancer cells in 
response to bacterial entry [182, 299]. Moreover, in a murine infection model, 
MyD88-mediated CXCL-1 production was shown to trigger neutrophil recruitment 
to the colonic lamina propria during infection.  Since dissemination of commensal 
intestinal bacteria to mesenteric lymph nodes is increased in Clostridium difficile -
infected mice that have undergone neutrophil depletion, neutrophil recruitment is 
thought to mediate defence by preventing dissemination of bystander bacteria to 
deeper tissues [300].  The data here, showing that intestinal cancer cells are capable 
of producing increased levels of IL-8 and CXCL-1 upon Fas and TLR4 and TLR5 
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ligation, indicate Fas activation may play a role in the recruitment of immune cells, 
such as neutrophils, upon bacterial infection. 
I also observed augmentation in TNFα production in response to both Fas and TLR 
stimulation at the mRNA level.  In the normal healthy colon, a number of roles have 
been ascribed to TNFα including regulation of epithelial cell proliferation [301] and 
cell survival [302] [303].  In addition to these cell survival roles, TNFα also 
modulates mucus secretion from intestinal cancer cells [304, 305] and may also 
actually induce a secretory phenotype in some colonic cells [306], thus promoting 
intestinal barrier function.  Uncontrolled TNFα synthesis, however, has been 
implicated in colonic tissue damage and the induction of apoptosis in intestinal 
cancer cells [307, 308].  TNFα synthesis is therefore tightly regulated in the healthy 
intestine by a variety of mechanisms such as the production of inhibitory cytokines 
like IL-10. Studies have shown that commensal bacteria that induce the biosynthesis 
of TNFα from intestinal cancer cells are also strong stimulators of IL-10 secretion 
from the underlying peripheral blood mononucleated cells, indicating that a negative 
feedback loop exists, presumably to limit TNF α-mediated pathology [309].  It 
remains to be determined whether the augmented levels described here upon Fas and 
TLR co-stimulation facilitates the protective role of TNFα in the colon or contributes 
to IBD pathology. 
Despite being best known for its ability to induce apoptosis, the augmentation in 
cytokine production seen in intestinal cancer cells upon Fas ligation did not require 
activation of the effector caspases, suggesting that it occurred independently of Fas-
mediated apoptosis.  Moreover, cell viability and cell proliferation were unaffected 
by any of the inducing ligands.  SW480 and HT29 cells have previously been shown 
to exhibit relative resistance to apoptosis induction [310].  Moreover, it is known 
that, under homeostatic conditions, intestinal cancer cells do not undergo Fas-
mediated apoptosis despite co-expression of Fas and FasL [311].  Proteins that 
mediate resistance include cellular FLICE-like inhibitory protein (c-FLIP) and 
inhibitor of apoptosis proteins (IAPs). intestinal cancer cells express high levels of 
cFLIP, which suppresses Fas-mediated apoptosis though its ability to prevent 
processing of pro-caspase-8 to its mature active form [312, 313].   Thus, under 
homeostatic conditions intestinal cancer cells are protected against Fas-mediated 
apoptosis.  Recent studies have suggested high expression levels of these traditional 
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negative regulators of cell death may actually promote alternative consequences of 
Fas receptor ligation.  For example, depletion of cIAP1 or cIAP2 by RNA 
interference in intestinal cancer cells has been shown to lead to the attenuation of 
cytokine and chemokine production in response to a NOD agonist [314].  
Furthermore, inhibition of IAPs and treatment with Zvad-fmk, a pan caspase 
inhibitor, dramatically decreased Fas-induced IL-8 and CXCL-1 expression in Hela 
cells suggesting that IAPs and caspases are required for optimal Fas-induced pro 
inflammatory cytokine production [221].  Although cytokine production by Fas was 
shown in this study to occur concomitantly with apoptosis, apoptosis was not 
required for cytokine production indicating that the production of inflammatory 
mediators can be uncoupled from Fas-mediated cell death [221].  In fact, this group 
confirmed what I have shown here, that despite being resistant to Fas-mediated 
apoptosis, HT29 cells are still able to respond to Fas ligation by the secretion of pro-
inflammatory cytokines.  It may well be that in intestinal cancer cells, the presence 
of such anti-apoptotic factors act to promote alternative consequences of Fas 
receptor ligation such as the expression of IL-8 and TNFα as seen in the data 
presented here. 
TLR signalling is tightly regulated in intestinal cancer cells by TLR inhibitory 
proteins. I therefore examined whether Fas signalling in intestinal cancer cells 
altered the expression of a panel of TLR inhibitory proteins known to play an 
important role in intestinal homeostasis.  I have shown here that stimulation of Fas in 
intestinal cancer cells reduced the expression of TOLLIP and SIGIRR by between 
20-40%.   Despite the relatively modest reduction, similar levels of suppression have 
previously been shown to relieve TLR signalling.  For example, a 30% reduction in 
SIGIRR expression has been shown to be sufficient to elicit a 50% increase in TNFα 
production in a murine model of DSS colitis [315].  TOLLIP expression is high in 
intestinal cancer cells and is increased upon LPS- or LTA-stimulation in these cells 
[203].  Furthermore, expression levels of TOLLIP were found to be associated with 
acquired hyporesponsiveness in intestinal cancer cells [180].  Intestinal cancer cells 
have also been shown to express high levels of SIGIRR [316], and deficiency in 
SIGIRR increases susceptibility to colitis induced by DSS [290].  In contrast to the 
downregulation of SIGIRR and TOLLIP expression in response to CH-11 on 
intestinal cancer cells, the expression levels of PPARγ and IRAKM remained 
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unaltered by Fas activation.  Although not initially characterised for its TLR-
inhibitory properties, PPARγ was subsequently shown to inhibit NF-κB activation 
and reduces inflammation in animal models of colitis [317]. Moreover, PPARγ 
expression is partially controlled by TLR4 and luminal bacteria signalling suggesting 
a homeostatic mechanism to prevent aberrant response to LPS [291].  Similarly, 
IRAKM is induced upon TLR stimulation. Due to its inactive kinase domain, 
IRAKM is known to be a negative regulator of TLR signalling in macrophages 
[318].  In the colon, IRAKM-deficient mice are more susceptible to DSS-induced 
colitis [319].  However, in spite of the fact that IRAKM co-localises with a 
susceptibility locus for IBD [320], a small scale study of Crohn’s patients failed to 
show an association between mutant IRAKM and UC [321].  So, although all the 
inhibitors examined play an important role in limiting intestinal inflammation, Fas 
does not ubiquitously suppress all of them.  The reduced expression of some of these 
inhibitors by Fas activation in intestinal cancer cells, may however explain the 
augmentation of TLR4 and TLR5-mediated cytokine production of IL-8 and TNFα. 
 
FADD is the primary adaptor domain for Fas.  The results presented here show that 
FADD interacts with MyD88 in intestinal cancer cells, providing further evidence of 
crosstalk between the TLR signalling pathway and Fas in intestinal cancer cells.  
FADD has been previously shown to inhibit TLR-mediated inflammation through its 
interaction with MyD88 and interleukin -1 receptor –associated kinase 1 (IRAK1) in 
macrophages [104, 223].  FADD was shown to dissociate from MyD88 upon Fas 
ligation, thus alleviating the inhibition of TLR signalling, leading to the 
augmentation of the pro-inflammatory response in macrophages.  Given that I have 
shown that FADD also associates with MyD88 in HCT116 cells under unstimulated 
conditions, the data presented here suggest a similar mechanism may exist in 
intestinal cancer cells.   Unfortunately, I was unable to examine the consequence of 
Fas ligation on this interaction in intestinal cancer cells as HCT116 cells appeared to 
have a limited response to Fas stimulation upon plasmid transfection.  Had it been 
possible, I would have been able to determine whether the association between 
FADD and MyD88 was disrupted upon Fas ligation in intestinal cancer cells, and 
also to determine whether this complex was inhibitory to TLR-induced cytokine 
production in intestinal cancer cells.  Although further work is required, the data 
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presented here suggests that the negative regulation of TLR mediated cytokine 
production by FADD may be common to both macrophages and intestinal cancer 
cells. 
I also examined the contribution of Fas activation to TLR-mediated cytokine 
production by knocking down Fas expression in intestinal cancer cells.  The near 
complete abrogation of TLR4 and TLR5-induced IL-8 production suggests that Fas 
ligation plays an important role in TLR4 and 5 signalling in the colon.  This may 
have important consequences for the conclusions that have been drawn from reports 
that have investigated Fas deficiency in the colon [147].  In one study, two different 
strains of mice were used in order to examine the cell autonomous function of Fas in 
IECs:  mice with a death domain mutation in the Fas receptor rendering all cells 
unable to undergo apoptosis (lpr
cg
), and mice that were Fas deficient specifically in 
IECs.  lpr
cg
 mice showed no difference in disease severity when compared to wild 
type (WT) mice.   However when reconstituted with bone marrow from WT mice, 
lpr
cg
 mice experienced hypersensitivity to DSS, suggesting that IECs become more 
sensitive to DSS only when Fas is mutated specifically in these cells.  Moreover, 
mice lacking expression of Fas specifically in IECs were also more sensitive to DSS 
colitis compared to their WT counterparts.  My findings suggest that IEC-specific 
deletion of Fas or abrogation of Fas signalling would also lead to a decrease in the 
ability of these cells to respond to TLR4 and TLR5 ligands.  Given that TLR4 and 
TLR5 activation have been shown to have protective and homeostatic roles in the 
intestine [322, 323], it could be argued that the hypersensitivity to DSS treatment 
exhibited by both of these models [147] is actually attributable to a loss of these 
protective mechanisms, rather than a de facto consequence of Fas receptor ablation 
in IECs.  
Interestingly, HT29
Fas shRNA #1
 and HT29
Fas shRNA #2
 cells showed a similar response to 
TLR9 ligands as HT29
scr shRNA
 cells.  This may be explained by the fact that Fas does 
not ubiquitously suppress all TLR inhibitory proteins.  For instance, expression 
levels of IRAKM remain unaltered upon Fas receptor stimulation in intestinal cancer 
cells.  Studies in macrophages revealed that suppression of IRAKM resulted in 
augmented CpGDNA (TLR9 agonist)-mediated pro inflammatory cytokine 
production [318] suggesting that IRAKM is a more potent negative regulator of 
CpG-mediated as opposed to LPS-mediated cytokine production.  This may 
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therefore account for the similarity of IL-8 response from HT29
Fas shRNA
 and HT29
scr 
shRNA
 cells to CpGDNA.  Alternatively, it may be that TLR9-mediated cytokine 
production is not regulated by the FADD-MyD88 complex.  TLR9 is an 
endosomally located PRR meaning that unlike LPS and Flagellin, which interact 
with their respective receptors at the cell membrane, CpG and TLR9 interact in an 
endosomal vesicle [186, 324].  The vesicular location of the receptor may mean that 
TLR9 is less susceptible to the cytosolic FADD-MyD88 complex and therefore less 
receptive to the FADD-mediated negative regulation of MyD88, thus accounting for 
the unaltered CpG response seen in HT29
Fas shRNA
 cells. 
Finally, I have shown that the production of IL-8 by intestinal cancer cells in 
response to S.typhimurium and L.monocytogenes requires Fas.  Salmonella is an 
important pathogenic Gram-negative bacterium, known to cause a wide variety of 
diseases ranging from mild diarrhoea to severe systemic infections such as typhoid 
fever.  S.typhimurium infection in humans commonly manifests as enterocolitis 
characterized by diarrhoea and neutrophillic infiltration into the intestinal submucosa 
[325].  Following oral infection, intestinal cancer cells represent the first barrier to be 
crossed by this pathogen in order to invade and colonize the intestinal tissues and 
other organs. Flagellin is known to be both necessary and sufficient for induction of 
nearly all epithelial pro-inflammatory gene expression induced by S. typhimurium 
[325] and I have shown here that intestinal cancer cells upregulate expression of IL-8 
in response to infection with S.typhimurium.  The augmentation of Salmonella-
mediated IL-8 response by Fas shown here is likely to promote neutrophil infiltration 
in response to this pathogen, thus indicating an important role for Fas in host defence 
against pathogens.  Similarly, Listeria monocytogenes is a ubiquitous, Gram-
positive, soil bacterium and facultative intracellular pathogen, which can cause 
severe food-borne disease in new-borns, pregnant women or other 
immunocompromised individuals.  Although best characterised for recognition by 
TLR2 [326], NOD1 [327], and NOD2 [328] and most recently, TLR10 [154],  L. 
monocytogenes is also a flagellated bacterium and has been shown to induce NFκB 
activity through TLR5 which is necessary for host defence [329].  It is possible 
therefore, that the augmentation of IL-8 in response to Listeria by Fas ligation in 
intestinal cancer cells, represents another mechanism of host defence, improving the 
likelihood of pathogenic clearance. 
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In conclusion, I have shown that there is extensive cross-talk between Fas and TLRs 
4 and 5 in intestinal cancer cells in vitro. The data here further advances the evidence 
in favour of non-apoptotic functions of Fas, in particular a pro-inflammatory role, in 
intestinal cancer cells.  The alterations in TLR-mediated cytokine production shown 
in this study, upon manipulation of both the activation and expression of Fas, suggest 
that Fas is required for optimal pro-inflammatory cytokine production in the case of 
pathogenic infection in the intestine.  This may encourage neutrophil infiltration into 
the colonic mucosa, thus promoting bacterial clearance from the host.  It may also be 
possible that by upregulating TLR-mediated cytokine production, Fas signalling 
promotes the unresolving inflammatory phenotype of the colon that characterises 
intestinal disorders of the intestine such as IBD. 
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6.1 Final Discussion  
Despite being constitutively expressed at the basolateral side of all epithelial cells of 
the colon, the role of Fas in the gastrointestinal tract is still unclear.  Fas has been 
best characterised as a major regulator of the extrinsic pathway of caspase-dependent 
apoptosis, yet mice lacking Fas and FasL display no abnormalities in their gut 
mucosa relative to WT mice, indicating that the Fas/FasL signalling system is 
unlikely to be involved in the physiological turnover of the gut epithelium.  Instead, 
emerging evidence suggests that Fas signalling may play a role in the host response 
to pathogens, specifically in pathogen clearance.  
Elimination of infected cells via programmed cell death is a defence strategy of 
multicellular organisms against bacteria, viruses, and parasites in a variety of tissues.  
By killing the infected cell, host cell apoptosis simultaneously confines and 
eliminates the infection as well as preventing dissemination to underlying tissue 
[384].  The importance of Fas-triggered cell death in modulating disease severity has 
been known for some time.   In comparison to wild-type (WT) mice, mice deficient 
in either Fas or FasL infected with Pseudomonas aeruginosa succumb to sepsis with 
increased splenic colonization with this bacteria [385].  These symptoms are 
associated with a reduction in lung epithelial cell apoptosis and markedly decreased 
survival.  Similarly, studies using Mycobacterium tuberculosis [386], Listeria 
monocytogenes [387] and Helicobacter pylori [388] have shown that deficiency of 
either Fas or FasL leads to decreased Fas-mediated apoptosis of host cells and 
increased disease severity as compared to WT controls.  Moreover, apoptosis has 
been associated with increased bacterial clearance during infection with 
Streptococcus pneumoniae [389].  Increased Fas and FasL expression in tissues that 
have an associated microbial flora such as the intestine may ‘prime’ the region by 
lowering the threshold for Fas-mediated apoptosis, should infection arise.  The 
upregulation of Fas and FasL upon TLR signalling in intestinal cancer cells seen in 
the data presented here may therefore be a mechanism to promote Fas-mediated 
apoptosis of infected epithelial cells of the intestine upon pathogenic infection. 
 
Consistent with a role for Fas-mediated apoptosis as a host defence mechanism, 
recent studies have shown that certain bacteria target host cell apoptosis.  For 
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example, in the genitourinary tract, Chlamydia trachomatis secretes chlamydial 
proteasome-like activity factor, which targets pro-apoptotic proteins for degradation 
[390].  Chlamydia trachomatis is also able to upregulate the inhibitors of apoptosis 
proteins, thus preventing the release of cytochrome C from mitochondria, an 
important step in the intrinsic apoptotic pathway [391]. In this way, the obligate 
intracellular pathogen ensures the survival of the infected epithelial cell, critical for 
the establishment of a persistent infection. Moreover, Yersinia pestis (Y.pestis), the 
causative agent of the pneumonic plague, has been shown to secrete a bacterial 
plasminogen activator protease called Pla, which degrades FasL, thus preventing 
pulmonary caspase-3/7 activation and host cell apoptosis [392]. In addition to Pla, 
Y.pestis produces multiple virulence factors that manipulate host defence strategies, 
including effector proteins that are injected via a Type III secretion system (T3SS) 
[393]. This syringe-like apparatus delivers bacterial effector proteins directly into the 
host cell cytoplasm [126].  For instance the T3SS effector protein, YopM, inhibits the 
activation of caspase-1 to prevent cell death via pyroptosis [394, 395].  In the colon, 
enteropathogenic Escherichia coli (EPEC) has been shown to inject the effector 
protein, NleB, which is capable of antagonising death receptor signalling by binding 
to, and modifying the death domain of FADD with an N-acetyl glucosamine residue 
[125].  This prevents DISC formation, prohibiting caspase activation and thus 
inhibiting cell death [124].  In addition to its role in Fas-mediated signalling, FADD 
is also an adaptor protein important in transducing the apoptotic signal via other 
members of the TNF superfamily, including tumour necrosis factor–related 
apoptosis-inducing ligand (TRAIL) receptors and death receptors 4 and 5 [396]. 
Indeed, the GlyNacylation of the death domain of FADD by NleB also blocked 
TRAIL-induced cell death [125].  This ability to prevent apoptosis of the infected 
cell thus enhances bacterial colonization, increasing the chances of dissemination to 
deeper tissues and ultimately, to other hosts [125, 397]. Whether these bacteria also 
target Fas-mediated inflammation is currently unclear.   In the data presented here, 
Fas ligation led to the secretion of proinflammatory mediators such as TNFα and IL-
8, suggesting they are predisposed to alternative consequences of Fas receptor 
ligation. 
 
Inflammation is one of the best characterised host responses to bacterial pathogenic 
infection and immune cells act in concert to fight and eradicate the pathogen. 
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Although several studies have shown the upregulation of a number of 
proinflammatory cytokines in response to Fas ligation, the role of Fas-mediated 
inflammation in the response to infection has been largely unappreciated thus far.  In 
contrast, signalling via TNFR-1 has been shown to have a prominent role in the 
immune response to infection as evidenced by several in vivo studies. Infection with 
Mycobacterium tuberculosis (M. tuberculosis) results in the TNFR1-mediated 
secretion of TNFα [398].  This pleotropic cytokine participates in host resistance to 
infection in a number of ways including the induction of chemokines and subsequent 
innate immune cell recruitment, as well as participating in the activation of 
macrophages and T cells [399].  The fundamental role that TNFR-1 signalling plays 
in the control of bacterial infections is evidenced by the fact that TNFR-1 deficient 
mice die when orally infected with a low-virulent strain of Toxoplasma gondii [400].   
Furthermore patients with rheumatoid arthritis receiving anti–TNFα therapy 
demonstrate an increased susceptibility to M. tuberculosis infection [401].  However, 
recent studies suggest that Fas-mediated inflammation may also play an important 
role in fighting infection, with Fas-mediated signalling resulting in IL-18/IL-1β 
production from peritoneal exudate cells in response to infection with Listeria 
monocytogenes (L.monocytogenes) [362].   In support of a role for Fas-mediated 
inflammation in the response to infection, I have shown that intestinal cancer cells 
demonstrate reduced IL-8 and TNFα production in response to the intestinal 
pathogens, L.monocytogenes and Salmonella typhimurium (S.typhimurium), upon 
Fas receptor downregulation. 
 
Infection with a mutant strain of Y. pestis lacking the effector protein Pla, not only 
prevented apoptosis but also led to the induction of proinflammatory cytokines, 
relative to infection with a WT strain [392]. This suggests that Pla-mediated FasL 
degradation delays induction of pulmonary inflammation compared to that caused by 
other Gram-negative bacteria [402].    By limiting cytokine production, Y. pestis is 
thought to avoid early detection by the innate immune system which allows for 
initial bacterial replication and the establishment of infection in a new host 
environment. Similarly, in addition to its role in preventing host cell death, NleB was 
also shown to abolish NFκB activation downstream of TNFR-1 activation in vitro 
[125].  NFκB is a central inflammatory mediator, essential for the induction of a 
variety of inflammatory cytokines in response to pathogenic infection.  By 
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preventing NFκB activation, pathogens may potentially subvert the host immune 
response.   Furthermore, SseK1, present in S. Typhimurium, is an NleB homologue 
which also inhibits TNF α-mediated NFκB signalling [125].  Since NleB requires its 
O-GlcNAc transferase activity for NFκB activation [403], this suggests that 
GlyNacylation is a previously unappreciated mechanism that bacterial pathogens 
utilise to subvert the inflammatory response in the host.   
 
Although best known as an apoptotic inducer, Fas has been shown to induce a 
number of cellular outcomes including proliferation, migration and inflammation and 
it is unclear what determine whether a cell responds to Fas ligation with apoptosis or 
inflammation. In the data presented here, I have shown that FADD and MyD88 exist 
in a complex which may limit the amount of FADD available to bind to the Fas 
receptor, potentially inhibiting the transduction of the Fas-mediated apoptotic signal. 
The authors of one study showed that FADD inhibited MyD88-transduced 
inflammation [223].  The sequestration of FADD by MyD88 may also predispose the 
cell to non-apoptotic consequences of Fas ligation, such as inflammation.   The 
ability of adaptor molecules to form a complex may be a regulatory mechanism that 
potentiates inflammation rather than apoptosis upon either TLR or Fas receptor 
ligation thus allowing for a vigorous inflammatory response against invading 
pathogens which may be common to those cells at the front line of host defence such 
as macrophages and intestinal epithelial cells. 
 
Receptor crosstalk has long been recognized as an important determinant of cellular 
response.  In vivo, a variety of different cellular signals are received simultaneously 
and receptor cross-talk represents a means of fine-tuning these signals so as to 
mediate an appropriate response.   For example, both TLR2 and TLR6 co-operate in 
detecting bacterial components such as peptidoglycan, but do not have identical 
specificity [404].  In macrophages, co-expression of CD4-TLR2 and CD4-TLR6 
resulted in the activation of TNF-α production, whereas expression of either receptor 
alone was insufficient to induce production of this proinflammatory mediator [404]. 
Since TLR2 can also form a functional signalling complex with TLR1, this may 
mean that different TLR pairs may stimulate different signalling pathways, hence 
allowing macrophages to tailor responses to individual pathogens by producing 
180 
 
specific patterns of inflammatory mediators.  Cells may therefore express a 
combinatorial repertoire of TLRs in order to discriminate among the large number of 
PAMPs.  Crosstalk may also be used to enhance a response.  For instance, LPS-
TLR4 signalling in polymorphonuclear leukocytes (PMN) has been shown to 
upregulate TLR2 expression in endothelial cells in an NFκB dependant manner.  
This promotes the enhanced activation of endothelial cells in response to bacterial 
components, LPS and PGN, thus amplifying the transmigration of transendothelial 
PMN to sites of infection [405].  Receptor crosstalk can also modify the original 
signal. Instead of inducing apoptosis, Fas ligation has been shown to induce 
proliferation in quiescent liver cells, with the mitogenic signal shown to be due to the 
FasL-mediated phosphorylation of the EGFR receptor [406], thus potentially playing 
a role in liver regeneration following injury. 
 
Crosstalk may also have pathological consequences.  At sites of macrophage 
accumulation, autocrine or paracrine Fas signalling has been shown to promote the 
TLR-mediated production of cytokines and chemokines in vitro, thus potentially 
contributing to chronic inflammation seen in the rheumatoid arthritis joint [104].  In 
the lung, Fas activation induces rapid, TLR4/IRAK4-dependent release of the 
proinflammatory molecule, high mobility group box 1, that contributes to Fas-
mediated pro-inflammatory cytokine production by macrophages seen in conditions 
of chronic inflammation [298].  Furthermore, FADD siRNA treatment greatly 
reduced the development of septic acute lung injury in a mouse model.  Specifically, 
TNFα and IL-6 production was inhibited which, in combination with the reduced cell 
death, led to a dramatic improvement in survival in FADD siRNA treated animals 
relative to untreated animals [407], indicating that enhanced inflammatory responses 
as a result of Fas and TLR crosstalk may influence the initiation of a pathological 
state.  Thus crosstalk between receptors appears to be an important determinant of 
ultimate cellular consequence, the characterisation of such necessary for efficacious 
therapy design. 
The importance of Fas-mediated inflammation in host response is evidenced by the 
fact that ALPS patients who lack a functional Fas receptor exhibit an increased 
susceptibility to invasive bacterial infection [408].  Low circulating counts of 
memory B cells were found in ALPS patients along with poor anti–Streptococcus 
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pneumoniae (S. pneumoniae) IgM production following administration of a vaccine 
against the bacterium [409]. These data suggest that antibody deficiency accounts for 
at least some of the observed vulnerability of ALPs patients to infection by S. 
pneumoniae.  Infection is also one of the leading causes of morbidity and mortality 
in SLE patients [410].  Affected individuals have lower than normal T cell counts 
and their macrophages display decreased phagocytic capabilities [411, 412].  
Cytokines such as TNF α and IL-8 are required for the priming of the adaptive 
immune response.  Thus, in light of the crosstalk shown here leading to the 
production of these cytokines, suboptimal cytokine levels in response to bacterial 
challenge may account, at least in part, for the abnormalities in B and T cells seen in 
SLE patients.   This may contribute to an increased vulnerability to infection.  
Indeed, a small scale study has suggested that a decreased ability to produce IL-8 by 
neutrophils in SLE patients may predispose patients to infection [413].  Thus, 
characterising crosstalk is relevant to understanding tissue in both the healthy and 
diseased state. 
Allogeneic bone marrow transplantation (BMT) is used as a treatment for 
haematological malignancies whereby elimination of residual tumour cells is 
achieved by the transplantation of mature allogeneic T cells.  However, the 
transplanted T cells are also responsible for the induction of graft-versus-host disease 
(GVHD), which leads to significant morbidity and mortality despite routine immune 
suppression [414].  
 
APG101, a novel recombinant human fusion protein consisting 
of the extracellular domain of Fas and the Fc domain of an IgG1 antibody [348] has 
been used successfully to prevent GVHD in murine BMT models. APG101 binds to 
FasL, blocking its ability to activate Fas. Treatment of mice with APG101 resulted in 
increased survival rates without interfering with the graft-versus-tumour (GVT) 
effect [415].  This suggests that APG101 therapy might be useful in preventing 
GVHD by preserving GVT activity without impairing T-cell function.  
Given that cell death manipulation by pathogens can promote virulence, inhibitors of 
specific bacterial virulence factors such as Pla of Y. pestis or NleB may confer 
targeted protection against specific bacterial infection [416].  Preliminary studies 
have been conducted using TRAIL.  Exogenous TRAIL administration during 
pneumococcal pneumonia restores apoptosis levels, and S. pneumoniae colonization 
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is reduced. Furthermore, survival of the host animal was enhanced, demonstrating 
the potential of targeting apoptosis in order to bolster host defence [417].   
Current cancer therapies such as chemotherapy, γ-irradiation, and immunotherapy or 
suicide gene therapy exert an antitumour effect primarily by triggering the activation 
of caspases which ultimately leads to apoptosis of the cancerous cells [418, 419]. 
Whilst the majority of cancers express a low level of Fas, tumours remain largely 
resistant to Fas-mediated apoptosis.  Instead, this basal level of expression is thought 
to be sufficient to activate pro-tumorigenic signalling pathways, such as those 
required for survival, proliferation and migration [420], with a low level of Fas in 
primary colon tumours predictive of metastatic tumour recurrence [421].  Early 
studies suggested that the levels of Fas expression on colon carcinoma cells may be 
the ultimate determinant of susceptibility to Fas-dependant apoptosis, indicating that 
modulating Fas expression levels may be a way to mediate cell death [422].  Indeed, 
increased expression of Fas, under conditions which p53 is inactivated by 
chemotherapeutics such as 5FU, has been shown to contribute to the apoptosis of 
colorectal cancer cell lines in vitro and this therapy has garnered some success in 
patients in vivo [423, 424].  However, pre-clinical studies have shown that systemic 
activation of Fas in mice using an agonistic Fas antibody caused massive apoptosis 
of hepatocytes, resulting in fatal hepatitis.  This acute liver toxicity was subsequently 
found to be dependent on the Fc receptors of the antibody with mice lacking 
FcγRIIB completely resistant to Jo2-mediated lethal hepatotoxicity, suggesting that 
hepatotoxicity may be limited through the use of non-antibody Fas-activating 
molecules [425].  Accordingly, recombinant mega FasL, or APO010, has been 
shown to have anticancer activity in vitro and has demonstrated an ability to reduce 
tumour incidence and size in murine xenograft models of multiple myeloma, non-
small cell lung and ovarian cancer [347, 426].   Indeed the efficacy of APG101 
treatment in combination with the existing radiotherapy protocol in progressive 
glioblastoma patients is indicative of the potential therapeutic potential of limiting 
tumour-expressed Fas activation [427].  There is evidence to suggest that crosstalk 
between the Fas and TLR signalling pathways also exists in tumour cells of neuronal 
origin, with the concomitant activation of TLR4 reported to inhibit Fas-mediated 
proliferation and migration in a glioblastoma model [88].  Given that human 
glioblastomas are highly resistant to conventional brain tumour therapies [428], 
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taking advantage of the apparent crosstalk TLR4 has with Fas signalling in these 
cells may be promising in the development of new cancer therapeutics. 
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6.2 Future perspectives 
In this study, I have demonstrated crosstalk between the Fas signalling pathway and 
the TLR 4 and 5 signalling pathway.  Fas is a member of the TNFR superfamily.  
Other members include TNF-related apoptosis-inducing ligand (TRAIL)-R1 and 
TRAILR2, both of which contain DD in their cytoplasmic domains and mediate a 
signalling pathway similar to that of Fas, utilising the FADD adaptor protein.  
Moreover, TRAIL also activated both apoptotic and non-apoptotic signalling 
pathways, including inflammation.  Another member of this superfamily that 
contains a DD is TNFR-1.  Ligation of TNFR-1 by TNF recruits the adaptor protein 
TNF receptor type 1-associated (TRADD).  Like FADD, TRADD is a death domain 
containing adaptor protein.  TRADD binds to TNFR-1, recruiting TRAF2, TRAF1 
and receptor-interacting protein (RIP), resulting in the production of 
proinflammatory cytokines and chemokines [429].  Following recruitment to TNFR-
1, TRADD can alternatively associate with FADD, thereby initiating the caspase-8 
activation pathway, leading to apoptotic cell death. Therefore, like Fas, TNFR-1 can 
also assemble a signalling complex that is capable of both apoptotic and 
proinflammatory outcomes.  Moreover studies have shown that TRADD can play a 
crucial role in TRIF-mediated NF-κB activation downstream of TLR3 and TLR4 
[364, 365, 430], with direct interactions between TRADD and TLR4 observed [364].  
Therefore, it is possible that activation of TNFR-1 may also modulate LPS- and poly 
I:C-induced cytokine production in a similar manner to that of Fas.  Taken together, 
these studies suggest that DD-containing proteins may represent a mechanism to 
modify TLR-mediated signalling in addition to the vital role they play in the 
determination of cell fate.  Further studies will be required to investigate the 
modulatory effects of other members of the TNF family, including TNFR-1, TRAIL 
-R1 and TRAIL-R2 on cytokine production following TLR activation. 
I have also shown that targeting Fas and TLR4 may lead to a reduction in 
tumorigenesis, suggesting that a FasL antagonist, such as APG101 could be used, in 
conjunction with a TLR4 antagonist, as a novel cancer therapy regime.  However, it 
is important to fully characterise the effects of suppressing Fas activation alone, as 
well as in combination with other therapies, on colon tumourigenesis in pre-clinical 
models.  Given the potential immunosuppressive role of Fas in tumour development, 
it would be important to further characterise the immune infiltrate of the tumours.  
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Tumour-associated neutrophils (TANs) can exert either pro- or anti-tumorigenic 
activities [431], with neutrophil infiltration known to be an indicator of poor 
prognosis in colon cancer.  It would therefore be worthwhile to determine the 
phenotype of the infiltrating neutrophils in my study.   Indeed, TGFβ has been 
shown to induce a population of TANs with a pro-tumour phenotype, with TGFβ 
blockade resulting in the recruitment and activation of TANs with an anti-tumour 
phenotype [431], suggesting that one may be able to manipulate the tumour infiltrate 
for therapeutic purposes.  In addition, since Fas ligation may promote a generalised 
immunosuppressive response in the host, identifying and quantifying the relative 
level of myeloid-derived suppressor cells between tumours generated in this study 
would indicate whether this is the case in colon cancer. Additionally, cytotoxic T 
cells (CTLs) are critical components of the immune response to the presence of 
neoplasia, and CTL activity has been shown to decline with progressive tumour 
growth [432, 433].  One could therefore determine if the cytotoxic activity of T cells 
from tumour-bearing mice is altered upon downregulation of tumour-expressed Fas 
and therefore assess the contribution that tumour-derived Fas plays in promoting an 
immunosuppressive environment. 
Studies such as these would enhance the findings of this thesis which demonstrated 
that crosstalk exists between Fas and TLRs 4 and 5 in the intestine, both in terms of 
expression and in cytokine production, which may have physiological and 
pathological consequences. 
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Appendix A 
Appendix A.  Suppression of tumour expressed Fas does not alter T helper cell, 
cytotoxic T cell, natural killer cell or eosinophil infiltration into the tumour 
microenvironment. 
Single cell suspensions were isolated from the tumours and surface stained with 
antibodies against (a) CD4, (b) CD8, (c) CD49b or (d) SIGLEC.  The percentages of 
each cell subset were assessed by gating on FSC populations using an Accuri C6 
Flow cytometer and analysis was carried out using CFlow software. Values are 
plotted as Mean ± S.E.M. n=4.  
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Appendix B 
The Journal of Immunology
Intestinal Expression of Fas and Fas Ligand Is Upregulated
by Bacterial Signaling through TLR4 and TLR5, with
Activation of Fas Modulating Intestinal TLR-Mediated
Inflammation
Philana Fernandes,* Charlotte O’Donnell,* Caitriona Lyons,† Jonathan Keane,†
Tim Regan,† Stephen O’Brien,† Padraic Fallon,‡ Elizabeth Brint,†,x,1 and
Aileen Houston*,x,1
TLRs play an important role in mediating intestinal inflammation and homeostasis. Fas is best studied in terms of its function in
apoptosis, but recent studies demonstrate that Fas signalingmaymediate additional functions such as inflammation. The role of Fas,
and the Fas ligand (FasL), in the intestine is poorly understood. The aim of this study was to evaluate potential cross-talk between
TLRs and Fas/FasL system in intestinal epithelial cells (IECs). IECs were stimulated with TLR ligands, and expression of Fas and
FasL was investigated. Treatment with TLR4 and TLR5 ligands, but not TLR2 and 9 ligands, increased expression of Fas and FasL
in IECs in vitro. Consistent with this finding, expression of intestinal Fas and FasL was reduced in vivo in the epithelium of TLR4
knockout (KO), 5KO, and germ-free mice, but not in TLR2KOmice. Modulating Fas signaling using agonistic anti-Fas augmented
TLR4- and TLR5-mediated TNF-a and IL-8 production by IECs. In addition, suppression of Fas in IECs reduced the ability of
TLR4 and TLR5 ligands and the intestinal pathogens Salmonella typhimurium and Listeria monocytogenes to induce the expres-
sion of IL-8. In conclusion, this study demonstrates that extensive cross-talk in IECs occurs between the Fas and TLR signaling
pathways, with the FasL/Fas system playing a role in TLR-mediated inflammatory responses in the intestine. The Journal of
Immunology, 2014, 193: 6103–6113.
T
he intestinal immune system consists of multiple cell
types, including intestinal epithelial cells (IECs), which
constitute a single monolayer of cells found at the mucosal
surface; specialized dendritic cells; and macrophages. In the
gastrointestinal tract, IECs are in constant contact with luminal
bacteria, their metabolites, and their various inflammatory prod-
ucts. The mucosal surface of the intestinal epithelium has evolved
to allow the correct balance of responsiveness, being broadly
unresponsive to the presence of the commensal bacteria in the gut
lumen while still being able to mount an immune response to the
presence of pathogenic bacteria (1). This colonic epithelial cell
homeostasis is tightly regulated, as adverse effects can lead to
inflammatory conditions such as inflammatory bowel disease or to
neoplastic conditions such as colon cancer (2).
TLRs are critical components of the innate immune response that
detect microorganisms through the recognition of conserved mo-
lecular motifs called pathogen-activated molecular patterns. Ex-
pression of TLRs in the intestine has been well characterized. IECs
express several TLRs, including TLR2, TLR4, TLR5, and TLR9,
with the location of these being restricted to either the apical or the
basolateral surface, or both (3). TLR5 is found exclusively on the
basolateral surface of IECs, thereby facilitating the detection of its
ligand, flagellin (4). Conversely, TLR2, TLR4, and TLR9 have
been found at both the apical and the basolateral surfaces (5, 6).
Studies performed to characterize signal transduction pathways of
TLRs in IECs have shown both inflammatory and homeostatic
roles for these receptors following binding of their cognate ligands
(7). TLR signaling in the intestine is tightly controlled, as aberrant
signaling can give rise to uncontrolled inflammation or impaired
defense against pathogens. Indeed, aberrant TLR signaling underlies
numerous pathologic conditions of the colon (5).
Several studies have also investigated the role of the death re-
ceptor Fas and the Fas ligand (FasL) in IECs (8–10). Fas has been
shown to be constitutively expressed in the normal intestinal ep-
ithelium, whereas the expression of FasL is more restricted, being
most pronounced in the hematopoietic cells. Although best studied
in terms of its role in apoptosis, recent studies have identified
several nonapoptotic processes for Fas, such as proliferation,
migration, invasion and inflammation and tissue regeneration
(11). In IECs, ligation of Fas has been shown to induce proin-
flammatory cytokines in vitro (12), while also having a prosurvival
function in dextran sodium sulfite (DSS)–induced colitis (13).
Several studies have shown that a level of cross-talk exists
between the Fas and TLR signaling pathways. TLR4 and IL-1R1
signaling is reduced in peritoneal macrophages from Fas-deficient
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(lpr) mice, whereas blocking FasL/Fas interactions in macrophages
suppresses LPS-induced (TLR4 agonist) and IL-1R1–induced in-
flammatory cytokine production (14). Furthermore, the Fas adaptor
molecule, Fas-associated protein with death domain (FADD), has
been shown to negatively regulate TLR signaling (15). Although no
study has directly investigated the cross-talk between these path-
ways in IECs, a recent investigation into Fas signaling in alveolar
epithelial cells indicated that Fas-induced inflammation occurred in
a MyD88-dependent manner in these cells (16).
In the current study, we sought to determine whether Fas plays
a role in the induction of TLR-induced inflammation in IECs. We
found that cross-talk exists between these receptors in IECs, in
terms of both the expression level of Fas and FasL, and the in-
duction of an inflammatory response. Collectively, these results
indicate a new role for Fas signaling in the intestine.
Materials and Methods
Reagents
Agonistic human anti-Fas Ab (CH-11) was obtained from Merck Millipore
(Billerica, MA), and Jo-2 (murine) was obtained from BD Biosciences (San
Jose, CA). LPS, flagellin, PGN-SA, Pam3CSK4, CpG DNA (ODN 2006),
and polyinosinic-polycytidylic acid were purchased from Invivogen (San
Diego, CA). Recombinant TNF-a was obtained from PeproTech (Rocky
Hill, NJ). The following Abs were obtained from Santa Cruz Biotech-
nology (Dallas, TX): anti–Fas C-20, Fas X-20, TNFR-1, IGF-IRb C-20,
TLR4 H-80 and TLR5 H-127, and normal rabbit IgG, sc-2027. Anti-FasL
Ab (ab15285) was obtained from Abcam (Cambridge, U.K.). Anti–b-actin
Ab, TPCA-1, and LY294002 were obtained from Sigma-Aldrich (St Louis,
MO). Anti-SIGIRR Ab was obtained from Pro-Sci (Poway, CA), anti–
IRAK-m from AbboMax (San Jose, CA), anti-TLR2, and anti-TLR9 Ab
from Novus (Littleton, CO)
Cell lines and tissue
HT29,HCT116, SW480, andCT26 colon epithelial cells and Jurkat T cellswere
obtained from the American Type Culture Collection (Rockville, MD). Cells
were maintained in DMEM containing 10% FCS and penicillin–streptomycin.
Cells were seeded at 1 3 105 cells per milliliter unless otherwise stated, cul-
tured overnight, and then treated as specified in the figure legends.
Tissue from Swiss Webster wild-type and germ-free mice and from
C57BL/6 TLR2, TLR4, and TLR5 knockout (KO) and wild-type mice was
kindly provided by the Alimentary Pharmabiotic Centre, University College
Cork. Germ-free mice were colonized for 49 d, and tissue was obtained.
Tissue from C57BL/6 MyD88 and TRIF KO mice was obtained from Prof.
P. Fallon, Trinity College Dublin (Dublin, Ireland).
Generation of Faslow/negative IECs
Cells were transfected with lentiviral particles containing target-specific
short hairpin RNAs (shRNAs) against Fas (sc-29311-V) or control lenti-
viral particles containing scrambled shRNA (sc-108080) (Santa Cruz
Biotechnology), according to the manufacturer’s instructions. Briefly, cells
were seeded in 12-well plates at a concentration of 7.5 3 103 cells per
milliliter. Cells were infected 24 h later with lentiviral particles in the
presence of 4 mg/ml polybrene, and cultured in selection medium con-
taining 6–8 mg puromycin until resistant clones could be identified. Re-
sistant clones were selected by limiting dilution. Knockdown of Fas
expression was determined by Western blotting and functional analysis.
FIGURE 1. Stimulation with LPS
and flagellin, but not Pam3CSK4 or
CpG DNA, upregulates Fas and
FasL expression in SW480 cells.
SW480 cells were seeded at a
concentration of 1 3 105 cells per
milliliter. Cells were treated with
increasing concentrations of TLR
agonists for 24 h, and Fas, FasL, and
b-actin were detected by RT-PCR
(A and D). Changes in protein ex-
pression were detected by Western
blotting (B, E, G, and I), with results
shown representative of three sepa-
rate experiments. Changes in protein
expression were quantified by den-
sitometry (C, F, H, and J), with
analysis performed on four inde-
pendent experiments. Values are
shown as mean 6 SEM (n = 4).
Statistical analysis was performed,
and statistical change was deter-
mined relative to untreated control.
*p , 0.05, **p , 0.01.
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Bacterial cell culture and infection
The Listeria monocytogenes strain EGD (serotype 1/2a) was a gift from
Prof. C. Hill (University College Cork, Cork, Ireland). The Salmonella
typhimurium strain SJW1103 (wild-type) was a gift from Prof. P. O’Toole
(University College Cork). L. monocytogenes was grown to the logarithmic
growth phase in brain–heart infusion broth (Sigma-Aldrich) at 37˚C,
shaking at 200 rpm, whereas S. typhimurium was grown in Luria–Bertani
broth (Sigma-Aldrich). Bacteria were diluted in PBS for infection at
multiplicity of infection of 10:1. IECs were seeded overnight at 5 3 105
cells per milliliter and cultured with L. monocytogenes or S. typhimurium
for 3 h. Supernatant was removed and replaced with gentamicin-containing
media (50 ng/ml), and 24 h later cell culture supernatant was harvested.
The Escherichia coli K-12 strain was obtained from the Alimentary
Pharmabiotic Centre, University College Cork. IECs were seeded overnight
at 5 3 105 cells per milliliter, stimulated for 1 h with CH-11(100 ng/ml),
and cultured with E. coli K-12 strain (10:1, bacteria/cells) for 8 h. Cells
were lysed for subsequent RT-PCR analysis.
Proliferation assay
Cell proliferation was measured by resazurin reduction (17). Cells were
seeded at 2 3 105 cells per milliliter in 96-well plates. After incubation for
24 h, medium supplemented with 44 mM resazurin was added, and resa-
zurin reduction to resorufin was measured fluorometrically using a GENios
plate reader (Tecan, Grodig, Austria) and Xfluor spreadsheet software.
Results obtained were expressed in fluorescence units (FU) and percentage
viability was calculated as follows: (FU treated/ FU control)3 100. Values
were normalized relative to the untreated cells.
Western blotting
Cells were lysed for 1 h on ice in ice-cold lysis buffer containing 50 mMTris-
HCl (pH 8.0), 150 mM NaCl, and 1% Triton X-100, supplemented with
complete protease inhibitors (Roche Diagnostics). The protein content of
each sample was analyzed using the BCA Protein Assay Kit (Pierce,
Rockford, IL). Equal amounts of protein were separated on a 10% SDS–
polyacrylamide gel and transferred to nitrocellulose membranes. Mem-
branes were probed overnight at 4˚C with primary Ab. As an internal
control, all membranes were subsequently stripped of the first Ab and
reprobed with anti–b-actin–specific Ab (Sigma-Aldrich). Protein bands were
analyzed using ImageJ (National Institutes of Health, Bethesda, MD; http://
imagej.nih.gov/ij/, 1997-2012). Changes in protein expression were deter-
mined after normalizing the band intensity of each lane to that of b-actin.
RT-PCR
Total cellular RNAwas isolated using the GenElute Mammalian Total RNA
Mini Kit (Sigma-Aldrich) according to the manufacturer’s instructions.
cDNAwas synthesized using the Bioline kit (London, U.K.). RT-PCR was
performed using an Applied Biosystems PRISM 7500 PCR system (Ap-
plied Biosystems, Life Technologies, Carlsbad, CA) and TaqMan Gene
Expression Master Mix and the following gene expression Taqman
primer-probe sets (Applied Biosystems): Fas, Hs00236330_m1; FasL,
Hs00181225_m1; IL-8, Hs99999034_ml; TNF-a, Hs00174128_ml;
GAPDH, 4352934E. RT-PCR for Tollip, SIGIRR, IRAK-M, PPARg, 14-3-
3 ε, and CXCL-1 was performed using the LightCycler480 System (Roche,
West Sussex, U.K.). Individual PCR primer pairs and probes were
designed using the Roche Universal ProbeLibrary Assay Design Centre
(www.roche-applied-science.com/sis/rtpcr/upl/adc.jsp). Primer sequences
and probe combinations are provided in Table I. All samples were run in
triplicate, and relative quantitation was calculated using the 22DDCt method.
Transcript levels were normalized to the amount of GAPDH/b-actin mRNA,
and expression levels shown as fold induction relative to untreated.
Caspase 3/7 assay
Cells were seeded overnight in black flat-bottom 96-well plates at a density of
20,000 cells per well, treated with CH-11 for 1 h and subsequently with 100
ng/ml flagellin or 100 ng/ml LPS for 24 h, or were treated with each agonist
separately. Apo-ONE caspase-3/7 reagent was added, and following 1 h
incubation, fluorescence (485 excitation, 530 emission) was measured using
a GENios Microplate Reader (Tecan Group, Ma¨nnedorf, Switzerland).
Changes in caspase 3/7 activation were normalized relative to untreated cells.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues were deparaffinized in xylene and
rehydrated prior to analysis. Ag retrieval was performed by microwave ir-
radiation in 0.01M citrate buffer, pH 6.0. Slides were washed twice for 5 min
in a wash buffer containing 50 mM Tris-Cl, pH 7.6; 50 mM NaCl; 0.001%
saponin. Endogenous peroxidasewas quenched with 3.0% hydrogen peroxide
in methanol for 10 min. Slides were washed as before, except that the wash
buffer for this and all subsequent steps included 1% normal goat serum.
Nonspecific binding was blocked using 5% normal goat serum in wash buffer
for 1 h. Sections were incubated overnight at 4˚C with primary Ab or normal
rabbit IgG (sc-2027). Ab binding was localized using a biotinylated secondary
Ab contained within the VECTASTAIN Elite ABC detection kit (Vector
Laboratories, Burlingame, CA). Slides were counterstained with hematoxylin.
A parallel negative control was also performed, using rabbit IgG instead
of the primary Ab.
IL-8 ELISA
Supernatants were harvested after 24 h, and IL-8 levels were determined in
triplicate by ELISA (eBioscience, San Diego, CA) according to the
manufacturer’s protocol.
FIGURE 2. Fas and FasL induction by flagellin
occurs in an NF-kB– and PI3K-dependent manner.
SW480 cells were seeded at a concentration of 1 3 105
cells per milliliter. Cells were pretreated with either
10 mM TPCA1 or 25 mM LY294002, followed by fla-
gellin (100 ng/ml) for 24 h, and Fas, FasL, and b-actin
were detected by Western blotting (A and C), with results
shown representative of three separate experiments.
Changes in protein expression were quantified by den-
sitometry (B and D), with analysis performed on three
independent experiments. Values are shown as mean 6
SEM (n = 3). Statistical analysis was performed, and
statistical change was determined comparing flagellin
stimulation alone with flagellin + TPCA1 or flagellin +
LY294002. *p , 0.05, ***p , 0.001.
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Statistics
Experiments were performed a minimum of three times in triplicate. Results
were statistically evaluated using one-way Anova with a Tukey posttest, or
by the Student paired t test. The p values , 0.001 are indicated by three
asterisks (***). The p values , 0.01 are indicated by two asterisks (**).
The p values , 0.05 are indicated by one asterisk (*).
Results
Ligands for TLR4 and TLR5, but not TLR2 or TLR9, increase
the expression of Fas and FasL in IECs in an NF-kB– and
PI3K-dependent manner
Because TLRs are well characterized as key innate immune sensors
in the intestine, to investigate cross-talk between Fas and TLR
signaling, we first sought to determine whether TLR stimulation
upregulated Fas or FasL expression in IECs. SW480 human IECs
were selected, as they have been previously shown to express TLRs
1–9 (18). We confirmed protein expression of TLR2, TLR4,
TLR5, and TLR9 by Western blotting (Supplemental Fig. 1). Cells
were stimulated with the TLR4 ligand, LPS, which upregulated
Fas and FasL expression in a dose-dependent manner, at both the
mRNA (Fig. 1A) and the protein levels (Fig. 1B, 1C). The TLR5
ligand, flagellin, also upregulated Fas and FasL in a dose-dependent
manner in SW480 cells (Fig. 1D–F). In contrast, despite ex-
pressing TLR2 and TLR9, neither stimulation with Pam3CSK4,
the TLR1/2 ligand (Fig. 1G, 1H), nor transfection with CpG DNA,
the TLR9 ligand (Fig. 1I, 1J), altered Fas or FasL expression. We
confirmed that SW480s could indeed respond to stimulation with
Pam3CSK4 and CpG DNA. Although IL-8 expression did not
change in response to stimulation with either ligand, we ob-
served an increase in the gap-junction protein Connexin-43 upon
TLR2 ligation and an increase in the Wnt-signaling protein
Frizzled5 in response to TLR9 stimulation (Supplemental Fig.
2A). Both these genes have been previously shown to be acti-
vated by Pam3CSK4 and CpG DNA, respectively, in IECs (6,
19). We also confirmed the lack of induction using a different
TLR2 ligand, peptidoglycan (PGN). Similar to results seen with
Pam3CSK4, no induction of Fas was observed following stim-
ulation with PGN (Supplemental Fig. 2B), whereas robust in-
FIGURE 3. Fas and FasL expression is reduced in the distal colons of germ-free, TLR4KO, TLR5KO, TRIFKO, andMyD88KOmice. Immunoperoxidase staining
for Fas andFasLwas performed on paraffin-embedded colonic tissue sections obtained fromwild-type, germ-free, and germ-freemice colonized for 49 d (A); wildtype,
TLR2KO,TLR4KO, andTLR5KOmice (C); andMyD88KOandTRIFKOmice (E). Scale bars, 100mM.Data shownare representative of colonic tissue obtained from
fivemice per group. Protein was extracted from colonic tissue, and changes in Fas, FasL, andb-actin were detected byWestern blotting. (B,D, and F). Data shown are
representative of tissue from five mice. Changes in protein expression were quantified by densitometry. Values are shown as mean6 SEM (n = 5). ***p, 0.001.
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duction of IL-8 was observed following stimulation of SW480
cells with PGN, indicating that these cells are capable of respond-
ing to PGN (Supplemental Fig. 2C).
TLR4 and TLR5 activate downstream signaling pathways, such
as the NF-kB signaling pathway, the MAPK, and the PI3K/Akt
pathway in response to stimulation, and both the FasL and Fas
promoter regions contain NF-kB binding sites (20–22). To elucidate
the signaling pathway downstream of TLR5-induced expression of
Fas and FasL, SW480 cells were pretreated with inhibitors of either
the NF-kB or the PI3K pathway prior to stimulation with flagellin.
We found that TPCA-1, an IKKb inhibitor, reduced flagellin-
induced upregulation of both Fas and FasL expression (p , 0.05)
(Fig. 2A, 2B), albeit to a low level. Pretreatment of cells with
LY294002, a PI3K inhibitor, also significantly prevented flagellin-
induced Fas and FasL expression (p , 0.001) (Fig. 2C, 2D).
Fas and FasL expression is reduced in the colons of germ-free,
TLR4, and TLR5 KO mice
To determine the in vivo relevance of the induction of Fas and FasL
expression by TLR4 and TLR5 ligands, colonic tissue from con-
ventionally rearedmicewas assessed for Fas and FasL expression. Fas
and FasL were found to be expressed in a uniform fashion extending
from the base to the surface of the colonic crypts (Fig. 3A). In
contrast, expression was reduced in the colonic epithelium of germ-
free mice, as assessed by both immunohistochemistry (Fig. 3A) and
Western blotting (Fig. 3B), consistent with the lack of exposure of
the IECs to commensal flora and thus TLR ligation. Colonization of
germ-free mice, however, restored Fas and FasL expression to levels
seen in conventionally reared animals, suggesting that Fas and FasL
expression is, at least, partially dependent on colonization of the
colon by commensal bacteria (Fig. 3A).
As we had observed that stimulation through TLR4 and TLR5
induced the expression of both Fas and FasL in SW480 cells
in vitro, we next examined colonic tissue taken from TLR4KO and
TLR5KO mice. In contrast to the immunohistochemical staining
pattern observed in wild-type mice, colonic tissue from both
TLR4KO and TLR5KO mice demonstrated a marked reduction in
expression of both Fas and FasL (Fig. 3C). This reduction in ex-
pression of Fas and FasL in TLR4KO colonic tissue was con-
firmed by Western blotting (Fig. 3D). Consistent with our in vitro
findings, Fas and FasL expression was unchanged in the epithelial
colonic cells of TLR2KO mice, although it appeared reduced in
the Western blot (Fig. 3C, 3D). This difference in expression may
be due to the mixed population of cells represented in the Western
blot compared with the specific IEC immunohistochemical stain-
ing. Expression of TNF receptor 1 (another member of the death
receptor family) or the insulin growth receptor 1b, however, was
unaltered in TLR4KO and TLR5KO mice (Supplemental Fig. 3A).
We subsequently examined whether the observed change in Fas
and FasL expression in the colonic tissue of TLR4 and TLR5 KO
micewas present in other tissues. The expression pattern in the lung
was similar to that observed in the colon; that is, expression of Fas
and FasL was downregulated in the lung epithelium (see arrows) of
both TLR4KO and TLR5KOmice (Supplemental Fig. 3B). In contrast,
expression of Fas and FasL was unchanged in the cerebellum or
kidneys (Supplemental Fig. 3C, 3D, respectively). This obser-
vation suggests that the regulation of Fas and FasL by TLR4 and
TLR5 is tissue specific and may be dependent on the presence of
the commensal flora.
These findings indicate that IECs show specificity in their ability
to upregulate Fas and FasL expression in response to TLR ligation.
One possible explanation for this specificity may be differences in
the signaling pathways activated by the TLRs. Although all four
TLRs examined in this study (TLR2, TLR4, TLR5, and TLR9) use
the TLR adaptor protein MyD88, only TLRs 4 (23) and 5 (24) use
the adaptor molecule TRIF. This utilization of TRIF by TLR5 was
shown specifically in IECs (24).Therefore we next examined Fas
and FasL expression in TRIF and MyD88 KO tissue. Expression
of both Fas and FasL protein was significantly reduced in TRIF
KO tissue, as assessed by both immunohistochemistry (Fig. 3E)
and Western blotting (Fig. 3F). Expression was also reduced, al-
beit to a much lower level, in MyD88 KO tissue (Fig. 3E, 3F).
These findings indicate that signaling through TRIF by TLR4 and
TLR5, but not TLR2 and TLR9, agonists may be responsible the
induction of Fas and FasL in IECs.
Stimulation of IECs with agonistic anti-Fas Ab and TLR4 or
TLR5 ligands results in augmented cytokine production
As TLR and Fas signaling can induce the production of inflam-
matory cytokines, we subsequently examined whether stimulation
of both receptors in IECs resulted in an altered cytokine profile. To
investigate this, SW480 cells were treated with the agonistic anti-
Fas Ab, CH-11, followed by stimulation with either LPS or fla-
gellin. Cytokine gene expression was initially analyzed by quan-
titative RT-PCR (Table I). Stimulation with CH-11, LPS, or
flagellin alone induced the expression of TNF-a and IL-8,
whereas stimulation with a combination of CH-11 and either
TLR agonist resulted in augmented transcription of these cyto-
kines (Fig. 4A, 4B). Similar findings were observed upon
stimulation of SW480 cells with CH-11 and the Gram-negative
bacterium E.coli, strain K-12, which would be expected to stim-
ulate cells through TLR4 (Fig. 4C, 4D).
The augmented production of IL-8 in SW480 cells was confirmed
at the protein level by ELISA, with stimulation of the cells with both
CH-11 and LPS or flagellin resulting in a statistically significant
increase in IL-8, relative to either treatment alone (Fig. 4E).We also
confirmed that the augmented cytokine production observed upon
Fas and TLR ligation was not specific to SW480 cells. HT29 and
HCT116 IECs, which express TLR4 and TLR5 (Supplemental
Fig. 1), were treated in the same fashion as the SW480 cells.
IL-8 protein secretion was significantly augmented following
stimulation of HT29 and HCT116 cells with flagellin and CH-11
Table I. qRT-PCR primers and corresponding UPL probe numbers
Gene DNA Sequence (Sense 59–39) DNA Sequence (Antisense 59–39) UPL Probe No.
b-actin ATTGGCAATGAGCGGTTC TGAAGGTAGTTTCGTGGATGC 11
14-3-3 ε TCTGGTGTACCAGGCGAAG CCATCCCTGCTACTTTCTTCA 22
SIGIRR AGCTCTTGGATCAGTCTGCTG GGCCCTATCACAGACACCTG 36
Tollip CAACCTCGTCATGTCCTACG GCTGGTACACTGTTGGCATC 38
IRAK-m AGAGCTCTGCGCTGTTCTG GCTGCTTGAAAGTCTCTCTCTGC 26
PPARg TGACAGGAAAGACAACAGACAAAT GGGTGATGTGTTTGAACTTGATT 7
Murine CXCL-1 GACTCCAGCCACACTCCAAC TGACAGCGCAGCTCATTG 83
Murine b-actin AAGGCCAACCGTGAAAAGAT GTGGTACGACCAGAGGCATAC 56
UPL, Universal ProbeLibrary.
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(Fig. 4F, 4G, respectively), and with LPS and CH-11 in HT29s
(Fig. 4F), compared with either stimulation alone.
The augmented cytokine production observed following
stimulation of IECs with CH-11 and TLR4 or TLR5 ligands is
independent of cell death
The Fas/FasL system is best characterized in terms of its role in
apoptosis, with some reports showing that cytokine expression
occurs concomitantly with apoptotic cell death (25). Moreover,
TLRs have been shown to induce apoptosis in certain cell types;
for instance, TLR5 stimulation can induce apoptosis in IECs (20).
To determine whether the augmented cytokine production ob-
served occurred concomitantly with, or was independent of, IEC
apoptosis, cells were stimulated with CH-11 and/or LPS or fla-
gellin, and cell viability and caspase 3/7 activation were assessed.
Treatment of cells with LPS, flagellin, or agonistic anti-Fas CH-11
alone or in combination did not alter cell viability in either SW480
or HT29 cells. In contrast, treatment of cells with staurosporine
resulted in substantially reduced cell viability (Fig. 5A). More-
over, no increase in caspase 3/7 activity was observed in either cell
line with either treatment (Fig. 5B), whereas a 4-fold induction in
caspase 3/7 activity was noted in Jurkat T cells, cells known to be
sensitive to Fas-mediated apoptosis, following CH-11 stimulation
relative to untreated control (Fig. 5C).
Stimulation of cells with agonistic anti-Fas reduces the
expression of TLR inhibitory proteins
Previous studies in macrophages have shown that in the absence of
Fas signaling, the Fas adaptor protein, FADD, is present in the
cytoplasm bound to the TLR adaptor protein, MyD88, suppressing
TLR-induced cytokine production (14, 15). Engagement of
Fas prevented this interaction, releasing MyD88 and promoting
TLR-mediated inflammation. To address the potential me-
chanism whereby stimulation of Fas augments TLR4- and TLR5-
induced TNF-a and IL-8 protein in IECs, we first investigated
whether FADD interacts with MyD88. Tagged constructs of
FADD and MyD88 were overexpressed in HCT116 cells, and
FIGURE 4. Stimulation of SW480,
HT29, and HCT116 cells with ago-
nistic anti-Fas Ab and TLR agonists
augments cytokine production. Cells
were treated with 200 ng/ml agonistic
anti-Fas Ab (CH-11) for 1 h followed
by stimulation with 100 ng/ml LPS or
100 ng/ml flagellin for 8 h. Changes
in TNF-a (A) and IL-8 (B) were
detected by qRT-PCR. Cells were
treated with 200 ng/ml agonistic anti-
Fas Ab (CH-11) for 1 h, followed by
stimulation with E. coli K-12 10:1
(bacteria/cells) for 12 h, and changes
in TNF-a (C) and IL-8 (D) were
detected by qRT-PCR. SW480 (E),
HT29 (F), and HCT116 (G) were
treated with CH-11, as above, fol-
lowed by stimulation with LPS or
flagellin for 24 h. Cell culture super-
natants were harvested, and changes
in IL-8 secretion were detected by
ELISA. Statistical analysis was per-
formed, and statistical change was
determined comparing either LPS or
flagellin stimulation alone with LPS +
CH-11 or flagellin + CH-11. Values
are shown as mean 6 SEM (n = 3).
*p, 0.05, **p, 0.01, ***p, 0.001.
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coimmunoprecipitation studies were performed. However, no in-
teraction between FADD and MyD88 was observed in this cell
type (data not shown).
TLR signaling is regulated by an extensive array of TLR in-
hibitory proteins such as SIGIRR and TOLLIP (26, 27). Thus, we
investigated whether signaling through Fas altered the expression
of TLR inhibitory proteins shown to be important in the intestine.
Cells were stimulated with CH-11, LPS, and/or flagellin, and
changes in a panel of TLR inhibitory proteins were assessed by
RT-PCR (Table I). Stimulation of SW480 cells with CH-11 re-
duced the transcription of SIGIRR, TOLLIP, and 14-3-3 ε, but not
IRAK-M or PPARg (Fig. 6A). Furthermore, costimulation with
CH-11 and either LPS or flagellin resulted in a greater reduction in
expression of 14-3-3 ε. The change in protein levels of SIGIRR,
but not IRAK-m, was confirmed by Western blotting (Fig. 6B).
Together these findings suggest that the augmentation in TLR4-
and TLR5-induced cytokine production by Fas may be due to its
ability to downregulate the expression of several key TLR inhib-
itory proteins.
Suppression of Fas expression limits the ability of HT29 cells to
respond to TLR4 and TLR5 ligands
Given the cross-talk seen between the Fas and TLR4 and TLR5
signaling pathways, we next sought to determine whether sup-
pression of Fas expression altered the response of the IECs to TLR
ligands. Fas was suppressed in HT29 cells, using shRNA specific
against Fas (HT29Fas shRNA). Suppression was confirmed by both
Western blotting (Fig. 7A) and functional analysis; CH-11 did not
induce IL-8 in HT29Fas shRNA cells, in contrast to the induction
seen in cells transfected with scrambled shRNA (HT29scr shRNA)
(Fig. 7C). The specificity of suppression was confirmed by im-
munoblotting for TNFR-1 (Fig. 7B).
Both LPS- and flagellin-induced IL-8 production was reduced to
the level of unstimulated control cells following suppression of Fas
expression (Fig. 7C). This reduction was not due to any altera-
tion in TLR4 or TLR5 expression in the knockdown cells
(Supplemental Fig. 1). To determine whether IL-8 secretion in
response to other TLR ligands, or known inducers of IL-8 such as
TNF-a, was also affected by Fas suppression, cells were stimu-
lated with Pam3CSK4, CpG DNA, and TNF-a. HT29 cells did not
secrete IL-8 in response to Pam3CSK4, irrespective of Fas ex-
pression. However, HT29 cells did secrete IL-8 in response to
stimulation with CpG DNA and TNF-a, and this was unaffected
by Fas suppression (Fig. 7C).
These results were confirmed in CT26 murine IECs. Fas was
stably suppressed in these cells by shRNA (CT26Fas shRNA)
(Fig.7D). As murine cells do not produce IL-8, the induction of
CXCL-1, a murine IL-8 homolog, was determined. Consistent
with suppression of Fas expression, the CT26Fas shRNA cells failed
to upregulate CXCL-1 in response to Jo-2 (a murine agonistic
anti-Fas Ab) (Fig. 7E). The ability of LPS to induce CXCL-1 in
CT26Fas shRNAwas also reduced to basal levels consistent with our
findings in HT29 cells. As CT26 cells do not express TLR5 (28),
we were unable to assess their response to flagellin (Fig. 7E).
These findings suggest that signaling through Fas augments
TLR4- and TLR5-induced cytokine and chemokine production in
IECs.
Fas is required for the response of IECs to intestinal pathogens
L. monocytogenes and S. typhimurium
Given that the IEC response to TLR4 and TLR5 ligands was
attenuated upon suppression of Fas expression, the ability of
HT29Fas shRNA cells to respond to the LPS-expressing Gram-
negative bacterium S.typhimurium or the flagellin-expressing bac-
terium L. monocytogenes was assessed. In contrast to HT29scr shRNA
cells, the ability of HT29Fas shRNA cells to produce IL-8 in response
to stimulation with either bacterium was suppressed (Fig. 8). This
finding was shown in two separately derived knockdown clones.
Taken together, these findings suggest that Fas signaling is likely
to play a role in intestinal host defense against pathogens.
Discussion
The aim of this study was to investigate the cross-talk between
TLRs and Fas in the intestinal epithelium. Our principal findings
are that stimulation through TLRs 4 and 5, either by their cognate
ligands or by commensal flora, increases expression of Fas and
FasL in vitro and in vivo, and that stimulation of Fas in intestinal
FIGURE 5. The augmented cyto-
kine production is not dependent on
caspase activation. Cells were trea-
ted with 50 ng/ml agonistic anti-Fas
(CH-11) for 1 h, followed by stim-
ulation with 100 ng/ml LPS and/
or 100 ng/ml flagellin for 24 h. Cell
proliferation was determined by resa-
zurin reduction (A) and caspase 3/7
activation by fluorescence (B and C).
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cells augments TLR4- and TLR5-induced cytokine and chemokine
production. These observations are significant, as they indicate
a hitherto unappreciated role for Fas in the intestinal immune
response.
Although upregulation of Fas by TLR2, TLR3, TLR4, TLR7,
and TLR9 ligands (29–31) has been previously reported in mac-
rophages, to the best of our knowledge no report has demonstrated
an upregulation of Fas and FasL by pathogen-activated molecular
patterns in IECs. In IECs, LPS and flagellin upregulated Fas and
FasL expression, whereas Pam3CSK4 and CpG DNA had no ef-
fect. Moreover, we found that expression of both Fas and FasL
was reduced in the epithelial cells of the colon of TLR4 and
TLR5, but not TLR2, KO mice. In addition to the obvious dif-
ferences in cell lineage, another possibility for the differences
observed between IECs and macrophages is that upregulation of
Fas and FasL expression may occur in a TRIF-dependent manner
in IECs. It is well established that TLR4 uses the adaptor molecule
TRIF (23), and more recently TLR5 has been shown to use TRIF
in IECs (24), whereas neither TLR2 nor TLR9 has been reported
to use TRIF. Of interest, a recent study examining the respective
importance of TRIF-dependent versus MyD88-dependent gene
expression in IECs revealed that the number of TRIF-dependent
genes by far exceeded the number of genes regulated by the
adaptor protein MyD88 (32). Consistent with this finding, ex-
pression of Fas and FasL was greatly reduced in TRIF KO mice,
with only a modest reduction observed in MyD88 KO mice. This
observation suggests that the specificity of TLR-induced upregu-
lation of Fas and FasL in IECs may be due to the ability of TLRs 4
and 5 to use TRIF.
In this study, we found that germ-free mice have reduced Fas and
FasL expression, and colonizing germ-free mice effectively “res-
cues” the phenotype of reduced Fas and FasL expression. This
finding suggests that signaling from the commensal microbiota in
IECs, via TLRs, regulates Fas and FasL expression. Recognition
of commensal bacteria through TLRs also plays a role in intestinal
homeostasis, as mice deficient in TLR4 or MyD88 exhibited in-
creased morbidity and mortality with DSS-induced colitis (33).
Our data indicate that TLR4 KO mice, as used in the study of
Rakoff-Nahoum et al. (34), would also have reduced Fas and FasL
expression. Of note, a recent study has shown that Fas can play
a cytoprotective role in the intestinal epithelium (13). Thus, failure
of the commensal flora to upregulate Fas and FasL in TLR4 KO
FIGURE 6. Fas activation reduces the expression of key TLR inhibitory proteins in IECs. SW480 cells were treated with 200 ng/ml agonistic anti-Fas Ab
(CH-11) for 1 h followed by stimulation with 100 ng/ml LPS or 100 ng/ml flagellin for 4 h. Changes in inhibitory proteins were detected by qRT-PCR (A).
Cells were treated with CH-11, as above, for 24 h, and changes in protein expression were detected by Western blotting and quantified by densitometry (B).
Results shown are representative of three independent experiments. Statistical analysis was performed using one-way ANOVA (A) and the paired Stu-
dent t test (B), and statistical change was determined compared with untreated control. Values are shown as mean 6 SEM (n = 3).*p , 0.05, **p , 0.01,
***p , 0.001.
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mice may exacerbate the intestinal injury seen in these mice upon
DSS administration. Our data would also indicate the possibility
that other, as yet unknown, proteins may also be absent in TLR4
and TLR5 KO mice, resulting in roles being ascribed to TLRs that
are actually due to the absence of other proteins.
Despite being best characterized as an apoptotic inducer, acti-
vation of Fas did not alter the sensitivity of the IECs to Fas-mediated
apoptosis. Fas activates the extrinsic apoptotic pathway, wherein
activation of Fas induces the formation of a death-inducing signaling
complex, resulting in the cleavage and activation of procaspase-8.
FIGURE 7. Suppression of Fas expression in HT29 cells prevents TLR4/5-induced IL-8 production. HT29 cells were lentivirally transfected with either
scrambled control shRNA or shRNA against Fas. Expression levels of Fas and TNFR-1 in HT29 scrambled control transfected (HT29scr shRNA) and HT29Fas shRNA
clones were determined by Western blotting (A and B). HT29scr shRNA and HT29Fas shRNA clones were treated with either 200 ng/ml agonistic anti-Fas Ab
(CH-11), 100 ng/ml flagellin, 100 ng/ml LPS, 5 mM CpG, 10 mM Pam3CSK4, or 100 ng/ml TNF-a for 24 h. Cell supernatants were collected, and IL-8
protein concentration was determined by ELISA (C). CT26 cells were lentivirally transfected as above, and expression levels of Fas were determined by
Western blot (D). CT26 cells were treated with either 100 ng/ml agonistic anti-Fas Ab (JO-2), 100 ng/ml LPS, 100 ng/ml flagellin, 1 mg/ml polyinosinic-
polycytidylic acid, or 100 ng/ml TNF-a for 4 h. Changes in mCXCL-1 were detected by qRT-PCR (E). Statistical analysis was performed, and statistical
change was determined between the scrambled and knockdown clones. Values are shown as mean 6 SEM (n = 3). **p , 0.01, ***p , 0.001.
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Caspase-8, in turn, activates a caspase cascade, culminating in the
apoptotic death of the cell. Numerous proteins, including c-FLIP,
have been shown to suppress Fas-mediated apoptosis. IECs ex-
press high levels of c-FLIP, which suppresses Fas-mediated ap-
optosis through its ability to prevent processing of procaspase-8 to
its mature active form (35, 36). Thus, despite coexpressing Fas
and FasL, IECs are protected against Fas-mediated apoptosis
under homeostatic conditions. Given that Fas has been shown to
mediate several nonapoptotic functions, such as inflammation
(11), our data suggest that in IECs, these nonapoptotic functions
of Fas may predominate.
The findings of this study also demonstrate extensive cross-talk
between the Fas and TLR signaling pathways in IECs in terms of
cytokine induction and response to bacterial infection. One of the
first indications of a cross-talk between the Fas and TLR signal-
ing pathways came from studies in macrophages. LPS-activated
macrophages produce a large amount of IL-1b upon FasL stim-
ulation (14, 31), and TLR4 signaling is reduced in lpr/lpr and
gld/gld peritoneal macrophages, which have mutations in Fas and
FasL, respectively (37). The proposed mechanism for this cross-
talk was that MyD88 was inhibited by FADD via a direct inter-
action between the adaptor proteins (14), and that activation of the
Fas signaling pathway prevented this interaction. We were, how-
ever, unable to detect this interaction in IECs, suggesting that the
cross-talk seen in IECs occurs via a different mechanism. We
subsequently determined that in IECs, Fas signaling alters the
expression levels of TLR inhibitory proteins. TLR signaling is
tightly regulated by a range of TLR inhibitory proteins, several of
which have been shown to be important in intestinal homeostasis
(38, 39). Stimulation of Fas in IECs reduced the expression of
three of the five inhibitory proteins examined by 20–40%. This
level of reduction is in line with that seen in other studies, and has
been shown to be sufficient to alleviate the suppression of TLR
signaling (40). Of those reduced, both SIGIRR and Tollip have
been previously shown to be essential negative TLR regulators in
IECs (38, 41), with a reduction in expression of SIGIRR, in par-
ticular, being associated with exacerbated colitis in murine models
(40, 42). We also observed a reduction in 14-3-3 ε, which has
recently emerged as a TLR inhibitory protein (43). It is worth
noting that we did not observe a reduction in CpG DNA–induced
IL-8 in our HT29Fas shRNA knockdown clones. This finding may be
attributed to the fact that the expression of several inhibitory
proteins examined remained unchanged upon Fas activation and
that these may be more important in suppressing TLR9-mediated
inflammation in IECs. Thus the augmentation of TLR4- and
TLR5-induced cytokine production seen upon Fas stimulation
may be, at least in part, due to the reduced expression of 14-3-3 ε,
Tollip, and SIGIRR.
In summary, we have shown that extensive cross-talk exists
between Fas and TLRs 4 and 5 in IECs in vitro and in vivo. Our data
further advance the evidence in favor of nonapoptotic functions of
Fas and reveal a hitherto unknown link between Fas and FasL
expression and the presence of commensal flora in IECs. The
alterations in TLR-mediated cytokine production shown in this
study, upon manipulation of both the expression and the activation
of Fas, suggest that targeting Fas has potential therapeutic appli-
cations and warrants further investigation.
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Supplementary Figure S1. Intestinal epithelial Cells express  TLRs 2, 4, 5 and 9.  
Cells were seeded at a concentration of 1 x 106 cells per ml.  Protein expression was 
detected by Western blotting.  
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Supplementary Figure S2. SW480 cells respond to TLR2 and TLR9 agonists. 
SW480 cells were seeded at a concentration of 1 x 105 cells per ml. Cells were treated with CpGDNA 
or Pam3Csk4 as specified and fold change of IL-8, Frizzled5 and Connexin43 determined by RT-PCR 
(a). Cells were treated with PGN for 24 hours and changes in Fas detected by Western blotting (b) 
and changes in Il-8 detected by ELISA (c).  
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Supplementary Figure S3: Fas and FasL expression is reduced in the lung but not the 
cerebellum or kidney of TLR4 and TLR5 knockout mice. 
Immunoperoxidase staining for TNFR-1, IGF-IRβ, Fas, FasL was performed on paraffin embedded 
a) colonic b) lung c) cerebellum and d) kidney tissue sections obtained from wildtype, TLR4KO 
and TLR5KO C57BL/6 mice.  Scale bar = 100μM where not otherwise specified 
